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Abstract 
The objective of this thesis was to improve the dissolution rate of the poorly water –
soluble drug, fenofibrate by processing it with a high surface area carrier, 
mesoporous silica. The subsequent properties of the drug – silica composite were 
studied in terms of drug distribution within the silica matrix, solid state and release.  
Prior to commencing any experimental work, the properties of unprocessed 
mesoporous silica and fenofibrate were characterised (chapter 3), which allowed for 
comparison with the processed samples studied in later chapters. Fenofibrate was a 
highly stable, crystalline drug that did not adsorb moisture, even under long term 
accelerated storage conditions (75% RH, 40 
o
C). It maintained its crystallinity even 
after SC-CO2 processing. Its dissolution rate was limited and dependent on the 
characteristics of the particular in vitro media studied. Mesoporous silica had a large 
surface area and mesopore volume and readily picked up moisture when stored under 
long term accelerated storage conditions. It maintained its mesopore character after 
SC-CO2 processing.  
A variety of methods were employed to process fenofibrate with mesoporous silica 
including physical mixing, melt method, solvent impregnation and novel methods 
such as liquid and supercritical carbon dioxide (SC-CO2) (chapter 4). It was found 
that it was important to break down the fenofibrate particulate structure to a 
molecular state to enable drug molecules enter into the silica mesopores. While all 
processing methods led to some increase in fenofibrate release properties, the 
impregnation, liquid and SC-CO2 methods produced the most rapid release rates.  
SC-CO2 processing was further studied with a view to optimising the processing 
parameters to achieve the highest drug-loading efficiency possible (chapter 5). In this 
thesis, it was observed that SC-CO2 processing pressure had a bearing on drug-
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loading efficiency. Neither SC-CO2 pressure nor duration time or CO2 
depressurisation rate affected drug solid state or release properties.  
The amount of drug that could be loaded onto to the mesoporous silica successfully 
was also investigated at different ratios of drug mass to silica surface area under 
constant SC-CO2 conditions; as the drug – silica ratio increased, the drug-loading 
efficiency decreased, while there was no effect on drug solid state or release 
properties.  
The influence of the number of drug-loading steps was investigated (chapter 6) with 
a view to increasing the drug-loading efficiency. A multiple step approach did not 
yield an increase in drug-loading efficiency compared to the single step approach. It 
was also an objective in this chapter to understand how much drug could be loaded 
into silica mesopores; a method based on the known volume of the mesopores and 
true density of drug was investigated. However, this approach led to serious 
repercussions in terms of the subsequent solid state nature of the drug and its release 
performance; there was significant drug crystallinity and reduced release extent.  
The impact of in vitro release media on fenofibrate release was also studied (chapter 
6). Here it was seen that media containing HCl led to reduced drug release over time 
compared to equivalent media not containing HCl.  
The key findings of this thesis are discussed in chapter 7 and included: 
  
1. Drug – silica processing method strongly influenced drug distribution within 
the silica matrix, drug solid state and release.  
2. The silica surface area and mesopore volume also influenced how much drug 
could be loaded.  
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3. It was shown that SC-CO2 processing variables such as processing pressure 
(13.79 – 41.37 MPa), duration time (4 – 24 h) and CO2 depressurisation rate 
(rapid or controlled) did not influence the drug distribution within the SBA-
15 matrix, drug solid state form or release. 
 
Possible avenues of research to be considered going forward include the 
development and application of high resolution imaging techniques to visualise drug 
molecules within the silica mesopores. Also, the issues surrounding SBA-15 usage in 
a pharmaceutical manufacturing environment should be addressed. 
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1 Introduction to this thesis: The exploitation of 
silicon dioxide (SiO2) for oral drug delivery 
1.1 Introduction 
Oral drug delivery is the most convenient method of drug administration for patients. 
In oral drug delivery, the administered drug normally needs to be dissolved in the 
gastrointestinal tract (GIT) in order to be absorbed into systemic circulation. 
Therefore, there are two issues that need to be considered for when assessing a drug 
candidate for oral delivery; its water solubility (hydrophobic or hydrophilic) and 
permeability into the bloodstream from the GIT (lipophobic or lipophilic). The ideal 
drug candidate for oral delivery should have high water solubility and permeability. 
The Biopharmaceutics classification system (BCS) was developed in order to 
classify drugs according to their water solubility and permeability. Four classes were 
proposed: BCS Class I drugs have high water solubility and high permeability (the 
ideal drug for oral delivery), BCS Class II drugs have poor water solubility and high 
permeability, BCS Class III drugs have high water solubility and low permeability 
and BCS Class IV drugs have low water solubility and low permeability (Amidon et 
al., 1995). Oral pharmaceutical products that have poor water solubility are said to be 
dissolution-rate limited which in turn limits their oral bioavailability. For these drugs 
to have enhanced oral bioavailability, considerable formulation and process 
development is required, which can be a significant challenge. It has been estimated 
that the cost of developing a new chemical entity (NCE) and bringing it to market as 
a new pharmaceutical drug product lies in the region of approximately $1.8 billion 
United States dollars (USD) (Paul et al., 2010); previously the cost was estimated to 
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be approximately $802 million USD (DiMasi et al., 2003). Many NCE’s developed 
through high-throughput screening and combinatorial chemistry exhibit poor water 
solubility because these methods tend to produce drugs that are more lipophilic than 
hydrophilic (Lipinski et al., 1997). In fact, it has been estimated that 40% of drugs 
developed through these methods exhibit poor water solubility (Merisko-Liversidge 
and Liversidge, 2008) . Drug dissolution rate can be expressed as Eq.1.1: 
 
Equation 1.1:    
 
where , the rate of drug dissolution is dependent upon: , the diffusion 
coefficient (m
2
/s), , the surface area (m
2
), , the thickness of the diffusion layer 
(m), , the volume of dissolution medium (ml), , the saturation solubility of a 
specific drug in a specific medium (mg/ml) and , the solubility of specific drug in 
a specific medium at a specific time (mg/ml) (Bruner, 1904, Nernst, 1904).  
If the drug dissolution rate can be improved, drug oral bioavailability can also be 
improved (Amidon et al., 1995). A well established method for improving the 
dissolution rate of a BCS Class II drug is to increase its effective surface area 
(Equation 1.1); this can be achieved by loading the drug onto a high surface area 
carrier like porous silica (Vallet-Regi et al., 2001).  Porous silicas are attractive for 
drug dissolution rate enhancement because of their high surface areas, high 
mesopore volumes and ordered mesopore networks  (Kresge et al., 1992) which 
permit homogeneous and reproducible drug-loading and release (Vallet-Regi, 2006). 
In this introductory chapter several aspects will be reviewed. Firstly the aim of this 
chapter was to understand of the key properties of amorphous, hydrophilic silicas 
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(SiO2) that affect drug-loading, drug solid state and dissolution rate enhancement. 
Mesoporous silica was employed in this thesis as the host matrix for the poorly water 
– soluble drug fenofibrate and therefore, it was important to understand its properties 
prior to any research being carried out.  Secondly this chapter aimed to understand 
the influence of drug-loading method on subsequent drug physicochemical 
properties. The work that will be outlined later in this thesis was focused on 
investigating methods of loading and the subsequent properties of the drug-silica 
systems. Finally, the in vivo performance of silica based oral drug delivery systems 
was also reviewed in this chapter.  
 
1.2 Silica  
Silicon dioxide (silica) describes materials with a wide range of properties. They can 
be crystalline or amorphous, hydrophilic or hydrophobic and porous or non-porous. 
Crystalline silicas are found mainly in quartz and sand and have melting points of 
1710 
o
C (Lewis, 2013), have densities of 2.6 g/cm
3
 (Lewis, 2013) and are non-
combustible materials (Daubert and Danner, 1989), bulk densities are generally low. 
Silicon dioxide is composed of the elements silicon (Si) and oxygen (O) bonded 
together via tetrahedral bonding (Zheng et al., 2001). There is cross-linking of the Si-
O-Si, which makes amorphous, hydrophilic, colloidal silica very stable; its glass 
transition temperature (Tg) is very high at 1202 
o
C (Ojovan, 2004).  
The main application of silica in the pharmaceutical industry has been as a glidant 
for improved powder flow and compression (York, 1975) and in powder tabletting 
processes (Lerk et al., 1977, Lerk and Bolhuis, 1977, Jonat et al., 2005).  
Hydrophobic colloidal silicas are similar to hydrophilic colloidal silicas except that it 
has been treated with hydrophobic moieties (Rowe et al., 2012). In this thesis, there 
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will be a focus on amorphous hydrophilic silica for oral drug delivery. Amorphous 
hydrophilic silica can be divided into two broad categories (1) non-porous silica and 
(2) porous silica; the surface (and porosity) properties of a range of silicas are 
presented in Table 1.1.  
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Table 1.1: Surface and mesopore properties of a range of amorphous, hydrophilic silica materials. 
Silica Type Surface area (m2/g) Mesopore volume (cm3/g) Mesopore size (nm) Reference 
Colloidal SiO2 Aerosil® 50 – 300 N/A N/A (Rowe et al., 2012) 
Colloidal SiO2 Cab-O-Sil® 90 – 380 N/A N/A (Rowe et al., 2012) 
Colloidal SiO2 HDK® 150 – 200 N/A N/A (Rowe et al., 2012) 
Mesoporous MCM-41 800 – 1000 0.50 – 1.5 1.5 – 10 (Kresge et al., 1992) 
Mesoporous MCM-48 1000 1.048 1.5 – 10 
(Izquierdo-Barba et al., 2005) 
(Kim et al., 1998) 
Mesoporous SBA-15 400 – 800 0.50 –0. 65 5 – 8 (Zhao et al., 1998) 
Mesoporous KIT-1 1000 Not reported 3.4 (Ryoo et al., 1996) 
Mesoporous FSM-16 680 – 1000 0.28 – 0.83 1.5 – 4 (Inagaki et al., 1996) 
Mesoporous BMM 1005 1.59 2.71,  23.8 (Gao et al., 2012) 
Mesoporous TUD-1 400 – 1000 0.50 – 1.7 4 – 18 (Jansen et al., 2001) 
Mesoporous HMS 1210 1.04 2.67 (Zhu et al., 2005a) 
Mesoporous COK-12 429 – 547 0.45 – 0.88 5.8 – 9.4 (Jammaer et al., 2009) 
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The differences across the mesoporous silicas discussed in this introduction in terms of mesopore array, order and direction, whether 
unidirectional, or 2 or 3 directional (2 or 3-D) are shown in Table 1.2.  
 
Table 1.2: Description of the mesoporous array, order, shape and structure. 
Material Mesopore array Ordered Mesopore description Reference 
MCM-41 Hexagonal Ordered Long unidirectional mesopores through the particle (Kresge et al., 1992) 
MCM-48 Cubic Ordered Long 3-directional mesopores through the particle 
(Izquierdo-Barba et al., 2005) 
(Kim et al., 1998) 
SBA-15 Hexagonal Ordered Long unidirectional mesopores through the particle (Zhao et al., 1998) 
KIT-1 Worm-like Disordered Short 3-directional mesopores (Ryoo et al., 1996) 
FSM-16 Honeycomb Ordered Long unidirectional mesopores through the particle (Inagaki et al., 1996) 
BMM Random Disordered Short  randomly connected mesopores through the particle (Gao et al., 2012) 
TUD-1 Foam-like Disordered Randomly connected mesopores through the particle (Jansen et al., 2001) 
HMS Hexagonal Ordered Short mesopores running into a hollow core (Zhu et al., 2005a) 
COK-12 Hexagonal Ordered 2-directional mesopores through the particle (Jammaer et al., 2009) 
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1.2.1 Non-porous amorphous hydrophilic silica 
The most common non-porous fumed silica is colloidal silicon dioxide (hydrophilic 
fumed silica). Cab-O-Sil
®
 (Cabot Corporation), Aerosil
®
 (Evonik Industries) and 
HDK
®
 (Wacker) are commercial varieties of colloidal silicon dioxide. The 
manufacturing process involves the hydrolysis of silicon tetrachloride vapour in a 
flame of hydrogen and oxygen at temperatures greater than 1000 
o
C, giving rise to 
the term fumed silica (Katz and Milewski, 1987).  Aerosil
®
 has a specific surface 
area from 50 – 300 m2/g (Table 1.1), depending on the particular grade (Rowe et al., 
2012). CAB-O-SIL
®
 has specific surface areas from 90 – 380 m2/g (Table 1.1). 
When discussing non-porous silica, the specific surface area is the most important 
parameter to consider as this determines how much drug can be loaded onto the 
silica.  
 
1.2.2 Porous amorphous hydrophilic silica 
Porous silica can be divided into macroporous (> 50 nm), mesoporous (2 – 50 nm) 
and microporous (< 2 nm) silica. Porous silica has been widely employed to improve 
the dissolution rate of poorly water – soluble drugs. Due to the porous nature, drug 
molecules can be confined and stabilised within the silica mesopores in a non-
crystalline form (Azais et al., 2006, Mellaerts et al., 2008a, Shen et al., 2010), with 
re-crystallisation prevented by nano-confinement because the ratio of drug molecule 
size to mesopore width is insufficient to permit drug re-crystallisation (Sliwinska-
Bartkowiak et al., 2001). There are many varieties of amorphous mesoporous silica. 
The Mobil composition of matter (MCM) range of mesoporous silicas were 
developed by researchers at the Mobil Corporation in 1992 and are part of the M41S 
family of molecular sieves. MCM-41 was synthesised by adding catapal aluminium, 
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tetramethylammonium silicate and precipitated silica (HiSil) to a solution of 
hexadecyltrimethylammonium, which was then autoclaved at 150 
o
C for 48 h 
(Kresge et al., 1992). MCM-41 has a well ordered, stable, hexagonal, unidirectional 
mesopore network. It has a large specific surface area that ranges from 800 – 1000 
m
2
/g, mesopore volumes from 0.5 – 1 .5 cm3/g, and mesopore sizes ranging from 1.5 
– 10 nm (Kresge et al., 1992).   
MCM-48 is a modification of MCM-41 where the mesopores are arranged in a cubic 
instead of hexagonal array (Fig.1.1) (Kim et al., 1998). It has been reported that a 
cubic mesopore array would increase molecular accessibility and transport 
(Izquierdo-Barba et al., 2005).              
                                                                                                                                                                                                                                                                                          
 
Figure 1.1: Field emission SEM image for MCM-48 synthesised at 413 K (Kim et 
al., 1998). 
 
The Santa Barbara Amorphous type mesoporous silica (SBA-15) was developed by 
researchers at the University of California, Santa Barbara in 1998. Using an 
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amphiphilic block co-polymer (Pluronic P123) dissolved in acidic aqueous 
conditions (pH 1) and tetraethyl orthosilicate (TEOS) as the silica source, Zhao and 
co-workers were able to produce a hexagonal mesopore structure with thick 
mesopore walls (3.1 – 6.4 nm) (Zhao et al., 1998). These mesopore walls are thicker 
than those of MCM-41 and ensure SBA-15 has higher hydrothermal stability 
compared to MCM-41 (Fulvio et al., 2005). SBA-15 has a large surface area (> 600 
m
2
/g) and mesopore volume (> 0.50 cm
3
/g) and a well ordered, stable, unidirectional 
mesopore network connected by micropores (Fulvio et al., 2005, Zhao et al., 1998). 
The ordered hexagonal pore array of SBA-15 can be seen below (Fig.1.2).  
 
 
Figure 1.2: TEM images of calcined hexagonal SBA-15 mesoporous silica with 
different average mesopore sizes (A) 60 Å, (B) 89 Å (Zhao et al., 1998).  
 
The mesopore sizes of SBA-15 tend to be larger than MCM-41 (Galarneau et al., 
2007); this property should facilitate faster release from SBA-15 than MCM-41 as it 
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has been previously reported that faster drug release is obtained from larger 
mesopore sizes (Horcajada et al., 2004). 
Researchers in Korea developed the Korea Advanced Institute of Science and 
Technology (KIT) range of mesoporous silicas. KIT-1 was synthesised by an 
electrostatic templating route using sodium silicate, hexadecyltrimethylammonium 
chloride and ethylenediaminetetraacetic acid tetrasodium salt. The silicate was 
hydrothermally polymerised at 97 
o
C (Ryoo et al., 1996). These mesoporous silicas 
contained short worm-like mesoporous channels, connected in a 3-directional, 
disordered manner through many branches. There was no evidence of any hexagonal 
structure in the TEM images of KIT-1. It was reported that the thermal and 
hydrothermal stabilities of KIT-1 were higher than MCM-41 (Ryoo et al., 1996). The 
disordered nature of KIT-1 mesoporous silica can be seen below (Fig.1.3).  
 
 
Figure 1.3: TEM of disordered molecular sieve, KIT-1 (Ryoo et al., 1996). 
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Folded sheet mesoporous silica (FSM-16) was first synthesised in the 1990’s with 
specific surface areas from 680 – 1000 m2/g, mesopore volumes from 0.28 – 0.83 
cm
3
/g and mesopore sizes up to 4 nm, depending on the surfactant chain length used 
in the synthesis step. It can be prepared by the intercalation of sodium silicate 
(Kanemite) followed by calcination (Inagaki et al., 1996, Tozuka et al., 2005). FSM-
16 has a highly uniform, mesopore structure with honeycomb one-dimensional 
straight channels (Inaki et al., 2000, Nishiwaki et al., 2009).   
Researchers at the Technische Universiteit Delft, Holland developed the TUD-1 
range of mesoporous materials. The TUD-1 materials were prepared with a range of 
surface areas (400 – 1000 m2/g), mesopore volumes (0.5 – 1.7 cm3/g) and tuneable 
mesopore diameters depending on the heating rate employed during hydrothermal 
treatment. The mesopore structure is described by a  foam-like network, with random 
connections between the mesopores (Fig.1.4) (Jansen et al., 2001).  
 
 
Figure 1.4: High resolution TEM image of the foam-like mesoporous structure of 
TUD-1 (Jansen et al., 2001). 
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Hollow mesoporous silica spheres (HMS) are another type of mesoporous silica that 
contain a hollow structure, with uniform, well-defined hexagonal and straight 
mesopore channels of about 2 – 3 nm length. The specific surface area of HMS can 
be up to 1000 m
2
/g, with mesopore volumes of 1 cm
3
/g. HMS are synthesised by the 
dissolution of polyvinylpyrrolidone (PVP) and sodium hydroxide in water. 
Cetyltrimethyllammonioum bromide was subsequently added to the solution, 
followed by TEOS. The solution was stirred and autoclaved at 80 
o
C for 48 h, the 
recovered product was then calcined (Zhu et al., 2005a). The spherical nature of 
HMS particles can be clearly observed (Fig.1.5).  
 
 
Figure 1.5: Field emission SEM micrograph of the calcined HMS (Zhu et al., 2005a). 
 
COK-12 is a type of ordered mesoporous silica developed by researchers in 
Katholieke Universiteit de Leuven, Belgium. It was synthesised by dissolving 
Pluronic P123 is an aqueous solution of citric acid and trisodium citrate. The silica 
was manufactured at various temperatures and pH values, increasing the temperature 
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resulted in larger mesopore sizes. The specific surface areas were in the range 429 – 
547 m
2
/g, the mesopore volumes were 0.45 – 0.88 cm3/g with the mesopore sizes 
from 5.8 – 9.4 nm (Figs.1.6&1.7) (Jammaer et al., 2009).  
 
 
Figure 1.6: SEM of COK-12 (Jammaer et al., 2009). 
 
 
 
Chapter 1   Introduction      Introduction 
 
14 | P a g e  
 
 
Figure 1.7: TEM of calcined COK-12 ) with the orientation perpendicular to the 
mesopores (left) and parallel to the mesopores (right) (Jammaer et al., 2009). 
 
1.3 The influence of drug-loading process on drug 
physicochemical properties 
In this section, the influence of drug-loading process on drug physicochemical 
properties will be discussed. There have been many loading methods proposed to 
load drugs onto silica materials. These include physical processes, melting processes, 
various organic solvent processes and alternative processes such as supercritical fluid 
(SCF) technology.  
 
1.3.1 Physical processes  
The simplest physical loading method published involved grinding 1 g of SBA-15 
and 1g ibuprofen in a mortar and pestle for 5 min, the drug remained crystalline post 
grinding (Shen et al., 2010). Another physical method reported in the literature 
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involved blending a mixture of flurbiprofen and FSM-16 in a glass vial for 1 min. 
Once more, the drug remained crystalline post blending and was only weakly 
adsorbed onto the silica surface, despite the range of FSM-16 properties investigated 
(surface areas: 700, 1250 and 1040 m
2
/g and  pore widths: 1.6, 2.16 and 4.5 nm). 
Also prepared were sealed – heated, physical mixtures of flurbiprofen and FSM-16 
which were heated to 100 
o
C for 6 h (Tozuka et al., 2005); this temperature was 
below the melting point of flurbiprofen which was 115 
o
C (Knox et al., 2011). In a 
previous publication, these researchers had reported that the sealed – heated method 
could reduce the crystallinity of drug in a drug – silica physical mixture (Tozuka et 
al., 2003). The drug was amorphous in the systems containing FSM-16 with 
mesopore widths of 2.16 and 4.5 nm but crystalline for the FSM-16 with the smallest 
pore width (1.6 nm) (Tozuka et al., 2005). This work showed the effect of loading 
process and silica properties on loaded drug physicochemical properties.  
There have been interesting reports of physically mixing crystalline compounds with 
mesoporous silica gels where the crystalline compounds subsequently transitioned to 
the amorphous state after storage with the silica gel, when stored in 0% RH 
environment. Qian and Bogner studied the interaction of naphthalene and ibuprofen 
with mesoporous silica gel. They found that crystalline naphthalene stored under 
conditions of 0% RH and 40 
o
C became amorphous after 2 weeks while ibuprofen 
was fully amorphous after 5 weeks. The vapour pressure of naphthalene was 45 Pa at 
40 
o
C while the vapour pressure of ibuprofen was 1.7 x 10
-2
 Pa at 40 
o
C. This 
phenomenon was attributed to compound sublimation through the vapour phase 
followed by adsorption onto the silica (Qian and Bogner, 2011). This amorphisation 
process was not dependent upon silica surface area or mesopore volume. Instead, 
they reported that the surface curvature/mesopore diameter determined the silica 
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amorphisation capacity, with smaller mesopore sizes leading to greater 
amorphisation capacity (Qian et al., 2011). The amorphisation process was reversible 
in the presence of moisture (Qian et al., 2012). This work highlighted that 
compounds with relatively high vapour pressures would readily convert to the 
amorphous phase after physical mixing with mesoporous silica, as long as there was 
no moisture present.  
  
1.3.2 Melt processes  
Melt processes involve the melting of a drug onto the mesoporous silica followed by 
cooling below the drug’s melting point. Mellaerts and co-workers utilised a melt 
method to load ibuprofen and itraconazole onto SBA-15. The mixture was heated 
above each of the drugs melting point for 5 min, vortexed and heated back up above 
the melting point for a further 5 min. The mixtures were then stored under vacuum at 
40 
o
C for 48 h (Mellaerts et al., 2008a). Itraconazole was not successfully loaded into 
the SBA-15 mesopores at any of the drug loads investigated, nor was it 
homogeneously distributed throughout the silica surface and it was still somewhat 
crystalline. Ibuprofen was successfully loaded into the SBA-15 mesopores, was in a 
non-crystalline state and achieved rapid in vitro release (Mellaerts et al., 2008a). 
This work highlighted that the melt method was highly dependent on drug molten 
viscosity for mesopore penetration.  
Another melt method reported was melt-quenching. Here, 50% w/w ibuprofen was 
mixed with SBA-15 and heated above 120 
o
C to melt the drug and subsequently 
quench cooled using liquid nitrogen. In this method some of the drug was located 
outside the SBA-15 mesopores in the crystalline state (Shen et al., 2010). 
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1.3.3 Solvent processes 
Organic solvent drug-loading methods have been extensively reported in the 
literature by several research groups. The first report of mesoporous silica (MCM-
41) for drug delivery was by Vallet-Regi and co-workers in 2001. They prepared a 
solution of ibuprofen in hexane (33 mg/ml) and added MCM-41 to the solution. The 
MCM-41 had a surface area of 1157 m
2
/g and a mean mesopore size of 2.5 nm. 
Loading of drug resulted in a lower surface area of 688 m
2
/g and reduced mean pore 
size of 1.9 nm. The drug-load was 30% w/w and the maximum in vitro drug release 
was 100% after 3 days (Vallet-Regi et al., 2001).    
Charnay and co-workers studied the loading of ibuprofen onto MCM-41 and 
Aerosil
®
 by preparing 2.5 ml solutions of drug in various solvents including 
dimethyl sulphoxide (DMSO), dimethyl acetamide (DMA), dimethyl formamide 
(DMF), ethanol and hexane at a concentration of 65 mg/ml; 0.05g of silica was then 
added to the 2.5 ml solution. Suspensions of silica and drug were stirred for 24 h and 
then filtered to recover the drug-loaded silica. The strongly polar solvents such as 
DMA failed to load any drug onto the either MCM-41 or Aerosil
®
, while DMSO and 
DMF also loaded low amounts of drug (<4.7% w/w). The less polar solvent ethanol 
and the non-polar solvent hexane loaded the greatest quantity of drug onto both 
silicas: hexane loaded 59% w/w onto MCM-41 and 10.4% w/w onto Aerosil
®
 while 
ethanol loaded 18.4% and 4.2% respectively (Charnay et al., 2004). This study 
highlighted very clearly that both the choice of solvent and silica material (porous or 
non-porous) are crucial factors for maximising drug-loading.  
Tozuka and co-workers loaded FSM-16 with flurbiprofen by dissolving the drug in 
ethanol, adding the FSM-16 to the solution, sonicating the suspension for 3 min and 
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then allowing the ethanol to evaporate at room temperature. They reported that the 
drug was deposited in the mesopores in the amorphous form (Tozuka et al., 2005).  
Mellaerts and co-workers loaded ibuprofen and itraconazole onto SBA-15 using 
dichloromethane (DCM) as the solvent. Physical mixtures of 7, 20 and 30% w/w 
drug to SBA-15 were first prepared, to which were added 6 ml of DCM. The 
suspensions were sonicated for 1 min and then agitated for 24 h using a rotary mixer 
at 20 rpm. The solvent was removed by drying at 35 
o
C, the mixtures were then 
vortexed for 20 sec and stored under vacuum for 48 h at 40 
o
C. The authors reported 
that this solvent method preferentially loaded the drug into the SBA-15 mesopores 
because this solvent method resulted in slow drug-loading as the drug had to diffuse 
out of solution and adsorb onto the SBA-15, which allowed the drug molecules to 
rearrange and aggregate themselves in the SBA-15 mesopores and not the 
micropores (Mellaerts et al., 2008a).  
A very interesting solvent based drug-loading method which involved the 
application of spray drying technology was reported by Shen and co-workers. A 100 
ml solution of ibuprofen dissolved in ethanol (10 mg/ml) was stirred with 1 g of 
SBA-15 overnight prior to spray-drying using a BUCHI B-290 spray-dryer with an 
inlet temperature of 81 
o
C, a feed rate of 4 ml/min and outlet temperature of 50 – 55 
o
C. The drug-loads achieved were 25, 50 and 75% w/w, although above 50% w/w 
the drug displayed evidence of crystallinity. At 50% w/w drug, there was no 
evidence of crystallinity while the drug release rate from this sample was 100% after 
20 min (Shen et al., 2010). 
Limnell and co-workers studied the loading of indomethacin onto MCM-41 by a 
solvent method, with different solvent removal processes post loading. In the 
immersion method, a drug – ethanol solution (17 mg/ml) was prepared, to which was 
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added the MCM-41. The suspension was stirred for 1.5 h, vacuum filtered through 
0.45 µm filter with the solid residue subsequently oven dried for 4.5 h at 60 
o
C. In 
the rotavapor method, a drug – ethanol solution (9 mg/ml) was prepared with MCM-
41 added to it; the resulting suspension was shaken for 1.5 h. The solvent was 
evaporated using a Hei-VAP Advantage rotavapor under reduced pressure in a water 
bath set at 45 – 50 oC for 15 min. The recovered powder was subsequently dried at 
room temperature for 5 days. In the fluidized-bed method, MCM-41 was again added 
to a drug – ethanol solution (9 mg/ml) and suspended for 1.5 h. The solvent was 
removed through a MINI-Glatt fluidized bed. The indomethacin load was 
approximately 27% w/w by the rotavapor, 24.4% w/w by the fluidized bed and 1.7% 
by immersion method. Post drug-loading, the drug was mainly in the amorphous 
form. The drug release from the samples prepared by the fluidised bed and rotavapor 
methods was approximately 50% after 60 min, while the release from the immersion 
samples was over 70% after 60 min. It was considered that the drug was not diffused 
deeply into the MCM-41 mesopores in the immersion method, hence the more rapid 
release (Limnell et al., 2011).  
  
1.3.4 Impregnation processes 
Several impregnation processes have been reported in the literature. A solvent 
impregnation process is based on the principle of preparing a concentrated solution 
of drug and adding this solution to the silica, whereas in the solvent method, there is 
a large volume of solvent used and the silica is added to it to form a suspension.  
Charney and co-workers loaded MCM-41 using an impregnation method over 
multiple steps with an  ibuprofen – ethanol solution (65 mg/ml); the rationale was to 
completely fill the mesopores. The solvent was evaporated at 50 
o
C after each 
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impregnation step and there was also washing step to remove any drug from the 
MCM-41 surface after the highest loading. The drug load increased with each step 
from 30 mg of drug per gram of MCM-41 to 1350 mg/g; at the highest drug load 
there was evidence of drug crystallinity ascribed to the presence of drug crystals 
outside the mesopores. After the washing step to remove surface drug, there was no 
evidence of drug crystallinity observed. It was suggested that the drug molecules 
were packed inside the mesopores but not uniformly distributed on the inner surfaces 
because while the mesopore volume was greatly decreased by drug-loading, the 
mesopore size distribution did not dramatically decrease until saturation of the 
mesopores by the drug. In other words, the mesopores had to be filled up before the 
mesopore size was greatly affected. The drug release of the amorphous drug from the 
MCM-41 was rapid (Charnay et al., 2004).  
A commonly reported single step incipient wetness impregnation involves preparing 
a concentrated solution of drug in solvent followed by its dropwise addition to the 
mesoporous silica. Depending on the drug, the wetted silica is stirred with a spatula 
or mortar and pestle. The powder is subsequently dried using air for 24 h and then 
placed under vacuum for 48 h at 40 
o
C (Mellaerts et al., 2010, Mellaerts et al., 2008a, 
Mellaerts et al., 2008b, Van Speybroeck et al., 2011, Van Speybroeck et al., 2010b, 
Van-Speybroeck et al., 2009). Mellaerts and co-workers employed the incipient 
wetness method to preferentially load itraconazole into SBA-15 micropores rather 
than the mesopores. It was suggested that the rapid solvent evaporation encountered 
in the incipient wetness method may have preferentially loaded the drug into the 
SBA-15 micropores, compared to solvent loading. However there was no difference 
in drug release between the impregnation and solvent methods (Mellaerts et al., 
2008a), which could have conclusively proved this point.   
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1.3.5 Supercritical drug-loading processes 
Drug-loading processes employing supercritical fluids (SCF) have recently been 
reported in the literature (Cha et al., 2012, Miura et al., 2010, Sanganwar and Gupta, 
2008). An SCF is a fluid that possesses the properties of the liquid and gaseous state; 
it has  liquid-like density and gas-like viscosity and diffusivity (Pasquali and Bettini, 
2008). Carbon dioxide (CO2) is the most commonly used SCF because it has a low 
critical point (7.4 MPa, 31.2 
o
C), is non-flammable, recyclable, environmentally 
benign and inexpensive (Pasquali and Bettini, 2008). The supercritical region of CO2 
can be seen in the CO2 pressure – temperature diagram (Fig.1.8).  
 
 
Figure 1.8: Pressure – temperature phase diagram of CO2 (Pasquali and Bettini, 
2008).  
 
SCF’s are dense but easily compressible; manipulation of the fluid pressure and 
temperature in the supercritical region can alter the fluid density and hence solvent 
power (Brunner, 1994). Another benefit of applying SCF for drug-loading is that the 
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final product is totally solvent free post fluid evacuation (Bush et al., 2007). 
Additionally, a great many compounds have been reported to be soluble in SC-CO2 
(Lucien and Foster, 2000). One of the first reports of the application of SCF 
technology for drug-loading was by Sanganwar and Gupta who loaded fenofibrate 
onto CAB-O-Sil M-5P
®
 by the application of supercritical CO2 (SC-CO2) under 
processing conditions of (i) 176 bar, 40 
o
C, and (ii) 176 bar, 50 
o
C. By increasing the 
temperature but maintaining constant pressure, the actual volume of CO2 used was 
lowered. The silica was physically separated from the drug as it had been placed in 
porous Whatman filter paper (11 µm pore size). The supercritical conditions were 
maintained for 150 min followed by controlled depressurisation over 4 h in a closed 
system. After SC-CO2 processing, some of the powder was stored under accelerated 
storage conditions of 40 
o
C and 75% RH. While the drug was amorphous after 
processing under SC-CO2 conditions at 40 
o
C there was drug re-crystallisation after 
storage. After processing at 50 
o
C, some drug crystallinity was evident which did not 
increase post storage. The drug release extent was over 90% after 30 min for the 
samples SC-CO2 processed with Aerosil
®
 whereas unprocessed fenofibrate did not 
achieve 100% dissolution until 24 h. Post storage, the release after 30 min of 
fenofibrate loaded after  SC-CO2 processing at 40 
 o
C fell to under 60% from 90% 
while the release after  SC-CO2 processing at 50 
o
C  decreased to 70%
 
(Sanganwar 
and Gupta, 2008).  
Belhadj-Ahmed and co-workers employed a supercritical flow through system where 
the drug, vitamin E acetate was first dissolved in the SC-CO2, with the fluid then 
passed through MCM-41. The processing conditions were 15 MPa, 40 
o
C with a 
flow rate of 500 g/l. There are more variables to be considered in this system; 
pressure, temperature, duration time, SCF flow rate, solute concentration the SCF 
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and its partition coefficient. They found that this system gave similar drug-loading 
(1.14 g drug/1 g MCM-41) in 1 h compared to solvent loading with hexane in 4 h  
(Belhadj-Ahmed et al., 2009).  
 
1.4 The influence of silica properties on drug-loading, 
solid-state form and release 
In this section of the thesis, the influence of the silica material properties on drug 
physicochemical properties such as solid state and release will be discussed. Silica 
particle properties such as particle size and morphology as well as silica surface 
functionalisation are pertinent properties that influence drug physicochemical 
properties and must be discussed. Silica material properties including surface area, 
mesopore volume, size, shape and arrangement are also considered.  
 
1.4.1 Silica particle properties 
Several studies have been reported that silica particle size, shape and morphology 
did not influence drug-loading and release (Chen et al., 2012, Manzano et al., 2008, 
Qu et al., 2006). Manzano and co-workers studied the influence of MCM-41 particle 
morphology on ibuprofen drug delivery. They studied spherical particles which had 
very defined particle sizes of either  490 nm, 615 nm or 770 nm; for comparative 
purposes they also included irregular shaped MCM-41 particles that contained 
particles sized from 300 nm to 10 µm in the sample. The drug load was 25-26% w/w 
for both the irregular and all spherical shaped MCM-41 particles, regardless of the 
particle size. The 770 nm sized spheres had a bigger surface area than the 615 and 
490 nm sized spheres but the same drug load; it will be shown in the following 
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section that drug load is influenced by available surface area. In this work, while the 
surface areas were different, the mean mesopore sizes were very similar at 3.2 nm 
for 490 nm spheres to 3.6 nm for the 770 nm spheres; this similarity of mesopore 
sizes may have contributed to the powders recording similar drug loads. They found 
no difference in drug release between the irregular and spherical shaped MCM-41 
particles, or between the different particle sizes of the spherical particles in simulated 
body fluid (SBF) (Manzano et al., 2008).  
Chen and co-workers prepared mesoporous silica nanoparticles (MSN) with varying 
concentrations of the triblock copolymer pluronic F127. They determined a 
relationship between increasing F127 concentration with decreasing particle length 
and diameter size for rod-shaped particles. At the highest level of F127 concentration 
(0.68 mM) employed in this study, the particles went from rod to spherical shaped. 
They reported that the particle dimensions and morphology (rod-like or sphere-like) 
of the MSNs did not have an impact on the amount of drug loaded. However, the 
impact on drug release was substantial; the spherical-shaped particles had faster drug 
release compared to the rods in simulated body SBF at 37 
o
C. Based on their results, 
it can be seen that the rods had a particle length of approximately 550 nm and a 
diameter of 250 nm; the equivalent particle diameter for the spheres was 200 nm. 
They reported that the difference in particle dimensions (particle length) led to the 
rods having a slower release than the spheres because of the shorter diffusion 
distance in the spheres (Chen et al., 2012).  
Qu and co-workers published work that also showed that drug release from MCM-41 
was faster from silica with a smaller particle size (120 – 250 nm) and spherical 
morphology compared to silica with a larger particle size of 20 µm and rod-like 
morphology (Qu et al., 2006). These studies highlighted silica particle size and to a 
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lesser extent shape (rod or spherical) were important factors to be considered for 
optimum drug release.  
 
1.4.2 Surface area 
Surface area is perhaps the most obvious silica material property to be considered in 
relation to drug-loading. As mentioned in the previous section, Chen and co-workers 
prepared mesoporous silica nanoparticles (MSN) using different concentrations of 
F127, which resulted in a range of MSN differentiated by particle size, morphology 
and specific surface area. They established a clear relationship between the surface 
area and drug content that was independent of particle size and morphology (Chen et 
al., 2012). Qu and co-workers similarly reported that specific surface area was the 
determinant in terms of drug-loading, similarly independent of silica particle size and 
shape (Qu et al., 2006).  
 
1.4.3 Surface chemistry 
Functionalisation of silica with various organic moieties has been reported in many 
papers. Functionalisation has been undertaken primarily to increase the attraction 
between drug and silica with the aim of extended release. Izquierdo-Barba and co-
workers studied the functionalisation of MCM-48 and large pore Ia3d by 
octyltriethoxysilane (C8) and octade-cyltrimethoxysilane (C18) using toluene and 
acetronitrile. Both MCM-48 and large pore Ia3d possessed a cubic mesopore array. 
They reported that the amount of functional groups was solvent dependent; there was 
higher functional group presence on MCM-48 when functionalisation was performed 
with acetronitrile (28%) than toluene (21.8%). The presence of the functional groups 
(C8) led to an almost complete reduction of the MCM-48 surface area and mesopore 
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volume. The large pore Ia3d contained less functional group (C8) than MCM-48, 
which was attributed to affinity differences between the silicas for C8. These affinity 
differences were suggested to be due to different populations of SiOH groups present 
in both silicas after calcination. The functionalised large pore Ia3d still recorded a 
large surface area and mesopore volume reduction. The implications for drug-
loading were profound; the functionalised large pore Ia3d achieved half the drug-
loading of non-functionalised large pore Ia3d because of the very large reduction in 
surface area and mesopore volume. The extent of erythromycin release from the 
functionalised large pore Ia3d was 6 times less that of the non-functionalised large 
pore Ia3d, which highlighted the potential benefits of functionalisation in achieving 
extended drug release from mesoporous silicas (Izquierdo-Barba et al., 2005).  
Song and co-workers described interesting results where they functionalised SBA-15 
with 3-aminopropyl-triethoxysilane (APTES) by 2 different processes. The first 
process was called one-pot synthesis where the SBA-15 was manufactured and 
functionalised in a single step. The APTES was introduced with the TEOS during 
the SBA-15 synthesis procedure. Due to the nature of the one-pot synthesis 
approach, at least 30% of the template surfactant was still present in the SBA-15 
which lowered the amount of functional group that could be added. The second 
process involved manufacturing the SBA-15 first and then carrying out the 
functionalisation post-synthesis, i.e. after calcination. They reported that there was 
no mesopore size reduction observed after the one-pot synthesis approach, which 
suggested that the functional groups were mainly in the mesopores and not surface 
located. After employing the post-synthesis approach, the mesopore size reduced 
from 86 to 78 Å while the surface area decreased from 860 to 479 m
2
/g. The surface 
area reduction was attributed to the disappearance of the micropores present in the 
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SBA-15; this was reflected in the typical mesoporous H1 hysteresis observed in the 
N2 adsorption/desorption isotherm. This behaviour was not observed in the samples 
prepared by the one-pot approach where as the amount of functional group 
increased, the hysteresis loop broadened, which indicated a widening of the 
mesopore size distribution (Song et al., 2005).  
The drug-loading increased as the amount of functional groups increased in the post-
synthesis sample, while drug release rates decreased with the increasing amount of 
functional group. In the one-pot synthesis sample, drug-loading also increased with 
increasing functional groups, except at the highest functional group level where 
drug-load decreased. This decrease at the highest level of functional group was 
considered to be result of the greater level of inaccessible micropores present in this 
particular sample (Song et al., 2005). This work highlighted that the choice of 
functionalisation process has an important bearing on drug-loading and release rates.  
Manzano and co-workers also reported that ibuprofen release was extended from 
amine-functionalised MCM-41 compared to standard non-functionalised MCM-41. 
They also observed a large increase in ibuprofen loaded onto the amine-
functionalised MCM-41 compared to standard MCM-41. In this work, the amine-
functionalised MCM-41 had maintained its mesoporous characteristics (Manzano et 
al., 2008). This work highlighted that silica functionalisation could aid increased 
drug-loading as long as the silica maintained its mesoporous properties post 
functionalisation.  
Moritz and Laniecki also looked at functionalising SBA-15 with APTES as a carrier 
for ketoprofen. They reported that the functionalisation of SBA-15 with APTES 
resulted in the silica material acquiring surface basic properties because the 
aminopropyl groups of the APTES were basic. The drug-loading achieved was 20% 
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w/w, while drug release rate was slower from the functionalised SBA-15 compared 
to the non-functionalised SBA-15 (Moritz and Laniecki, 2012b).  
Guo and co-workers utilised MCM-41 and SBA-15 to improve the dissolution rate 
of naproxen; both silicas were functionalised with APTES. They reported that 
functionalisation decreased the surface areas, mesopore volumes and sizes of both 
silicas; they achieved slightly higher drug content in the non-functionalised silicas. 
Controlled release was observed from the functionalised silicas; for the 
functionalised SBA-15, total release was not achieved until after 900 min while the 
corresponding time for the functionalised MCM-41 was 1800 min. The drug was in 
the amorphous state in the functionalised SBA-15 while in the non-functionalised 
SBA-15 there was still residual crystallinity, which was attributed to the fact that 
non-functionalised SBA-15 had larger mesopore sizes than functionalised SBA-15 
which may have permitted some drug re-crystallisation (Guo et al., 2013).   
 
1.4.4 Mesopore properties 
The mesopore properties of silica materials have a very important impact on drug-
loading and other properties, namely solid state structure and long term stability. 
Numerous studies have looked at the impact of mesopore volume (Charnay et al., 
2004, Heikkila et al., 2007), mesopore size (Aerts et al., 2007, Andersson et al., 
2004, Horcajada et al., 2004, Izquierdo-Barba et al., 2005, Limnell et al., 2011, Qu et 
al., 2006, Tozuka et al., 2005, Ukmar et al., 2011b), mesopore geometry, whether 
unidirectional mesopores or 2-D/3-D (Gao et al., 2012, Heikkila et al., 2007) and 
mesopore morphology (cubic or hexagonal) (Zhu et al., 2005b). Heikkila and co-
workers investigated the impact of mesopore volume on drug-loading by loading 
ibuprofen onto different mesoporous silicas (TUD-1, SBA-15 and MCM-41) by the 
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solvent method. TUD-1 had a mesopore volume of 0.57 cm
3
/g, while SBA-15 had a 
mesopore volume of 1.067 cm
3
/g and MCM-41 a mesopore volume of 0.72 cm
3
/g. 
They reported that the total mesopore volume was the determining factor for drug-
loading and that drug in the mesopores was in the amorphous state (Heikkila et al., 
2007).  Several other studies have reported the ability of mesoporous silica to 
stabilise amorphous drugs inside the mesopores (Shen et al., 2010, Mellaerts et al., 
2010). The importance of the mesopores can also be observed where drug is loaded 
onto a non-porous silica. Sanganwar and Gupta loaded fenofibrate onto Aerosil
®
 by 
SC-CO2 processing;  the drug was not completely amorphous and displayed 
evidence of crystallinity, which was accentuated after 1 month under accelerated 
storage conditions (Sanganwar and Gupta, 2008). 
Mesopore size has an important role to play in long-term drug stability. As 
mentioned earlier, if a drug is loaded into a confined space it cannot re-crystallise as 
long as the confinement space diameter does not exceed the drug molecule diameter 
by a factor of 20 (Rengarajan et al., 2008, Sliwinska-Bartkowiak et al., 2001). 
Horcajada and co-workers probed the influence that mesopore size had on drug-
loading and release using MCM-41 with various mesopore sizes. They reported that 
as the mesopore size decreased, drug-loading and release rate decreased. The 
maximum ibuprofen loaded (34% w/w) into MCM-41 occurred at an average 
mesopore size of 3.6 nm; this also yielded the fastest and highest release rate. They 
postulated that the ibuprofen deposited into the MCM-41 (3.6 nm) mesopores lined 
the mesopore walls, leaving space between the drug molecules for the release media 
to penetrate and liberate the drug molecules. In contrast, when loading ibuprofen into 
MCM-41 which had an average mesopore size of 2.5 nm, the drug content was 11% 
w/w while the release was slower compared to MCM-41 (3.6 nm). The authors 
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hypothesised that the drug molecules loaded into MCM-41 (2.5 nm) were closely 
packed together. They presented evidence using N2 adsorption to support the 
contention that the mesopore volume occupied by ibuprofen loaded in the MCM-41 
(2.5 nm) was higher than that loaded in the MCM-41 (3.6 nm) (Horcajada et al., 
2004). Limnell and co-workers also reported the important influence that mesopore 
size has on drug release rate. They loaded indomethacin onto Syloid which had a 
mean mesopore size of 19 nm and MCM-41 which has a mean mesopore size of 3.4 
nm. They reported that the fastest drug release was obtained from the Syloid due to 
its larger mesopore size (Limnell et al., 2011).  
Gao and co-workers looked into mesopore channel length and morphology; in 
particular they studied bimodal mesoporous silica (BMM) which had short, random 
mesoporous channels and MCM-41, which had long, ordered mesoporous channels. 
The BMM had both small mesopores sized 2.71 nm and large mesopores sized 23.8 
nm, while the MCM-41 had a mean mesopore size of 2.73 nm. They reported that 
the BMM achieved greater drug-loading and faster release than MCM-41 (Gao et al., 
2012).   
Heikkila and co-workers investigated the influence of mesopore morphology in oral 
drug delivery using MCM-41, SBA-15 and TUD-1 which had pore sizes of 2 – 3 nm, 
5 – 12 nm and 2.5 – 20 nm, respectively. They reported that the fastest drug release 
was obtained from the TUD-1 material due to its highly accessible mesopore 
network compared to the unidirectional, uniform hexagonal mesopores of SBA-15 
and MCM-41 (Heikkila et al., 2007). Zhu and co-workers studied the application of 
HMS spheres for hosting drug in comparison to MCM-41. They reported that despite 
the MCM-41 and HMS having similar surface areas, mesopore volumes and 
mesopore sizes, much greater drug could be loaded into the HMS because this silica 
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material contained mesopore channels that ran into a hollow core, whereas the 
MCM-41 had long mesopore channels running throughout (Zhu et al., 2005b). 
 
1.4.5 In vivo studies of silica – based drug delivery systems 
Although, it is now well established that loading poorly water – soluble drugs onto 
mesoporous silicas can lead to greatly enhanced in vitro drug dissolution rates (Cha 
et al., 2012, Sanganwar and Gupta, 2008, Vallet-Regi et al., 2001) it is important to 
investigate how this dissolution rate enhancement affects in vivo oral bioavailability. 
Several studies have been conducted to address the challenge of improving oral 
bioavailability through the application of silica drug delivery systems. Mellaerts and 
co-workers compared the in vivo performance of crystalline itraconazole, 
itraconazole loaded by the solvent method onto SBA-15 and the commercial 
formulation Sporanox
®
 by administering the powders in hard gelatin capsules 
(Capsugel, Belgium) to both dog and rabbit models. Crystalline itraconazole and its 
metabolite hydroxyitraconazole did not enter systemic circulation in the dog model. 
The SBA-15 formulation and Sporanox
®
 showed broadly similar results in terms of 
itraconazole and hydroxyitraconazole in both animal models. This result showed that 
the SBA-15 formulation was equivalent to the commercial formulation and 
highlighted the potential of SBA-15 to improve oral bioavailability (Mellaerts et al., 
2008b). 
Van Speybroeck and co-workers assessed the in vivo performance of glibenclamide 
– SBA-15 formulation against the commercial product Daonil®. The weakly acidic, 
drug was loaded onto the SBA-15 using the incipient wetness (solvent impregnation) 
method. The researchers hypothesised that significant precipitation in the stomach 
would lower the amount of drug absorbed in the small intestine; however, if the 
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precipitation was avoided there would be enhanced in vivo performance. Dosing was 
by hard gelatin capsules (Capsugel, Belgium) administered to male wistar rats. They 
showed that the drug did not dissolve in SGF (pH 1.2), whereas there was rapid 
release in FaSSIF (pH 6.8). They reported that the glibenclamide – SBA-15 
formulation resulted in a much larger plasma concentration compared to Daonil
®
. 
The results highlighted the potential of SBA-15 to increase drug oral bioavailability 
and showed the impact of pH and surface charge on the in vitro and in vivo release of 
weakly acidic drugs from SBA-15 (Van Speybroeck et al., 2011).  
In another study, Van Speybroeck and co-workers investigated the in vivo 
performance of itraconazole loaded onto SBA-15, which was physically mixed with 
precipitation inhibitors, either hydroxypropylmethylcellulose (HPMC) or 
hydroxypropylmethyl acetate succinate (HPMCAS). Hard gelatin capsules 
(Capsugel, Belgium) containing crystalline itraconazole, drug loaded SBA-15 with 
precipitation inhibitor and the commercial product Sporanox
®
 were administered to 
male wistar rats. They reported that HPMC aided the absorption of the drug, the 
extent was 60% greater compared to drug-loaded SBA-15 only, whereas the 
HPMCAS did not enhance drug absorption as it did not dissolve in the stomach (Van 
Speybroeck et al., 2010b).  
In an additional study, Van Speybroeck and co-workers evaluated the impact that the 
rate and extent of fenofibrate release had on its in vivo absorption. Mesoporous 
silicas with different mesopore sizes of 2.7, 4.4 and 7.3 nm were employed to control 
the in vitro drug release. As previously mentioned, decreasing the mesopore size can 
slow the in vitro release rate; this was also observed in this study. In FaSSIF, they 
reported that the degree and duration of fenofibrate supersaturation increased with 
decreasing mesopore size.  The formulations were administered to male wistar rats 
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as hard gelatin capsules (Capsugel, Belgium). They reported that slowing the 
fenofibrate release rate by applying silica with a small mesopore size (2.7 nm), 
allowed for a greater duration of drug supersaturation and enhanced the in vivo 
absorption (Van Speybroeck et al., 2010a).  
Miura and co-workers studied the oral absorption of K-832 loaded onto Sylysia 350 
in a beagle dog model. They dosed the dogs with silica-drug formulations prepared 
by a solvent method and SC-CO2 loading, where supercritical conditions of 18 MPa 
and 60 
o
C were maintained for 5 h, followed by controlled depressurisation. The 
drug in these formulations was mainly amorphous, however there was a slight 
melting endotherm observed in the sample prepared by SC-CO2. They reported that 
the SC-CO2 prepared sample achieved a higher maximum drug plasma concentration 
(Cmax) of 0.40 µg/ml, than that prepared by the solvent method which resulted in a 
Cmax of 0.25 µg/ml. Both formulations outperformed crystalline K-832 by a factor 13 
and 8 respectively in terms of the Cmax (Miura et al., 2010).  
Kiekens and co-workers investigated the potential of ordered mesoporous silica 
(OMS) to improve the oral bioavailability of ezetimibe using a dog model. Ezetimibe 
was loaded onto the OMS (COK-12) using the incipient wetness solvent 
impregnation method and was in a non-crystallise form. They compared the 
commercial product, Ezetrol
®
 which is available as a tablet containing 10 mg 
ezetimibe against the OMS tablet formulations containing either 10 or 5 mg 
ezetimibe and an OMS capsule formulation containing 5 mg ezetimibe. They 
reported that the 5 mg OMS capsule resulted in a higher plasma profile compared to 
the Ezetrol
®
 tablet. The 5 mg OMS capsule allowed the drug to enter into systemic 
circulation more quickly compared to the 10 mg Ezetrol tablet; in fact ezetimibe 
absorption from the 5 mg OMS capsule was double the amount from the Ezetrol
®
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tablet (Kiekens et al., 2012). However, it was also reported that the plasma 
concentrations of drug from the OMS tablet formulations were lower than expected, 
based on the in vitro data. It was seen that in vitro the OMS tablet formulations 
initially released more drug than the Ezetrol
® 
tablet over first 15 min but after 120 
min, some of the drug released from the OMS tablets had re-crystallised out of 
solution. These results showed the great potential of utilising mesoporous silicas for 
oral bioavailability enhancement, but also that the in vitro release performance may 
not always reflect the in vivo performance.  
Cha and co-workers described the effect on fenofibrate oral bioavailability of 
processing the drug with Neusilin UFL2 using hot-melt, solvent and SC-CO2 loading 
in male Sprague Dawley rats. They reported that the drug entered into the mesopores 
when loaded using SC-CO2, but was not in the pores after the hot-melt method 
because of fenofibrate’s high molten viscosity. Some of the fenofibrate loaded by the 
solvent (4.21% (±1.09)) and hot-melt (9.43% (±2.11) methods had retained 
crystallinity while the fenofibrate loaded by the SC-CO2 was amorphous. They 
reported that the drug – silica composite prepared by SC-CO2 loading achieved faster 
in vitro release kinetics compared to the commercial product Lipidi Supra
®
, however 
both formulations recorded similar drug serum concentrations, in vivo profiles and 
Cmax values, 92.88 (±7.05) µg/ml and 89.60 (±12.02) µg/ml for the SC-CO2 and 
commercial formulations, respectively (Cha et al., 2012).    
A human trial has also been reported where drug-loaded mesoporous silica was 
successfully used to significantly increase the rate and extent of absorption of 
fenofibrate into systemic circulation compared to the commercial product Lipantyl
®
 
micro (67 mg). There was a 54% increase in systemic exposure of fenofibrate’s 
metabolite, fenofibric acid and a 77% increase in the dose-normalised fenofibric acid 
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plasma peak concentration after administration of the mesoporous silica formulation. 
The subjects were dosed in a random order with 33.5 mg of a fenofibrate – 
mesoporous silica formulation with 200 ml of water under fasted conditions. After a 
7 day washout period the subjects were dosed orally with a 67 mg Lipantyl
®
 micro 
formulation and 200 ml water, also under fasted conditions (Verheyden et al., 2012). 
A summary of the in vivo research involving mesoporous silica in terms of how the 
drug is loaded, the in vivo model and dosage size and form is shown Table 1.3.  
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Table 1.3: Summary of the in vivo research involving silica materials for enhanced drug dissolution and oral bioavailability.   
Mesoporous silica Drug Dosage Loading process Delivery platform Animal model Reference 
SBA-15 Itraconazole ~2 mg/kg Solvent Hard gelatin capsule NZ white rabbit (Mellaerts et al., 2008b) 
SBA-15 Itraconazole ~2 mg/kg Solvent Hard gelatin capsule Beagle dog (Mellaerts et al., 2008b) 
SBA-15 Fenofibrate 2.63 mg/kg Impregnation Hard gelatin capsule Male wistar rat (Van Speybroeck et al., 2010a) 
SBA-15 Itraconazole 2.63 mg/kg Impregnation Hard gelatin capsule Male wistar rat (Van Speybroeck et al., 2010b) 
Sylysia K-832 10 mg/kg SC-CO2 flow through Oral suspension Dog (Miura et al., 2010) 
SBA-15 Glibenclamide 2.29 mg/kg Impregnation Hard gelatin capsule Male wistar rat (Van Speybroeck et al., 2011) 
COK-12 Ezetimibe 0.5 – 1 mg/kg Impregnation Tablet / capsule Dog (Kiekens et al., 2012) 
Neusilin UFL2 Fenofibrate 50 mg/kg SC-CO2 Oral suspension Male Sprague Dawley rat (Cha et al., 2012) 
Mesoporous silica Fenofibrate 33mg Impregnation Tablet Human (Verheyden et al., 2012) 
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1.4.6 Summary 
Silica materials, in particular ordered mesoporous materials have demonstrated 
excellent properties for the enhancement of drug dissolution and oral bioavailability 
of a variety poorly water – soluble BCS Class II compounds such as fenofibrate, 
ibuprofen and itraconazole. The key silica parameters that influence drug-loading 
and release are the surface area, mesopore volume, size and geometry. It is important 
to also recognise that the silica particle size and morphology are important factors to 
be considered. The greater the silica surface area, the more drug that can be hosted 
by the silica material. If the silica material is porous, the porosity allows stabilisation 
of the drug in the amorphous or non-crystalline form due to the restricted nature of 
the drug inside the mesopores, as long as the mesopore diameter is not greater than 
20 times the drug molecule width (Sliwinska-Bartkowiak et al., 2001). The mesopore 
diameter also influences drug release rate; larger mesopore sizes encourage faster 
drug release compared to smaller mesopore sizes. Silica particle size also influences 
drug release rate; smaller silica particle sizes allow for faster drug release than larger 
particle sizes, where there are unidirectional mesopores running through the particle.  
The oral bioavailability enhancement of poorly water – soluble drug from loading 
onto mesoporous silica has been demonstrated in different in vivo models, including 
dog, rat and rabbit. Based on the research, the application of mesoporous silica 
creates a supersaturation of the drug in the GI tract, leading to enhanced absorption 
in the upper intestinal region. However, there is evidence that precipitation inhibitors 
like HPMC would be beneficial to ensure maximum absorption.  
Excitingly, a recent human trial involving a fenofibrate – mesoporous silica 
formulation has shown promising results in comparison to an currently marketed oral 
formulation, Lipantyl
®
 micro (67 mg) (Verheyden et al., 2012). This report serves to 
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highlight the strong potential of mesoporous silica for oral drug delivery and rapid 
strides taken in this field in the last number of years.  
 
1.5 Fenofibrate 
The model poorly water-soluble drug chosen for this research was fenofibrate 
(C20H21ClO4), chemical name isopropyl 2-[4-(4-chlorobenzoyl)-phenoxy]-2-
methylpropionate (Kemprotec Ltd, UK). It is a white crystalline powder, has a 
melting point in the region of 79 – 82 oC and a molecular weight (MW) of 360.84 
kmol/kg. The molecular structure of fenofibrate is shown here (Fig.1.9).  
 
 
Figure 1.9: Molecular structure of fenofibrate (Knox et al., 2011).  
 
It is a non-ionizable compound, therefore it is not affected by changes in pH (Jamzad 
and Fassihi, 2006). Fenofibrate does not have strong intermolecular bonds such as 
hydrogen bonding (Heinz et al., 2009). It does not have hydrogen-donor groups and 
has only 2 hydrogen-acceptor groups (carbonyl groups) (Van Speybroeck et al., 
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2010a). It is practically insoluble in water and is a neutral highly lipophilic drug (log 
P = 5.3) (Huang et al., 2009, Van Speybroeck et al., 2010a, Jamzad and Fassihi, 
2006). Fenofibrate is considered to be a BCS Class II drug; it is very lipophilic but 
hydrophobic (Amidon et al., 1995). The oral bioavailability of fenofibrate is 
dependent upon its dissolution rate in the GI tract; therefore increasing its dissolution 
rate can potentially increase its bioavailability. Historically, fenofibrate has had very 
low bioavailability of its active metabolic fenofibric acid, when administered on an 
empty stomach (Guivarc'h et al., 2004). In fact, it has been advised that fenofibrate 
should be administered with meals (Guivarc'h et al., 2004). Fenofibrate has been the 
subject of many different processing and formulation approaches to improve its 
bioavailability, such as micronisation and wet milling (Juenemann et al., 2011), co-
grinding and coating onto hydrophilic matrices such PVP (Vogt et al., 2008), loading 
onto high surface area carriers (silica substrates) (Sanganwar and Gupta, 2008), solid 
dispersion and emulsions (Huang et al., 2009). An early fenofibrate formulation 
Lipanthyl
(R)
, was a 200 mg tablet which contained coarse fenofibrate and exhibited 
high inter-individual variability in its plasma profiles, this formulation was 
recommended to be taken with food (Juenemann et al., 2011). Some data has been 
published in literature which showed that 84% of orally administered fenofibrate was 
recovered in the urine and faeces (Weil et al., 1990). Most of the fenofibrate 
recovered in the faeces was unchanged fenofibrate while that recovered in the urine 
was fenofibric acid, the active metabolite of fenofibrate. A new formulation of 
micronised fenofibrate, Lipidil – Ter(R), was introduced in 2000 which had a dose of 
160 mg and less inter-individual variability (Juenemann et al., 2011). Even more 
recently, nanosized fenofibrate formulations (500 nm) such as Tricor
(R)
 and Lipidil – 
145 ONE
(R)
,  have been developed that have further increased oral bioavailability as 
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evidenced by the reduced dosage amount of 145 mg and which removed the effect of 
food on the bioavailability (Juenemann et al., 2011).  
 
1.6 Objectives of thesis 
The objectives of this research were to: 
 
 Enhance fenofibrate release through the application of the high surface area 
carrier,  SBA-15, 
 Investigate various processing methods to load fenofibrate onto SBA-15 and 
determine what impact the loading process had on fenofibrate loading and 
release from SBA-15 (chapter 4),  
 Investigate how SC-CO2 processing conditions influenced drug-loading and 
release from fenofibrate – SBA-15 systems, 
 Investigate physicochemical factors influencing drug release from fenofibrate 
– SBA-15 systems.  
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2 Materials and Methods 
In this chapter, the materials used in this thesis, the experiments performed across 
the various chapters and the subsequent analytical techniques employed will be 
presented.  
 
2.1 Materials 
The materials, suppliers and their application in this thesis are listed in Table 2.1 
below.  
 
Table 2.1: List of materials with supplier information and application in this work. 
Material Formula Supplier Application 
Fenofibrate C20H21ClO4 Kemprotec Ltd., UK Drug 
Mesoporous silica (SBA-15) SiO2 Glantreo Ltd. Ireland Carrier 
Phencyclidine 
hydrochloride (P123) 
C17H25N.HCl 
Sigma-Aldrich Ltd., Ireland SBA-15 synthesis 
Tetraethyl orthosilicate 
(TEOS) 
Si(OC2H5)4 Sigma-Aldrich Ltd., Ireland SBA-15 synthesis 
Carbon dioxide CO2 Irish Oxygen Ltd., Ireland Drug-loading 
Methylene chloride (DCM) 
CH2Cl2 
Sigma-Aldrich Ltd., Ireland Drug-loading 
Hydrochloric acid, 37% HCl Sigma-Aldrich Ltd., Ireland Dissolution media 
Sodium dodecyl sulphate 
(SDS) 
C12H25SO4Na Sigma-Aldrich Ltd., Ireland Dissolution media 
Deionised water H2O UCC, Ireland Dissolution media 
HPLC grade acetronitrile C2H3N Sigma-Aldrich Ltd., Ireland 
HPLC mobile 
phase 
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HPLC grade water H2O Sigma-Aldrich Ltd., Ireland 
HPLC mobile 
phase 
Potassium bromide KBr Sigma-Aldrich Ltd., Ireland FT-IR analysis 
Methanol CH3OH Sigma-Aldrich Ltd., Ireland Solvent 
 
2.2 Preparation of SBA-15 
SBA-15 was synthesised according to the method outlined in the literature (Zhao et 
al., 1998). Briefly, 200 g of tri-block polymer (P123) was dissolved in 1.6 M HCl 
solution. The solution was heated to 40 
o
C to completely dissolve the polymer, after 
which 607 ml of 98% TEOS was added to the solution. The solution was stirred for 
24 h at 40 
o
C and dried for a further 96 h at 60 
o
C. The SBA-15 was recovered by 
filtration, washed with deionised water to remove any remaining amounts of ethanol 
and HCl, prior to calcination in an Ashing furnace (Carbolite Ltd., UK), which was 
set to 550 
o
C for 14 h to remove the polymer template.  
 
2.3 Chapter 4: Preparation of fenofibrate – SBA-15 
systems 
Drug – silica samples were prepared with a ratio of 1 mg drug per 3 m2 mesoporous 
silica surface area. Approximately 400 mg of drug was combined with 2 g 
mesoporous silica and processed according to the methods detailed below. All 
samples were prepared in triplicate. 
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2.3.1 Physical Mixing  
Drug – mesoporous silica physical mixes were prepared by placing the fenofibrate 
and mesoporous silica inside 50 ml capped plastic containers (Sarstedt AG, 
Germany) and blending for 30 min at 100 revolutions per minute (rpm) using an 
AR402 Erweka blender (Erweka GmbH, Germany).  
 
2.3.2 Melt method 
The melt method involved heating the drug above its melting point (> 80 
o
C) and 
relied on its molten viscosity to distribute the drug on the mesoporous silica surface 
and into the mesopores. The drug was manually combined with the mesoporous 
silica to increase the homogeneity of drug distribution. The sample was maintained 
above 80 
o
C for 24 h using an E-series binder oven (Erweka GmbH, Germany) and 
thereafter cooled to ambient temperature.  
 
2.3.3 Solvent impregnation 
Samples were prepared according to the method reported by Mellaerts and co-
workers (Mellaerts et al., 2008a). Approximately 8 ml of a concentrated solution of 
fenofibrate (50 mg/ml) in DCM was added dropwise to the mesoporous silica, after 
each addition the powder was intensively ground with a pestle. Thereafter, the 
sample was dried at 40 
o
C for 48 h under vacuum (100 Pa).  
 
2.3.4 Liquid CO2 processing 
The drug and mesoporous silica were combined in a high-pressure reactor (BC 316), 
(High Pressure Equipment Company, USA) and stirred using a magnetic stirrer. The 
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reactor cell was filled with liquid CO2 directly from the CO2 dispensing cylinder up 
to an initial pressure of 5.5 MPa. The cell was then heated to 25 
o
C using heating 
tape and maintained at this temperature for the duration of the experiment using a 
temperature monitor (Horst GmbH, Germany). A high pressure pump (D Series 
Syringe Pump 260D, Teledyne ISCO, USA) was used to pump additional CO2 into 
the cell to reach the final pressure of 27.58 MPa. The pressure was monitored with a 
pressure gauge. At the end of the experiment the cell was rapidly depressurised by 
venting the CO2.  
 
2.3.5 SC-CO2 processing 
The supercritical processing method followed the exact same procedure as the liquid 
CO2 process, except that the experimental temperature was 40 
o
C.  
 
2.4 Chapter 5: Preparation of fenofibrate – SBA-15 
systems 
2.4.1 Investigating SC-CO2 processing pressures and duration 
times 
A 3
2
 factorial design was used to determine the optimum SC-CO2 processing 
pressure (13.79, 27.58, 41.37 MPa) and time duration (4, 12, 24 h) for loading of 
SBA-15 with fenofibrate. In all these experiments, the temperature was maintained 
at 40 
o
C. For each run, a constant drug to silica ratio of 1 mg of fenofibrate for every 
3 m
2
 surface area of SBA-15 was maintained. The complete list of the design of 
experiments is shown in Table 2.2.   
Chapter 2  Materials and Methods 
 
45 | P a g e  
 
Table 2.2: Design of experiments for SC-CO2 pressure and time optimisation. 
Run No. Pressure (MPa) Time (h) Blocks 
1 13.79 12 1 
2 13.79 4 1 
3 41.37 24 1 
4 27.58 12 1 
5 27.58 24 1 
6 41.37 12 1 
7 13.79 24 1 
8 41.37 4 1 
9 27.58 4 1 
10 27.58 24 2 
11 27.58 4 2 
12 41.37 4 2 
13 13.79 24 2 
14 41.37 24 2 
15 13.79 12 2 
16 13.79 4 2 
17 27.58 12 2 
18 41.37 12 2 
19 27.58 24 3 
20 13.79 24 3 
21 41.37 4 3 
22 13.79 4 3 
23 27.58 12 3 
24 27.58 4 3 
25 41.37 12 3 
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26 41.37 24 3 
27 13.79 12 3 
 
2.4.2 The effect of drug – silica ratios on drug physicochemical 
properties 
The influence of increasing the amount of fenofibrate to silica surface area was 
investigated at (i) 1 mg to 3 m
2
, (ii) 1 mg to 1.24 m
2
 and (iii) 1 mg to 0.82 m
2
 to 
determine what effect this had on drug-loading efficiency, solid state and release. 
These experiments were conducted at a SC-CO2 processing pressure of 27.58 MPa, 
for 12 h time duration with a temperature of 40 
o
C.  
 
2.4.3 Methods of drug – silica combination 
Normally, the drug and silica were placed together in the reactor and exposed to SC-
CO2 conditions, under the influence of a magnetic stirring bar (‘mix method’). In an 
effort to determine the impact of directly combining the drug and silica, an 
alternative method termed the ‘bag method’ was also investigated The SBA-15 was 
placed in a porous muslin bag which was placed at the top of the high-pressure cell, 
this had the effect of physically separating the SBA-15 from the fenofibrate, which 
was placed at the bottom of the cell. The porous bag allowed the SC-CO2 and 
solubilised drug to permeate into the bag during processing. A SC-CO2 pressure of 
27.58 MPa and 12 h duration was employed for both loading methods, also at 40 
o
C.  
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2.4.4 Effect of SC-CO2 depressurisation rate 
The effect of depressurisation rate was investigated to determine its impact on drug – 
SBA-15 physicochemical properties. The depressurisation step was controlled by 
allowing enough CO2 gas to escape in order to reduce the pressure by 0.69 MPa 
every minute. SC-CO2 conditions of 27.58 MPa, 12 h duration time and temperature 
of 40 
o
C were employed with a drug – silica ratio of 1 mg to 3 m2 in the ‘mix 
method’.  
 
2.5 Chapter 6: Preparation of fenofibrate – SBA-15 
systems 
2.5.1 Multiple step drug-loading 
It was desired to increase drug-loading efficiency without compromising drug 
release by loading the drug with a multiple step drug-loading approach. Details of 
preparation of each of these drug-silica samples are given below. The SC-CO2 
conditions were 27.58 MPa, 12 h and 40 
o
C with rapid depressurisation. The drug 
and silica were combined with the ‘mix method’.  
 
Drug – silica ratio of 1 mg – 1.24 m2 
This drug – silica ratio was prepared in two SC-CO2 processing steps. Step 1 
involved taking 2 g of SBA-15 and the addition of sufficient fenofibrate to produce 
the initial ratio of 1 mg: 3 m
2
. This mixture was then SC-CO2 processed and the 
powder recovered. The drug content analysis (% w/w) of recovered powder from 
step 1 was determined and used to calculate how much extra drug was required for 
step 2 to achieve a drug – silica ratio of 1 mg – 1.24 m2. 1.5 g of mixture from step 1 
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was taken forward for step 2, where the drug – silica ratio of 1 mg: 1.24 m2 would be 
prepared.  
 
Drug – silica ratio of 1 mg – 0.82 m2 
This drug – silica ratio was prepared in three SC-CO2 processing steps.  Step 1 
involved taking 2 g of SBA-15 and adding sufficient fenofibrate to produce the 
initial ratio of 1 mg: 3 m
2
. This mixture was then SC-CO2 processed and the powder 
recovered. 1.5 g of the step 1 mixture was taken forward for step 2, in order to 
prepare the drug – silica ratio of 1 mg: 1.24 m2. The rest of the recovered powder 
from step 1 was used for drug content analysis (% w/w), which was needed to 
calculate the extra drug required for step 2. After step 2 SC-CO2 processing, 
approximately 0.78 g of the step 2 mixture was taken forward for processing in step 
3, with enough drug added to produce the theoretical drug – silica ratio of 1 mg: 0.82 
m
2
 . As with step 1, a portion of the sample processed in step 2 was retained for drug 
content (% w/w) analysis to determine the extra drug required for step 3. After 
processing the samples were recovered and analysed. The actual amounts of silica 
and fenofibrate employed for each of the steps is shown here, Table 2.3.  
 
Table 2.3: Formulations employed at each step of multiple loading approach. 
Number of Steps Drug – silica ratio Mass of SBA-15 (g) Mass of fenofibrate (mg) 
1 1 mg : 3 m
2 
2.00 545.00 
2 1 mg : 1.24 m
2
 1.22 – 1.27 806.90 – 834.02 
3 1 mg : 0.82 m
2
 0.49 – 0.5 484.12 – 497.87 
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2.5.2 Maximum drug-loading based on SBA-15 mesopore 
volume and drug true density 
In chapter 6 it was desired to load as much drug onto the silica as possible without 
compromising the subsequent drug release rate. To that end, the maximum mass of 
drug that could be theoretically hosted within the silica mesopores was calculated 
based on the measurement of SBA-15 mesopore volume and the measured drug 
density (determined by helium pycnometry section 2.6.3.) according to Eq. 2.1. 
 
Equation 2.1: drugSBASBA PVM   1515(g)  mesoporesin    drug  Maximum  
 
Where MSBA-15 is the mass of SBA-15 (g), PVSBA-15 is the available SBA-15 mesopore 
volume (cm
3/g) and ρdrug the true density of fenofibrate (g/cm
3
).   
 
The % theoretical mesopore fill was then calculated according to Eq. 2.2, 
 
Equation 2.2: 100%)
(g) mesoporesin  drug Maximum
(g) loaded be  todrug of Mass
 (= fill  Mesopore %   
 
Where the numerator refers to the mass of drug actually loaded and the denominator 
refers to maximum mass of drug that could be hosted by the SBA-15 mesopores 
based on Eq.2.1.  
 
Samples were prepared that contained (1) less than, (2) equal to and (3) more than 
the maximum fenofibrate that could be loaded into the available SBA-15 mesopores. 
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These samples were termed the standard, maximum and excess samples and further 
details on each the preparation of each are provided below.  
 
‘Standard sample’ 
The ‘standard sample’ was based on the drug – silica ratio of 1 mg fenofibrate to 3 
m
2
 SBA-15 surface area; this ratio was the drug – silica ratio used throughout this 
thesis. The ‘standard sample’ was processed with SC-CO2 conditions of processing 
pressure, 27.58 MPa, with 12 h time duration and temperature of 40 
o
C. 
 
‘Maximum sample’ 
Based on Eq. 2.1, the ‘maximum sample’ contained enough drug to theoretically fill 
99% of the available SBA-15 mesopore volume. The ‘maximum sample’ was 
processed with SC-CO2 conditions at a pressure of 27.58 MPa, for 12 h duration and 
at a temperature of 40 
o
C. 
 
‘Excess sample’ 
The ‘excess sample’ contained enough fenofibrate to theoretically fill the available 
SBA-15 mesopore volume 2.86 times. This sample was prepared by taking 2.00 g of 
the ‘maximum sample’ and carrying out a second SC-CO2 processing step to load 
extra drug on to the sample, per the multiple step drug-loading procedure outlined 
above. The ‘excess sample’ was processed under the SC-CO2 conditions at a 
pressure of 27.58 MPa, for 12 h duration and at a temperature of 40 
o
C. The % 
mesopore fill, actual amounts of silica and fenofibrate and % drug (w/w) for each of 
the samples is shown here, Table 2.4.  
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Table 2.4: % mesopore fill, mass of SBA-15 and fenofibrate and % drug (w/w) of 
the standard, maximum and excess samples.  
Sample % Mesopore fill SBA-15 (g) Fenofibrate (mg)  % Drug (w/w) 
Standard 32.50
 
2.00 545.00 21.41 
Maximum 99.00 2.00 1700 45.95 
Excess 286.00 1.08 2619 70.78 
 
2.6 Characterisation techniques 
2.6.1 Scanning electron microscopy / energy dispersive X-ray 
spectroscopy 
Scanning electron microscopy (SEM) was used to obtain images of the mesoporous 
silica and fenofibrate. Using a JSM-5510 SEM, (Jeol, UK), with heated tungsten as 
the electron beam source, the morphology and particle size of the samples was 
acquired. The voltage was constant at 5 kV. Samples were gold coated in SEM gold 
coater (Jeol, UK) prior to analysis to prevent charging of the samples by the SEM 
electron beam. A coating time of approximately 45 seconds was used to deposit a 
thin layer onto the samples.  
Environmental scanning electron microscopy (SEM) and energy dispersive X-ray 
spectroscopy (EDX) were performed with a Hitachi VP-SEM S-37900N (Hitachi 
High-Technologies Europe GmbH, Germany) with an Oxford Instruments X –Max 
80 mm
2
 (Oxford Instruments Ltd., United Kingdom). SBA-15 was probed via its 
silicon (Si) atom, while fenofibrate was probed via its chlorine (Cl) atom.  
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2.6.2 Particle size analysis  
The particle size distributions of mesoporous silica and fenofibrate were determined 
using a Retsch AS 200 sieve shaker (Retsch GmbH, Germany). Sieving was 
performed with the amplitude set at 1.5 mm/g for 15 min.   
 
2.6.3 Density testing 
Bulk density was calculated using a SVM 122/222 tapped density tester, (Erweka 
GmbH., Germany) using the procedure as outlined in Section 2.9.15 of the European 
Pharmacopoeia (Ph Eur 5.0). A 100 ml cylinder was filled up to the mark with 
powder of a known mass; it was then possible to calculate the powders bulk density. 
The cylinder was tapped 10, 500 and 1250 times which compacted the powder by 
removing air from voids within the sample. The Hausner ratio (H.R.) was calculated 
according to Eq.2.3 and was used to determine the powder flow characteristics.  
 
Equation 2.3: 
)(V
)(V
 =(H.R.) ratioHausner 
Tapped
Bulk 
ml
ml
 
 
Where )(VBulk ml was the initial bulk volume of the powder and )(V  Tapped ml was the 
final tapped volume of the powder.  
 
Absolute or true density was calculated using a gas pycnometer, AccuPyc II 1340, 
(Micromeritics, USA), with helium, 99.995% purity, supplied in the pressure range 
19 – 23 psig. All samples analysed were prepared in an E-Series binder oven 
(Erweka GmbH., Germany) at 50 
o
C for 24 h prior to analysis. During the analyses, 
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the samples were placed in a sample cup that had a volume of 11.7180 cm
3
. The 
instrument performed 10 cycles with 10 purges each throughout the analysis.   
 
2.6.4 Contact angle 
Contact angle measurements were performed using a PG-X Measuring Head under 
dynamic mode (Fibro System AB, Sweden). Solid discs of the powder were prepared 
by placing the powder inside a punch and dye apparatus (Specac Ltd., UK) that was 
subsequently compacted in a press (Specac Ltd., UK) for 5 min under 10 ton 
compression. Afterward, the solid disc was placed under the PG-X Measuring Head 
with a drop of water deposited onto the surface of the solid disc. The PG-X measured 
the contact angle made by this drop of water on the solid surface over 60 s.  
 
2.6.5 Surface area and pore size analysis 
Surface area and pore size analyses by N2 absorption were carried out using a 
Gemini VI Surface Area and Pore Size Analyser, (Micromeritics, USA) with 
nitrogen gas utilised as the adsorbate. The operating pressure of the analysis gas was 
maintained in the range 15 to 18 psig (pounds per square inch gauge). All samples 
analysed were degassed for 24 h at 50 
o
C in a FlowPrep 060 sample degas system, 
(Micromeritics USA) prior to analyses. During analysis, liquid nitrogen was used to 
maintain isothermal conditions (-196 
o
C).The specific surface area was calculated 
according to the Brunauer-Emmett-Teller (BET) mathematical equation (Brunauer et 
al., 1938). The pore volume, pore area and pore width were calculated using the 
Barrett-Joyner-Halenda (BJH) equation (Barrett et al., 1951).  All samples were 
analysed in duplicate. Using the amount of drug present in the sample as calculated 
in TGA studies, it was possible to predict the specific surface area (S.S.A.) and pore 
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volume (P.V.) of the processed fenofibrate-silica samples. Eq.2.4 was the equation 
used to predict the S.S.A:  
 
Equation 2.4:    DrugDrugSBASBA FASSFASS   ...... S.S.A. Predicted 1515  
 
Where F is the fraction of drug and silica in the samples, and S.S.A. is the specific 
surface area (m
2
/g) of each.  
 
Calculation of the predicted P.V. was according to Eq.2.5:  
 
Equation 2.5:  1515. P.V. Predicted   SBASBA FVP  
 
Where F is the fraction of silica in the samples, and P.V. is the SBA-15 pore volume 
area (cm
3
/g).  
 
These equations were based on the assumption that there was no physical or 
chemical interaction between silica and fenofibrate. The percentage difference 
between the theoretical and measured pore volumes (% ΔPV) was calculated 
according to Eq.2.6:  
 
Equation 2.6: 100%P.V) PredictedP.V.)/  measured - P.V. d((Predicte = PV %   
 
The % ΔPV expression was used to determine the location of drug within the silica 
matrix.  
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2.6.6 Thermogravimetric analysis 
Thermogravimetric analysis (TGA) was carried out using a TGA 500, (TA 
Instruments Ltd., UK). Samples in the range 2 to 10 mg were loaded on tared 
platinum pans and heated from ambient temperature to 900 
o
C at a heating rate of 10 
o
C/ min. Nitrogen was used to maintain an inert atmosphere. TGA was used to 
quantify the presence of moisture in the mesoporous silica, fenofibrate and processed 
fenofibrate-silica samples. TGA was also used to determine the presence and amount 
of drug in the processed fenofibrate-silica samples. The amount of moisture present 
in the samples was calculated from the weight loss between ambient and 100 
o
C, 
while the amount of drug present in the fenofibrate-silica samples was calculated 
from the weight loss between 100 to 900 
o
C, corrected for the weight loss from SBA-
15 over the same temperature range, this method has previously been reported 
(Ambrogi et al., 2008, Hillerström et al., 2009, Li-hong et al., 2013, Van Speybroeck 
et al., 2009). TGA analysis was conducted using Universal Analysis 2000 software, 
(TA Instruments Ltd., UK). All samples were analysed in triplicate to determine 
intra-batch variation. 
 
The % drug load (w/w) was calculated from Eq.2.7: 
 
Equation 2.7: )
(
( (w/w) load drug %
15

SBADrug
Drug
MM
M
 
 
Where MDrug is the mass of drug (mg) and MSBA-15 was the mass of SBA-15 (mg) 
 
The drug-loading efficiency was calculated according to Eq.2.8: 
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Equation 2.8: %100)
 (w/w) load drug %
 (w/w) load drug actual %
( (%) efficiency loading-Drug TGA   
 
Where the % actual drug load represents the % drug w/w present in the drug – silica 
sample determined by TGA analysis and the % drug load was the theoretical % in 
the sample, as calculated from Eq.2.7. Each prepared was analysed in triplicate in 
TGA to account for intra-batch variation.  
 
2.6.7 Differential scanning calorimetry 
Differential scanning calorimetry (DSC) was carried out using a DSC Q1000, (TA 
Instruments Ltd., UK). DSC was used to measure the glass transition temperature 
(Tg), melting point (Tm) and enthalpy of melting of fenofibrate and drug-silica 
samples. Enthalpy of fusion was used to quantify drug crystallinity in the processed 
fenofibrate-silica samples. Modulated DSC was employed because this mode 
measures both thermodynamic and kinetic events by superimposing a sinusoidal 
temperature modulation onto the heat flow (Verdonck et al., 1999). Samples in the 
range, 3 to 5 mg were prepared in Tzero aluminium pans (TA Instruments Ltd., UK) 
and weighed on a MX5 microbalance (Mettler Toledo International Inc., USA). The 
samples were heated from -40 to 120 
o
C at a heating rate of 3 
o
C/min. Modulation 
was set at  1 oC/min, while an inert atmosphere was maintained using nitrogen. A 
refrigerant cooling system (RCS 40), (TA Instruments Ltd., UK) was used to cool 
samples below ambient temperature. DSC analysis was conducted using Universal 
Analysis 2000 software, (TA Instruments Ltd., UK). All samples were analysed in 
triplicate to determine intra-batch variation. 
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2.6.8 Powder x-ray diffraction 
Powder x-ray diffraction (pXRD) was performed at ambient temperature using a 
Stadi MP diffractometer, (Stoe GmbH., Germany) operating in transmission mode 
with a linear position-sensitive detector, an anode current of 40 mA, an accelerating 
voltage of 40 kV and Cu Kα1 X-radiation (λ = 1.5406 Å) typically over a scan range 
of 3.5 to 60 ° 2θ, scanning in steps of 2 ° for 90 s per step. Samples were held 
between acetate foils. 
 
2.6.9 Fourier transform infrared spectroscopy 
Fourier transform infrared spectroscopy (FT-IR) was used to determine possible 
chemical interactions or chemical bonding between the fenofibrate and mesoporous 
silica in the processed fenofibrate-silica samples. This was performed using a 
Spectrum One FT-IR Spectrometer, (Perkin Elmer Inc., USA). During FT-IR 
analysis, radiation was passed through a sample where some of it was absorbed and 
some transmitted; thus generating a molecular “fingerprint”. Samples were prepared 
by grinding in excess potassium bromide (KBr) under infrared light and making 
solid discs using a punch and dye apparatus (Specac Ltd., UK), that was then placed 
in a press (10 ton for 5 min) (Specac Ltd., UK). Samples were run over the spectrum 
range of 450 to 4000 cm
-1
 with a resolution of 4 cm
-1
. Each sample was scanned 32 
times during a run to complete the final spectrum. 
 
2.6.10 Surface tension  
The surface tensions of all media employed in this thesis were determined 
experimentally through application of the KRUSS processor tensiometer K12 
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(KRUSS GmbH, Germany). The surface tension was measured using a platinum 
Wilhelmy plate. The plate was washed with deionised water, then ethanol and 
flamed over a Bunsen burner after each measurement. All measurements were 
performed at 37 
o
C which was maintained with the HAAKE water bath (Thermo 
Fisher Scientific Inc., USA). Full independent replicates were performed in 
triplicate.  
 
2.6.11 Solubility studies 
Solubility studies were carried out by dissolving excess fenofibrate in each particular 
media (n=3). The samples were placed in screw capped 50 ml tube plastic tubes, 
(Sarstedt AG., Germany) sealed with plastic tape and incubated in a shaker water 
bath (speed 200 rpm) at a temperature of 37 
o
C. Samples were withdrawn in 
triplicate from each tube after 24 and 48 h. Unknown drug concentration was 
calculated reversed-phase HPLC (See section 2.6.13). In chapters 3, 4 and 5, the 
solubility of fenofibrate was determined in 0.3% w/v SDS in 0.1M HCl solution. In 
chapter 6, it was additionally determined in 0.3% w/v SDS in deionised water, 1.5% 
w/v SDS in deionised water and 1.5% w/v SDS in 0.1M HCl solution.  
 
2.6.12 In vitro release testing  
The dissolution rate of the unprocessed fenofibrate and release rates of the processed 
fenofibrate-silica samples were investigated using a 900 ml volume of 0.3% w/v 
SDS in 0.1M HCl solution at a temperature of 37 
o
C in chapters 3, 4 and 5. In 
chapter 6, fenofibrate in vitro release was also evaluated in media composed of 0.3% 
w/v SDS in deionised water, 1.5% w/v SDS in deionised water and 1.5% w/v SDS in 
0.1M HCl solution, all at 37 
o
C. The dissolution apparatus used was the USP Type 2 
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apparatus with paddle speed of 100 rpm. The sink amount of fenofibrate for each 
dissolution or release experiment was one quarter of the unprocessed fenofibrate 
solubility in the particular media. In drug – silica samples, the quantity of sample 
required to ensure sink conditions was normalised based on the mass fraction of 
fenofibrate in each particular sample. The weighing boats containing the processed 
fenofibrate – silica samples were fully submerged in the dissolution medium at the 
start of the study. Samples were withdrawn at defined time points and replaced with 
fresh media which ensured a constant volume in the dissolution baths. All samples 
were filtered through a 0.2 µm syringe filter, (Sarstedt AG., Germany) prior to 
HPLC analysis.  
Dissolution and release profiles are presented in this thesis with % 
dissolution/release on the y-axis and time on the x-axis. The y-axis error bars 
represent the standard deviation (SD) associated with % dissolution/release at each 
time point. This standard deviation included both the intra-and-interbatch variation 
(N = 9).   
In chapter 6 during release experiments for the ‘standard sample’ (1 mg to 3 m2), the 
undissolved powder in the release media was recovered after either 15 min or 24 h. 
The release media was vacuum filtered through 0.45 µm Whatman filter paper. The 
filtrate was discarded and the solid residue on the filter paper recovered and oven 
dried at 40 
o
C for 3 days. The residue termed the recovered powder was analysed for 
drug content and surface and mesopore properties. The % recovery of fenofibrate 
from the drug – silica release experiment was calculated by Eq.2.9: 
 
Equation 2.9: %100)
 (w/w) load drug actual %
 (w/w) amount drug recovered %
( (%)recovery  Drug
TGA
TGA   
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Where the % recovered drug amount (w/w) was the % of drug in the recovered solid 
residue calculated by TGA and the % actual drug load was the % drug load in the 
sample after preparation.  
 
2.6.13 Reversed phase, high performance liquid 
chromatography 
Reversed phase, high performance liquid chromatography (RP-HPLC) analysis was 
performed using an Agilent 1200 series HPLC system with a UV/VIS detector 
(Agilent Technologies, USA). A reversed-phase column Kinetex C-18 column (150 
mm x 4 mm) with internal pore width 2.6 µm (Phenomenex Ltd., United Kingdom), 
a mobile phase of acetronitrile and water (70:30) at a flow rate of 1 ml.min
-1
 and an 
injection volume of 5 µl were employed. The wavelength for fenofibrate detection 
was set at 286 nm. The retention time for fenofibrate was 4.5 min.  
 
2.6.14 Stability studies 
Stability studies were carried according to the ICH (Q1A, R2) guidelines for 
accelerated storage of pharmaceutical preparations (FDA, 2003). All samples were 
placed inside 50 ml capped plastic containers (Sarstedt AG, Germany) and stored at 
40 
o
C and 75% RH in an Erweka (Erweka GmbH., Germany) controlled 
temperature-humidity oven for various periods of time, e.g. 1 month up to a 
maximum of 12 months.  
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2.7 Statistics 
2.7.1 Statistical analysis 
The data was tested for normality through the Anderson-Darling equation and the 
equality of variances were analysed with Levene’s Equation. When investigating 2 
different datasets, either the parametric 2 sample t-test or the non-parametric Mann-
Whitney test was employed. When analysing 3 or more datasets with only variable, 
either the parametric one-way ANOVA or non-parametric Kruskall-Wallis test was 
carried out. Two-way ANOVA was used to compare 2 independent factors and any 
interaction between these factors. A p value less 0.05 would indicate that the datasets 
were significantly different. The Minitab 16 statistical package (Minitab Inc., USA) 
was the software used to conduct the statistical analysis.  
 
2.7.2 Comparison of dissolution and release profiles 
Dissolution and release profiles were also compared by the difference (f1) and 
similarity tests (f2) (Moore and Flanner, 1996). A modified difference factor (f1
1
) was 
also utilised (Costa and Sousa-Lobo, 2001). The difference and modified difference 
factors measure the percent error between 2 dissolution or release profiles over all 
time points. A value of < 15 suggests that the profiles are not different to each other 
(Costa and Sousa-Lobo, 2001). The difference factor was given by Eq.2.10: 
  
Equation 2.10: The f1equation was:  
 
The Costa modified difference factor was given by Eq.2.11: 
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Equation 2.11: The modified f1 was:   
 
The similarity factor measures the logarithmic transformation of the sum-squared 
error of differences between 2 dissolution or release profiles over all time points. 
Above a value of 50, the profiles would be considered similar. The equations are 
reproduced below from the work of Costa and Sousa-Lobo (Costa and Sousa-Lobo, 
2001). The similarity factor was given by Eq.2.12: 
 
Equation 2.12: The similarity was         
 
Where n is the number of samples (time points), Rj is the percent dissolved of the 
reference product and Tj is the percent dissolved of the test product.   
Concurrently, repeated measures ANOVA was also employed to compare drug 
dissolution/release over multiple timepoints. The theory behind repeated measures 
ANOVA can be studied in greater detail in these references (Dunn and Clark, 1987, 
Jones, 2002).   
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3 Physicochemical characterisation of  SBA-15 
and fenofibrate  
3.1 Introduction 
In this thesis, a range of analytical techniques were employed to study drug – silica 
systems. It was necessary to thoroughly investigate the properties of fenofibrate and 
SBA-15 prior to processing in order to understand the subsequent properties of the 
drug – silica systems. 
It has been reported that silica particle size and shape can influence drug 
physicochemical properties post processing. Chen and co-workers reported that as 
the silica particle size decreased, the drug release rate increased (Chen et al., 2012).  
Previously Qu and co-workers reported that spherical particles which had a smaller 
particle size achieved a faster drug release rate than rod-shaped particles with larger 
particle sizes (Qu et al., 2006). Therefore, it is important to characterise the silica 
particle morphology and size with a view to understanding their subsequent effect on 
drug physicochemical properties, namely drug release rate, post loading.  
Bulk density differences between powders can represent potential processing 
challenges such as achieving blend uniformity when physically mixing powders (Fan 
et al., 1990, Williams, 1976). Bulk and tapped densities and volumes are also 
important in terms of understanding powder flowability indicated by the Hausner 
Ratio (Hausner, 1967) and powder compressibility as defined by  Carr’s Index (Carr, 
1965).  
As mentioned previously in section 1.4, the mesoporous silica surface area and pore 
properties have important ramifications for drug-loading, solid state and release 
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(Sanganwar and Gupta, 2008, Vallet-Regi et al., 2001). For example, knowledge of 
the silica surface area and mesopore volume will determine the amount of drug that 
can be theoretically loaded onto the silica surface (Chen et al., 2012, Heikkila et al., 
2007). Therefore, it was important to fully investigate the surface area and porosity 
properties of SBA-15; also such knowledge of the unprocessed SBA-15 surface area 
and mesopore volume could be used to deduce the distribution of the drug post 
processing. 
TGA has been applied as a tool to quantify the drug-load on mesoporous silicas 
(Hillerström et al., 2009, Van Speybroeck et al., 2009). The TGA profiles of 
fenofibrate and SBA-15 were evaluated with a view to confirming that TGA could 
be applied in this work for drug-load quantification. Also, TGA facilitated 
measurement of the moisture content of both SBA-15 and fenofibrate (0 – 100 oC), 
which would provide information on their hydrophilicity and hydrophobicity. This 
information was important because it would shed light on what to expect when the 
SBA-15 was stored under accelerated storage conditions and how fenofibrate would 
behave in vitro.  
The solid state structure of both SBA-15 and fenofibrate was probed with DSC and 
pXRD. It has been reported that crystalline drugs loaded onto mesoporous silicas can 
transition to an amorphous (Shen et al., 2010) or non-crystalline form (Mellaerts et 
al., 2008a). Therefore, it was necessary to understand the solid state characteristics of 
fenofibrate prior to processing with SBA-15. Thermal events such as glass transition 
(Tg), melting point (Tm) and recrystallization can be investigated by DSC while 
pXRD provided a solid state “fingerprint” of crystalline fenofibrate starting material. 
Therefore, it was necessary to understand the solid state characteristics of fenofibrate 
prior to processing with SBA-15, in addition to determining if processing led to 
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changes in the powders. Through the use of FT-IR the presence of hydrogen bonding 
between the powders as indicated by shifts of existing bonds in the FT-IR spectrum 
could be probed 
Loading poorly water – soluble drug onto mesoporous silicas has been widely 
reported to increase the dissolution rate and oral bioavailability of drugs such as 
carbamazepine, (Ambrogi et al., 2008), ibuprofen, (Vallet-Regi et al., 2001) and 
itraconazole, (Mellaerts et al., 2008b). Therefore before processing fenofibrate with 
SBA-15 it was important to study unprocessed fenofibrate solubility and dissolution 
behaviour in a range of dissolution media to determine if processing the drug with 
SBA-15 had a positive effect on the rate and extent of fenofibrate dissolution. 
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3.2 Results: Fenofibrate 
3.2.1 Particle morphology and size distribution 
The SEM image of unprocessed fenofibrate showed crystalline particles with a range 
of shapes and sizes (Fig.3.1). It can be observed that many of the fenofibrate 
particles were irregularly shaped and others spherical.  
   
 
Figure 3.1: SEM image of unprocessed fenofibrate, with magnification X1000. 
 
Sieve analysis showed the majority of the particles were greater than 180 µm 
(Fig.3.2).  
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Figure 3.2: Particle size distribution of unprocessed fenofibrate determined using 
sieve analysis, size distribution standard deviations indicated by y-axis error bars (n 
= 3). 
 
3.2.2 Derived surface properties: density, surface area and 
porosity 
The bulk density, Hausner ratio, Carr’s index and specific surface area of fenofibrate 
are displayed in Table 3.1 below.  
 
Table 3.1: Bulk density, Hausner ratio, Carr’s index and surface area of unprocessed 
fenofibrate, standard deviation in brackets (n = 3). 
Property Bulk Density Hausner Ratio Carr’s Index Surface area 
Result 0.64 g/cm3 (±0.01) 1.13 11.33 0.12 m2/g (±0.02) 
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The Carr’s Index was 11.33 which was well below the cut-off value of 25. Above a 
value of 25, the powder would be considered to have poor flowability (Carr, 1965). 
The Hausner ratio was 1.13 which was below the cut-off point of 1.25, above which 
indicated poor flowability (Hausner, 1967).  
The surface area of fenofibrate was low; therefore, dispersing or loading fenofibrate 
onto a high surface area, hydrophilic material like mesoporous silica offered the 
potential to enhance fenofibrate’s dissolution by increasing its effective surface area 
in contact with the dissolution medium (Bruner, 1904, Nernst, 1904). 
 
3.2.3 Thermogravimetric properties 
The thermogravimetric profile of unprocessed fenofibrate is shown in Fig.3.3. 
Fenofibrate possessed very little surface bound water, approximately 0.04% (±0.02), 
as indicated by the weight loss between ambient and 100 
o
C, an indication of both its 
low surface area and extreme hydrophobicity. Fenofibrate started to decompose at 
approximately 121.16 
o
C ( 23.11) and was fully decomposed at approximately 
302.82 
o
C ( 22.84), (Fig.3.3).  
 


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Figure 3.3: TGA profile of unprocessed fenofibrate determined over the temperature 
range ambient to 900 
o
C.  
 
3.2.4 X-ray diffraction analysis 
Fenofibrate is a crystalline powder. Its powder X-ray diffractogram shows strong 
peaks at 14, 16 – 17 and 22 – 23 2 theta, (Fig.3.4).  
 
Chapter 3  Raw Materials      
70 | P a g e  
 
 
Figure 3.4: pXRD of (1) unprocessed fenofibrate, (2) SC-CO2 processed fenofibrate 
and (3) unprocessed fenofibrate post 12 month storage. 
 
These peaks were previously reported for crystalline fenofibrate (Karmarkar et al., 
2009). Fenofibrate retained its crystallinity after SC-CO2 processing and after 12 
months storage under 40 
o
C and 75% RH which is indicative of its stability in the 
crystalline form. 
 
3.2.5 Differential Scanning Calorimetry 
Thermal analysis of fenofibrate using DSC yielded information about its solid state 
nature. Fenofibrate’s melting endotherm was measured in the DSC thermogram at 80 
o
C which corresponded well to literature value (Heinz et al., 2009, Zhou et al., 2002). 
No glass transition temperature was observed in samples of unprocessed, SC-CO2 
processed or those stored for 12 months under accelerated conditions. Completely 
amorphous fenofibrate has a reported Tg of -20
 o
C and a ΔCp of 0.72 J/g. 
o
C (Zhou et 
al., 2002). In this work, amorphous fenofibrate was prepared by melting the drug 
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inside a DSC Tzero aluminium pan followed by rapid quench-cooling in liquid 
nitrogen and immediate DSC analysis. The drug was observed to re-crystallise if left 
exposed on the bench. It can be seen from the results in Table 3.2, that quench-
cooling did not result in completely 100% amorphous fenofibrate.  
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Table 3.2: Reported and experimentally determined thermal properties of fenofibrate, determined by DSC, standard deviations in 
brackets (n = 9).  
Sample Tg (
oC) ΔCp (J/g.
oC) at Tg Tcr (
oC) ΔHcr (J/g) Tm (
oC) ΔHm (J/g) 
Reported values -20
# 
0.72
# 
30 – 40
#
* N/R 79 – 81
#
*
 
91.0
#+ 
Unprocessed N/P N/P N/P N/P 78.87 (±0.81) 90.18 (±3.95) 
Processed N/P N/P N/P N/P 77.00 (±0.28) 94.32 (±1.49) 
12 month stored (40 
o
C, 75% RH) N/P N/P N/P N/P 78.34 (±0.76) 96.76 (±4.17) 
Quench-cool fenofibrate -22.11 (±0.37) 0.44 (±0.06) 40.62 (±7.39) 64.87 (±8.92) 77.79 (±0.35) 87.16 (±5.43) 
 
Note: N/R not reported, N/P not present 
# 
(Zhou et al., 2002) 
* (Heinz et al., 2009) 
+ 
(Srinarong et al., 2009) 
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The re-crystallisation enthalpy (ΔHcr) was 64.87 (J/g) (±8.92), while the melting 
enthalpy was 87.17 (J/g) (±5.43). The percentage crystallinity (Xcr) is related to the 
enthalpy of re-crystallisation and enthalpy of melting (Wang et al., 2006). Based on 
this approach, the percentage of amorphous drug post quench-cooling was about 
74%. The DSC thermogram of unprocessed fenofibrate (Fig.3.5) and quench-cooled 
fenofibrate (Fig3.6) can be seen below.  
 
 
Figure 3.5: DSC thermogram of unprocessed fenofibrate indicating Tm at 80 
o
C. 
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Figure 3.6: DSC thermogram of quench-cooled fenofibrate indicating Tg at -20 
o
C, 
Tcr at approximately 40 
o
C and the Tm a 80 
o
C. 
 
3.2.6 FT-IR spectroscopy 
The fenofibrate molecule C20H21ClO4; contains C-H, C-O, C=O, C-CH3, C-Cl, C-C 
and C=C bonds (Heinz et al., 2009). The FT-IR spectrum of unprocessed fenofibrate 
shows a sharp peak at wavenumber 2984 cm
-1
 which was proposed to be alkane 
stretching. Alkane (C-H) stretching and bending is reported between wavenumbers 
2750 – 3300 cm-1 (Heinz et al., 2009, Pavia et al., 1979). The sharp peaks at 
wavenumbers 1651 and 1729 cm
-1
 were assigned to carbonyl (C=O) stretching, as 
previously reported in the literature (Heinz et al., 2009, Pavia et al., 1979). C-Cl 
bonds are reported to occur near wavenumber 650 cm
-1
; there was a sharp peak at 
656 cm
-1
 observed in the experimental fenofibrate spectrum which was categorized 
as the C-Cl bond. The FT-IR spectrum of fenofibrate is displayed below (Fig.3.7). 
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Figure 3.7: FT-IR spectrum of unprocessed fenofibrate.   
 
3.2.7 Fenofibrate solubility in 0.3% w/v SDS in 0.1M HCl 
solution 
The solubility of unprocessed fenofibrate in 0.3% w/v SDS in 0.1M HCl solution 
was investigated at 37 
o
C for 48 h and was found to be 67.21 µg/ml (±4.81).  
 
3.2.8 In vitro dissolution studies 
Unprocessed fenofibrate displayed a slow rate and low extent of dissolution, 
achieving 24.25% (±1.14) dissolution after 2 h. This was unaffected by 12 months 
under accelerated storage conditions. Processing fenofibrate in SC-CO2 lowered the 
percentage extent of fenofibrate’s dissolution to 6.54% (±1.46) after 2 h. It was 
observed that when the fenofibrate was recovered from the SC-CO2 cell, it had 
visibly larger particles. The in vitro release profiles of fenofibrate under sink 
conditions are shown below (Fig.3.8). 
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Figure 3.8: Dissolution profiles of fenofibrate (mean ± SD, n = 3), (♦) unprocessed, 
(■) SC-CO2 processed and (◊) stored for 12 months under accelerated storage 
conditions in 0.3% (w/v) SDS in 0.1M HCl media.  
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3.3 Results: Mesoporous silica 
3.3.1 Particle morphology and size distribution 
The SEM image shows the SBA-15 submicron particles are present as agglomerates 
(Fig.3.9). The SEM images appear to show individual particles as small as 4 µm.   
 
 
Figure 3.9: SEM image of unprocessed SBA-15, at magnification X5500. 
 
Sieve analysis was employed to determine the particle size distribution of 
unprocessed SBA-15 and SBA-15 after SCF processing (Fig.3.10).   
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Figure 3.10: Size distribution of (□) unprocessed and (■) processed SBA-15 (MS-6), 
standard deviation indicated by y-axis error bars (n = 3). 
 
The size distribution recorded for unprocessed SBA-15 indicated that the silica 
particles were agglomerated together. SC-CO2 processing of SBA-15 appeared to 
shift the size distribution, toward smaller sizes. This may be the result of agitation by 
the magnetic stirrer or the exposure of SC-CO2 or a combination of both effects 
during processing resulting in the breaking up of silica agglomerates.  
 
3.3.2 Bulk/true density  
The bulk density, Hausner ratio and Carr’s index of unprocessed SBA-15 powder are 
detailed in Table 3.3. Powders with a Hausner  ratio less than 1.25 and Carr’s index 
less than 15 are considered to have good flowability characteristics (Carr, 1965, 
Hausner, 1967), based on these values SBA-15 has poor flowability characteristics. 
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Table 3.3: Bulk density, Hausner ratio and Carr’s index of unprocessed SBA-15, 
standard deviation in brackets (n = 3).  
Property Bulk Density Hausner Ratio Carr’s Index 
Result 0.09 g/cm3 (±0.01) 1.33 25 
 
The true density of mesoporous silica was 2.31 g/cm
3
 (±0.14).  
 
3.3.3 Surface area and pore properties 
The surface area and pore properties of a number of batches of SBA-15 investigated 
in this study were determined and are detailed in Table 3.4. Major differences 
existed between batches MS-2 to MS-5B compared to MS-6 and 7. This was the 
result of variability in the manufacturing process when different equipment was 
employed.  
 
Table 3.4: Surface area and pore properties of unprocessed SBA-15, standard 
deviations in brackets (n = 6).  
SBA-15 Batch Surface area (m2/g) Mesopore volume (cm3/g) Mesopore size (Å) 
MS-2 600.47 (±37.02) 0.57 (±0.03) 50.60 (±0.77) 
MS-3 496.31 (±4.34) 0.55 (±0.01) 52.57 (±0.06) 
MS-5A 637.61 (±42.38) 0.63 (±0.04) 52.16 (±0.01) 
MS-5B 666.94 (±17.34) 0.64 (±0.02) 51.85 (±0.05) 
MS-6 833.22 (±48.13) 0.68 (±0.02) 50.70 (±0.20) 
MS-7 818.97 (±42.28) 0.80 (±0.04) 55.65 (±1.68) 
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Processing the SBA-15 in SC-CO2 did not affect the surface are, pore volume and 
pore size, however after 12 months storage under accelerated conditions (75% RH, 
40 
o
C), there were significant reductions in the measured surface area and pore 
volume as shown in Table 3.5. This was caused by the pickup of moisture by the 
SBA-15.  
 
Table 3.5: Comparison of surface area and pore properties of unprocessed MS-2, SC-
CO2 processed and SBA-15 after 12 months storage under accelerated storage 
conditions, standard deviations in brackets (n = 3).  
SBA-15  Surface area (m2/g) Mesopore volume (cm3/g) Mesopore size (Å) 
Unprocessed  600.47 (±37.02) 0.57 (±0.03) 50.60 (±0.77) 
SC-CO2 processed  590.77 (±6.51) 0.58 (±0.01) 51.27 (±0.24) 
12 month  storage 324.94 (±30.18) 0.48 (±0.05) 57.97 (±0.06) 
 
The decrease in surface area can be observed clearly in the BET isotherms (Fig.3.11) 
and pore size distributions (Fig.3.12). The smaller mesopores were closed after 12 
months under accelerated storage conditions; this was indicated by the shift of the 
pore size distribution to the right.   
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Figure 3.11: BET isotherms of SBA-15 (MS-2) (♦) unprocessed, (□) processed and 
(▲) processed after 12 months under accelerated storage conditions. 
 
 
Figure 3.12: Pore size distributions of SBA-15 (○) unprocessed, (▲) processed and 
(□) processed after 12 months under accelerated storage. 
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It should be noted that sample degassing prior to analysis was carried out at 50 
o
C for 
24 h. This degassing regime appears to be insufficient to remove all of the physically 
bound or molecularly bound/chemisorbed water. Degassing at higher temperatures 
was considered however as fenofibrate melted at 80 
o
C, it would not be possible to 
degas above 50 
o
C in a drug – SBA-15 sample.  
 
3.3.4 Thermogravimetric properties 
The TGA profiles of unprocessed, processed and processed SBA-15 post 12 months 
under accelerated storage are show below (Fig.3.13).  
 
 
Figure 3.13: TGA profiles of SBA-15 (MS-2), (1) unprocessed, (2) processed and (3) 
processed, post 12 months under accelerated storage conditions.  
 
SBA-15 does not decompose when heated from 0 – 900 oC; however there was some 
weight loss. Coutinho and co-workers employed TGA in the analysis of uncalcined 
SBA-15; they reported that over 30 – 100 oC, physically bound moisture evaporated 
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from the SBA-15, the surfactant template (Pluronic P123) was removed from SBA-
15 between 100 – 450 oC, while over the range 450 – 600 oC residual decomposition 
of the template and condensation of water from silanol occurred (Coutinho et al., 
2007). As all the mesoporous silicas used in this thesis had been calcined at 550 
o
C, 
i.e. the template had already been removed; any weight loss from 100 – 550 oC could 
not be the result of template removal. The weight loss of a number of different 
mesoporous silica samples is shown below in Table 3.6.  
 
Table 3.6: Comparison of surface moisture and silanol decomposition of SBA-15 
unprocessed, SC-CO2 processed and processed, after 12 months storage under 
accelerated storage conditions (MS-2), standard deviation in brackets (n = 9).  
SBA-15 % Weight Loss, 0 – 100 oC % Weight Loss, 100 – 900 oC 
Unprocessed  1.26 (±1.73) 2.24 (±0.45) 
SC-CO2 processed  4.79 (±1.84) 3.85 (±0.37) 
Processed, 12 month  storage 5.16 (±0.21) 4.72 (±0.02) 
 
Unprocessed MS-2 contained 1.26% (±1.73) physically bound moisture, while after 
12 months storage there was 5.16% (±0.21).The SBA-15 molecular moisture 
content, which was measured over 100 – 900 oC, increased from 2.24% (±0.45) for 
unprocessed SBA-15 to 4.72% (±0.02) for processed SBA-15 post 12 months under 
accelerated storage conditions, which was a significant increase. The act of SC-CO2 
processing did not influence the moisture content of SBA-15; there was no 
significant change observed between the unprocessed to processed silicas (p > 0.05).  
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3.3.5 Powder X-ray diffraction 
SBA-15 is an amorphous powder; no peaks were observed on its pXRD 
diffractogram, (Fig.3.14). This remained the case after SC-CO2 processing and when 
subjected to 12 months storage under accelerated conditions.  
 
 
Figure 3.14: pXRD diffractograms of (1) unprocessed SBA-15, (2) after SCF 
processing SBA-15 and (3) post 1 month storage under accelerated conditions, (75% 
RH, 40 
o
C) using MS-2 batch. 
 
3.3.6 Differential scanning calorimetry  
The DSC thermogram of unprocessed SBA-15 (MS-2) is displayed below (Fig.3.15).  
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Figure 3.15: Unprocessed SBA-15 (MS-2) total heat flow DSC thermogram over the 
temperature range -30 – 100 oC. 
 
The large endotherm from 0 – 100 oC is the result of evaporation of surface water 
from the SBA-15. This is a typical DSC thermogram for SBA-15 when studied in 
standard DSC mode. It is not possible to identify any thermal events from the total 
heat flow DSC thermogram. The reversing heat flow thermogram of unprocessed 
SBA-15 (MS-2) shows thermal events around -20 and 80 
o
C (Fig.3.16).  
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Figure 3.16: Unprocessed SBA-15 (MS-2) reversing heat flow DSC thermogram 
over the temperature range -30 – 100 oC. 
 
The reversing heat flow thermograms of SC-CO2 processed SBA-15 and that stored 
for 12 months under accelerated storage conditions can be seen below (Fig.3.17).  
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Figure 3.17: Reversing heat flow DSC thermograms of SBA-15 (MS-2) (1) 
unprocessed, (2) processed and (3) post 12 months storage under accelerated 
conditions over the temperature range -30 – 100 oC. 
 
SC-CO2 processing and storage for 12 months under accelerated conditions did not 
influence the presence of these events. It was previously reported that the events 
observed on the SBA-15 DSC profile from -20 to -12 
o
C were the melting of frozen 
water confined in the mesopores (Kittaka et al., 2011). The thermal events observed 
around 60, 80 and 90 
o
C on the reversing heat flow DSC thermograms of all the 
silicas could be the evaporation of water from the mesopores. It is reasonable to 
assume that if the melting point of frozen water in the mesopores is depressed, then 
so would the boiling point. It was previously reported by Sliwinska-Bartkowiak and 
co-workers that nitrobenzene in controlled pore glass (CPG) had a depressed or 
lowered melting temperature compared to bulk nitrobenzene (Sliwinska-Bartkowiak 
et al., 1999).  
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3.3.7 FT-IR spectroscopy 
The molecular formula of SBA-15 is SiO2. There were several distinct peaks in the 
FT-IR spectrum of SBA-15, (Fig.3.18).  
 
 
Figure 3.18: FT-IR spectrum of unprocessed SBA-15. 
 
The presence of adsorbed water on SBA-15 was highlighted by the broad peaks 
present at wavenumbers 3437 and 1630 cm
-1
 (Izquierdo-Barba et al., 2010).  In the 
case of the peak at 3437 cm
-1
, this was the result of hydroxyl stretching (-OH) in the 
surface silanol groups (Si-OH) (Izquierdo-Barba et al., 2010, Pavia et al., 1979). The 
peak at 1630 cm
-1
 was the result of hydroxyl bending (Parida et al., 2006). The other 
peaks observed in the SBA-15 spectrum were caused by cross-linking of the siloxane 
(Si-O-Si) bonds (Das et al., 2007, Zheng et al., 2001). The largest peak on the SBA-
15 spectrum occurred at wavenumber 1083 cm
-1
, which was caused by asymmetric 
stretching of the siloxane bonds, while that at 814 cm
-1
 resulted from symmetric 
stretching of the siloxane bond. Finally, the peak at wavenumber 450 cm
-1
 was 
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ascribed to the stretching/rocking motion of the oxygen atom in the siloxane bond 
(Swann and Patwardhan, 2011).  
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3.4 Discussion 
While the SEM image showed the SBA-15 particles to be small (< 5 µm), particle 
size analysis showed the silica particles to be agglomerated together, a reflection of 
the high surface area (Zhao et al., 1998) and surface energy (Masuda et al., 2006). 
Fenofibrate had a much higher bulk density than SBA-15; this meant that any type of 
physically processing of these powders would run a high risk of powder segregation.  
The determined SBA-15 surface areas and mesopores volumes compared well with 
previously published data (Mellaerts et al., 2008a, Heikkila et al., 2007). It has been 
reported that the surface area is a crucial property in terms of how much drug can be 
loaded onto mesoporous silicas (Chen et al., 2012) and that the porous nature of the 
SBA-15 allows for the stabilisation of drug in the an amorphous (Shen et al., 2010) 
or molecularly dispersed form for up to 12 months under accelerated storage 
conditions (Mellaerts et al., 2010). SC-CO2 processing did not alter the surface area 
and porosity of SBA-15; however storage for 12 months under accelerated storage 
conditions of 40 
o
C and 75% RH resulted in a significant decrease in the SBA-15 
surface area and porosity. This was caused by the adsorption of moisture by SBA-15. 
The variations in SBA-15 specific surface area and mesopore volume observed 
across the batches had important implications; it was necessary to normalise these 
samples to allow for direct comparisons across the batches. In this work, the drug – 
silica ratio was based on the amount of drug to silica specific area which removed 
the influence of different absolute values. The reduction in SBA-15 specific surface 
area and mesopore volume was caused by the adsorption of moisture; TGA results 
showed that after storage, there was a significant increase in the amount of 
molecularly bound water on the SBA-15. The extreme hydrophobicity of fenofibrate 
was highlighted by the fact that there was practically no moisture present on its 
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surface; in fact fenofibrate did not pick up moisture after 12 months under 
accelerated storage conditions. Fenofibrate decomposed between 120 – 300 oC, 
while the SBA-15 remained stable apart from some moisture loss over the same 
temperature range. Therefore, TGA can be applied later in this thesis for the 
determination of the drug-load on SBA-15, as previously reported (Van Speybroeck 
et al., 2009).  
Fenofibrate is a stable crystalline drug, unaffected by SC-CO2 processing or long 
term accelerated storage. The Tg of fenofibrate occurs at -20 C (Zhou et al., 2002), 
which also coincides with the melting point of water frozen in the SBA-15 
mesopores (Kittaka et al., 2011). This draws attention to the fact that the detection of 
amorphous fenofibrate loaded onto SBA-15 may be confounded when there are 
drug-loaded samples to be studied.  
The FT-IR spectra showed the chemical bonds present in both SBA-15 and 
fenofibrate. Any hydrogen bonding that may occur between them after processing 
together can be expected to centre on the silica silanol groups and fenofibrate’s 
carbonyl groups because these are the bonds that contain hydrogen and oxygen.   
Fenofibrate dissolution rate and extent was challenged in 0.3% (w/v) SDS + 0.1M 
HCl; there was approximately 25% dissolution after 2 h. It was seen earlier that 
fenofibrate was in the crystalline form, extremely hydrophobic with a low specific 
surface area; processing with SBA-15 should be able to overcome these difficulties 
and lead to enhanced dissolution.  
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3.5 Summary 
Fenofibrate is a highly stable, crystalline drug; it maintained its crystallinity even 
after SC-CO2 processing. It was extremely hydrophobic; it did not adsorb moisture 
under long term accelerated storage conditions. Its dissolution rate in 0.3% w/v SDS 
in 0.1M HCl was very limited. Mesoporous silica was characterised as a mesoporous 
material, with a high surface area and mesopore pore volume, with well defined 
mesopore sizes. It maintained these characteristics even after SC-CO2 processing. 
Mesoporous silica readily adsorbed moisture when under long term accelerated 
storage conditions.  
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4 Mesoporous silica for oral drug delivery  
4.1 Introduction 
It has been long established that increasing the effective surface area of a poorly 
water-soluble drug in contact with the dissolution medium can enhance drug 
dissolution (Bruner, 1904, Nernst, 1904). This can be achieved by loading drugs onto 
silica-based ordered mesoporous materials (OMMs) which are characterised by high 
surface areas, large mesopore volumes, narrow mesopore size distributions (5 – 8 
nm) and ordered unidirectional mesopore networks. These properties allow for 
homogeneous and reproducible drug-loading and release (Manzano et al., 2009, 
Vallet-Regi et al., 2007, Vallet-Regi et al., 2001). Many publications have focussed 
on understanding the key properties of OMMs that influence drug-loading and 
dissolution rate enhancement. It has been reported that the surface area determines 
how much drug can be loaded onto OMMs and OMM particle size has an impact on 
drug release rate, with larger silica particles resulting in slower drug release because 
of the longer mesopore length (Chen et al., 2012). The mesopore volume influences 
the amount of drug loaded, especially if the drug is dissolved in a solvent that can 
carry it into the mesopores (Vallet-Regi et al., 2007). Larger mesopore sizes 
encourage greater drug release rates (Horcajada et al., 2004), while mesopore 
geometry has also been shown to affect drug-loading and release (Izquierdo-Barba et 
al., 2005). Stabilisation of amorphous drug for up to 12 months has been attributed to 
the mesopores of the OMM (Mellaerts et al., 2010, Shen et al., 2010). The silica 
surface can be functionalised with organic groups to encourage greater drug-loading 
by creating stronger bonding between the silica surface and drug (Manzano et al., 
2008), and to extend drug release (Vallet-Regi et al., 2007).  
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Despite the body of literature evaluating the different properties of OMM affecting 
drug-loading and release, there seems to be a lack of clarity regarding the optimum 
processing method to load drug onto the OMM and the subsequent implications for 
drug delivery. Various loading methods have been employed including physical 
mixing (Ambrogi et al., 2010, Song et al., 2005, Qian and Bogner, 2011), solvent 
based methods that either involve the suspension of the OMM in a drug-solvent 
solution (Ambrogi et al., 2012, Andersson et al., 2004, Izquierdo-Barba et al., 2005, 
Charnay et al., 2004) or impregnation of the OMM by dropwise addition of a 
concentrated drug solution (Mellaerts et al., 2008a, Van-Speybroeck et al., 2008). 
Some researchers have mixed the drug and silica and heated the resultant mixture to 
below (Tozuka et al., 2005) or above the drug’s melting point (Aerts et al., 2010, 
Mellaerts et al., 2008a, Shen et al., 2010). Alternative loading methods such as 
supercritical CO2 (SC-CO2) (Sanganwar and Gupta, 2008) have also been proposed 
to load drug onto OMMs. The high density of SC-CO2 should permit a large amount 
of drug to be solubilised, while its high diffusivity should facilitate ready access to 
the mesopore network (Fages et al., 2004, Pasquali and Bettini, 2008, York, 1999). 
This is the first study to directly compare physical mixing, melt, solvent 
impregnation and CO2 based drug-loading methods in terms of the subsequent 
impact on drug – OMM properties; in particular drug distribution throughout the 
mesoporous silica matrix, solid state properties and drug release. To our knowledge, 
this is also the first study to enhance drug dissolution by loading drug onto OMM 
using a liquid (near-critical) CO2 loading method. The model OMM in this study was 
SBA-15 and fenofibrate was employed as a representative Class II drug as defined 
by the biopharmaceutics classification system (BCS) (Amidon et al., 1995). It is 
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highly lipophilic (log P = 5.3) (Wishart et al., 2008) and  practically insoluble in 
water (< 0.8 µg/ml) (Jamzad and Fassihi, 2006).  
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4.2 Results 
4.2.1 Drug-loading 
The drug-loading efficiencies were calculated using Eq.2.8. Similar loading 
efficiencies of greater than 90% were determined for the impregnation, liquid and 
SC-CO2 methods, Table 4.1.  
 
Table 4.1: Comparison of drug-loading efficiency and % ΔPV before and after 
storage for 1 month for all processed drug – SBA-15 samples, standard deviations in 
brackets.  
Processing 
Method 
Loading Efficiency (%)  
(n = 9) 
% ΔPV  
(n = 6) 
% ΔPV, 1 month storage  
(n = 6) 
Physical Mix 106.26 (±42.83) 1.88 (±5.41) 15.29 (±6.08) 
Melt Method 103.90 (±30.22) 36.84 (±5.63) 35.09 (±3.89) 
Impregnation 92.55 (±5.14) 33.12 (±2.26) 44.40 (±15.92) 
Liquid CO2 93.25 (±5.35) 32.06 (±1.66) 33.68 (±3.66) 
SC-CO2 91.98 (±6.34) 19.64 (±5.30) 21.27 (±4.16) 
 
Large intra-batch variabilities were evident in physical mix and melt samples that 
may be attributed to segregation during preparation due to density differences 
between the mesoporous silica and fenofibrate. In the case of both the physical and 
melt samples, poor mixing resulted in heterogeneous distribution of drug throughout 
the silica substrate. The low variability in drug-loading for the impregnation, liquid 
and SC-CO2 processed samples was indicative of more homogeneous drug 
distribution. All loading methods, with the exception of the physical mix, involved 
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the disruption of the drug solid particles by melting or dissolution. For the melt 
samples, drug distribution was reliant on the viscosity of molten drug and the degree 
of drug and silica mixing. The disruption of the drug particulate form that occurred 
in the impregnation, liquid and SC-CO2 samples facilitated more uniform drug 
distribution in these samples. 
 
4.2.2 Porosity analysis 
Changes in silica porosity after drug-loading can assist in understanding how the 
drug is distributed throughout the silica sample. Mesoporous silica starting material 
had a very large mesopore volume (>0.50 cm
3
/g) and displayed the type IV 
adsorption-desorption isotherm and H1 hysteresis loop (Fig.4.1) characteristic of 
mesoporous materials (Sing et al., 1985).  
 
 
Figure 4.1: N2 adsorption/desorption isotherms of (■) unprocessed SBA-15, (◊ with 
dashed line) physical mix and (●) melt method. 
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These characteristics were retained post drug-loading (Fig.4.2), which indicated that 
silica was still mesoporous.  
 
 
Figure 4.2: N2 adsorption/desorption isotherms of (■) unprocessed SBA-15, (▲) 
impregnation, (♦ with dashed line) liquid and (○) SC-CO2 prepared samples. 
 
With the exception of the physical mix, all drug loaded samples showed marked 
reductions in the mesoporous silica pore size and volume. The closure point (P/Po) of 
the hysteresis loop was reduced for all samples, with the exception of the physical 
mix (Fig.4.1), indicating a reduction in pore sizes (Izquierdo-Barba et al., 2005). The 
greatest reduction was observed for the sample prepared by the melt method.  
 
The pore size distribution in relation to the pore volume for the various samples is 
shown (Fig.4.3).  
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Figure 4.3: Pore size distribution of (■) unprocessed SBA-15, (● with dashed line) 
physical mix, (♦) melt sample, (□) Impregnation, (▲ with dashed line) liquid CO2 
and (∆) SC-CO2. 
 
There appeared to be slight change in the pore size distribution for the physical mix, 
however this was not quantified. Both impregnation and liquid CO2 samples show 
similar reductions in pore size; interestingly the SC-CO2 sample showed a lower 
reduction in pore size compared to these samples. The melt sample showed the 
greatest spread of pore sizes. The % ΔPV values calculated from Eq.2.6 were used to 
quantitatively compare the reduction in mesopore volumes of the processed samples 
compared to the theoretical mesopore volume (Table 4.1). The % ΔPV of the 
physical mix was negligible showing that the presence of the drug had little effect on 
the silica mesopore volume in these samples. Statistical analysis showed that all the 
other samples had a significantly greater % ΔPV compared to the physical mix 
indicating that processing by these methods resulted in a reduction in the silica 
mesopore volume due to drug deposition into the silica mesopores and blocking of 
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the mesopores. Despite having similar loading efficiencies, impregnation and liquid 
CO2 samples had a significantly higher % ΔPV values compared to the SC-CO2 
samples.  
 
4.2.3 SEM-EDX 
Qualitative analysis of the drug, SBA-15 and drug/SBA-15 samples conducted using 
SEM showed that SBA-15 was composed of agglomerated sub-micron particles and 
fenofibrate was composed of distinct crystalline particles (Fig.4.4). 
 
 
Figure 4.4: SEM images of (left) unprocessed SBA-15 and (right) unprocessed 
fenofibrate. 
 
EDX analysis was used to probe the distribution of fenofibrate and SBA-15 in these 
samples. SBA-15 was probed via its silicon (Si) atom and fenofibrate via its chlorine 
(Cl) atom. The EDX images shown are the Cl atom distribution of the powder under 
the SEM. Fenofibrate particles were observed in the SEM image of the physical mix 
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but not in the melt sample. The Cl atom distribution was observed to be more intense 
in the EDX image of the physical mix but less so in that of the melt sample, 
(Fig.4.5).  
 
 
Figure 4.5: SEM/EDX images of (top) physical mix and (bottom) melt sample; the 
SEM images are on the left while the EDX images are on the right. 
 
The SEM images highlighted that fenofibrate is present as distinct particles in the 
physical mix whereas in the melt sample the drug was dispersed through the SBA-15 
material and there was no evidence of distinct drug particles. This was also the case 
for the impregnation, liquid and SC-CO2 samples (Data not shown). 
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4.2.4 Solid state analysis 
Powder XRD and DSC analysis of samples was undertaken to determine whether the 
loading methods resulted in differences in fenofibrate solid state behaviour. The 
pXRD diffractogram of the fenofibrate crystalline starting material was in 
accordance with that previously reported (Heinz et al., 2009). The pXRD 
diffractograms of drug – silica samples, with the exception of the physical mix, 
showed no peaks indicating that the drug in these samples was in a non-crystalline 
state (Fig.4.6).  
 
 
Figure 4.6: pXRD diffractograms of the (1) physical mix and (2) melt sample.  
 
The peaks observed in the pXRD of the physical mix corresponded to the peaks 
observed earlier for unprocessed crystalline fenofibrate (Fig.3.4). The pXRD 
diffractograms of drug – silica samples prepared by impregnation, liquid and SC-
CO2 showed no peaks indicating that the drug in these samples was in a non-
crystalline state (Fig.4.7).  
Chapter 4  Comparison of drug-loading processes 
103 | P a g e  
 
 
 
Figure 4.7: pXRD diffractograms of the (1) impregnation, (2) liquid and (3) SC-CO2 
samples.  
 
The melting point for the starting crystalline fenofibrate agreed with the reported Tm 
of 79 – 81 oC (Heinz et al., 2009). Thermal events in the temperature range -20 to -
12 
o
C were noted during DSC analysis of the silica starting material (Fig.4.8).  
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Figure 4.8: Unprocessed SBA-15, MDSC thermogram. 
 
This behaviour was previously reported as the melting point of frozen water confined 
in the mesopores of mesoporous silica (Kittaka et al., 2011). Endothermic thermal 
events in the same range -20 to -12 
o
C were noted in all drug-silica samples 
regardless of the method of the loading.  As fenofibrate’s Tg was reported in this 
temperature region at -20 
o
C, (Heinz et al., 2009) it was not possible to conclusively 
detect the Tg of amorphous fenofibrate in any of these drug-silica samples. A large 
melting endotherm with an onset of 78 
o
C was visible in DSC thermogram of the 
physical mix, while there was a slight melting endotherm in the melt sample, 
indicative of the presence of residual crystalline drug (Fig.4.9).  
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Figure 4.9: (1) Unprocessed SBA-15, (2) physical and (3) melt MDSC thermograms. 
 
The absence of melting endotherms in the impregnation, liquid and SC-CO2 samples 
supported the pXRD results that the drug was in a non-crystalline state in these 
samples (Fig.4.10).  
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Figure 4.10: (1) Unprocessed SBA-15 thermogram, no evidence of drug melting in 
(2) impregnation, (3) liquid and (4) SC-CO2 MDSC thermograms. 
 
4.2.5 In vitro drug release 
The release of drug from the silica carrier is a key performance indicator to consider 
when employing OMMs for drug dissolution enhancement. The in vitro release of 
drug from drug – silica samples prepared by physical mixing and melt method 
compared to the dissolution of the starting fenofibrate are shown (Fig.4.11). 
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Figure 4.11: Release profiles of (◊) unprocessed fenofibrate, (♦ with dashed line) 
physical mix and (●) melt sample in 0.3% w/v SDS in 0.1M HCl media (mean ± SD, 
n = 9).  
 
The in vitro release profiles of the impregnation, liquid and SC-CO2 showed similar 
results, with very rapid release achieved (Fig.4.12). 
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Figure 4.12: Release profiles of (▲) impregnation, (♦ with dashed line) liquid CO2 
and (○) SC-CO2 sample in 0.3% w/v SDS in 0.1M HCl media (mean ± SD, n = 9).  
 
Utilising mesoporous silica as a carrier material improved the drug dissolution rate 
for all processed samples. The physical mix showed a slower rate and lower extent 
of drug release compared to all other loading methods. The release profile of the 
physical mix was significantly lower that of the melt sample when investigated with 
repeated measures ANOVA. The release profiles of drug from the impregnation, 
liquid and SC-CO2 loaded samples were similar according to the f1, modified f1
’
and f2 
factors. (Moore and Flanner, 1996)Drug was released in a rapid manner in the first 
20 min. After 20 min the drug release levelled between 70 – 80 % and did not 
increase between 20 and 120 min. The release from the melt sample was 
significantly less that the impregnation, liquid and SC-CO2 samples according to the 
f1, modified f1
’
, and f2 values. When the release of the melt sample was compared to 
the SC-CO2 sample by repeated measures ANOVA, there was also significant 
difference observed. In the case of physical mix and melt samples, the variability in 
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drug release at each time point was high in contrast to the other samples reflecting 
the heterogeneous drug-loading in these samples referred to previously in Section 
3.1. The similarity of the drug release profiles for the melt, impregnation, liquid and 
SC-CO2 samples indicated that the deposition behaviour of drug in the mesopores 
did not adversely affect its release.  
 
4.2.6 Stability analysis 
The presence of amorphous drug in the processed samples potentially posed a risk to 
the drug solid state stability of these formulations. Re-crystallisation of unstable 
amorphous forms can adversely affect drug properties such as dissolution 
performance (Hancock and Parks, 2000). While it has been reported that the OMMs 
can stabilise non-crystalline drug forms (Mellaerts et al., 2010, Shen et al., 2010), the 
influence of loading method on stability has not been reported. After 12 months 
accelerated storage at 40 
o
C and 75% RH in 50 ml screw-capped plastic containers 
(Sarstedt AG, Germany), there was no evidence of re-crystallisation in the pXRD 
diffractograms of the melt, impregnation, liquid and SC-CO2 samples (Fig.4.13).  
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Figure 4.13: pXRD diffractograms of (1) melt, (2) impregnation, (3) liquid and (4) 
SC-CO2 post 12 months under accelerated storage conditions.  
 
This was despite the fact the moisture content of these samples increased over time 
under accelerated storage conditions. For example, the SC-CO2 processed sample 
recorded a significant increase in the amount of surface and molecular bound 
moisture after 12 months compared to its as-prepared state; the surface moisture 
content increased from 0.72% w/w (±0.14) to 1.82% w/w (±0.42). The surface 
moisture contents of the impregnation and liquid CO2 also significantly increased 
after 12 months under accelerated storage. However no significant increase in 
moisture was observed for the melt sample. Interestingly, the mesopore volume of 
the physical mix sample post 1 month storage was significantly reduced compared to 
the as-prepared sample (Table 4.1). The reduction of the mesopore volume was 
evident in the decrease in the mesopore size distribution (Fig.4.14). The pore volume 
and size of the melt, impregnation liquid and SC-CO2 samples remained unchanged 
post 1 month storage.  
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Figure 4.14: Pore size distribution of (■) physical mix as-prepared and (▲) post 1 
month storage.  
 
The mesopore volume and size of the melt, impregnation liquid and SC-CO2 samples 
remained unchanged post 1 month storage compared to their as-prepared state. This 
may be explained by the fact that there was no significant increase in the surface 
moisture content for any of these samples after 1 month. After storage for 1 month, 
there was some improvement in drug release from the physical mix samples 
(Fig.4.15).  
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Figure 4.15: Release profiles of (◊ with dashed lines) physical mix as-prepared and 
(∆) physical mix post 1 month storage in 0.3% w/v SDS in 0.1M HCl media, sample 
in 0.3% w/v SDS in 0.1M HCl media (mean ± SD, n = 9).  
 
The f1, modified f1
’
, and f2 values showed a difference between the profiles. A 
significant increase in the release profile of the physical mix after 1 month under 
accelerated storage conditions was also observed when the profiles were compard 
through repeated measures ANOVA. Drug release rate from the impregnation, liquid 
and SC-O2 samples was not enhanced even after 12 months accelerated storage (data 
not shown). 
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4.3 Discussion 
The results of this work highlighted the influence of the drug-loading process on 
drug distribution within the mesoporous silica structure. The physical mixing and 
melt methods employed here resulted in heterogeneous distribution of drug 
throughout the mesoporous silica due to blending difficulties arising from 
differences in density between the drug and silica. The impregnation, liquid and SC-
CO2 methods obtained samples with drug homogeneously dispersed throughout the 
mesoporous silica surfaces similar to that reported previously (Van-Speybroeck et 
al., 2009). This was facilitated by disruption of the drug particulate form. 
Changes in the porosity of silica post processing also highlighted differences in drug 
distribution resulting from different loading methods. For all loading methods 
examined, the mesoporous silica retained its type IV adsorption isotherm indicative 
of its mesoporous nature. Similar findings have been reported previously (Mellaerts 
et al., 2008b, Morere et al., 2012, Moritz and Laniecki, 2012a). The deposition of the 
drug molecules inside the mesoporous silica mesopores resulted in some of the 
mesopores being fully or partially filled with drug molecules, which prevented the 
adsorption and condensation of the N2 molecules in the mesopores during 
subsequent mesopore volume measurement. Ukmar and co-workers reported that 
indomethacin loaded onto MCM-41 and SBA-15 using a solvent impregnation 
method formed a condensed phase that could block passage of the mesopore 
channels (Ukmar et al., 2011a). The melt method resulted in the greatest reduction in 
mesopore size and largest reduction in mesopore volume. This behaviour was 
attributed to the molten viscosity of drug preventing deep penetration of the 
mesopores and causing blockage of mesopores. Mellaerts and co-workers utilised a 
melt method to load itraconazole and ibuprofen onto SBA-15; the subsequent 
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itraconazole–SBA-15 surface area, mesopore volume and size were similar to the 
SBA-15, while for ibuprofen-SBA-15 the surface area, mesopore volume and size 
were reduced (Mellaerts et al., 2008a). Therefore, the distribution of drug in samples 
prepared using melt methods is strongly dependent on the drug’s molten viscosity, 
while the ability to form a homogeneous mixture of drug and silica prior to the 
melting step of the process depends on the density difference of the powders. The 
decrease in mesopore size observed was evidence of the drug coating/lining the 
inside of the mesopores and was also observed by Mellaerts and co-workers 
(Mellaerts et al., 2008a). These results were supported by the SEM image of the melt 
sample which did not show any individual fenofibrate particles in the sample 
indicating the drug was dispersed on or within the SBA-15 material. EDX images of 
the melt sample showed a reduced intensity of the Cl atoms which supports the 
porosity data suggesting some drug is inside the SBA-15 mesopores. This was also 
the case for the impregnation, liquid and SC-CO2 but the data was not shown. Due to 
the greater diffusivity and extremely low surface tension of SC-CO2 compared to 
solvents in a liquid state, there appears to be deeper drug penetration of the silica 
mesopores (Belhadj-Ahmed et al., 2009). This is reflected in the lower reduction of 
mesopore volume and mesopore size observed for the SC-CO2 samples compared to 
the impregnation and liquid CO2 samples, despite all samples having similar drug-
loading. Similar results were also reported by Li-hong and co-workers who loaded 
ibuprofen onto MCM-41 using both a solvent immersion and SC-CO2 drug-loading 
procedure (Li-hong et al., 2013). From these data it appears that although the drug 
deposition causes a narrowing of the mesopore network, it does not preclude N2 
access during measurement to the same extent as in the melt, impregnation and 
liquid CO2 samples. In this work, it was apparent that the processing method has an 
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important influence on the distribution of drug and subsequent porosity of samples 
with similar drug-loading.  
Loading fenofibrate onto SBA-15 using the impregnation, liquid and SC-CO2 
processes resulted in the drug changing from the crystalline to a non-crystalline state. 
This is in agreement with previous reports showing the crystalline to non-crystalline 
transition observed when processing drugs with OMMs (Miura et al., 2010, 
Nishiwaki et al., 2009, Tozuka et al., 2005, Tozuka et al., 2003). Qian and co-
workers demonstrated that crystalline to amorphous transitions occurred in physical 
mixes of drug and silica via a vapour phase-mediated pathway for compounds with a 
relatively high vapour pressure in the absence of moisture  (Qian and Bogner, 2011). 
The physical mixing conditions investigated in this study did not result in any 
detectable amorphization of fenofibrate, perhaps due to the relatively high vapour 
pressure of fenofibrate and presence of moisture. Azais and co-workers studied the 
solid state of ibuprofen confined MCM-41 mesopores (35 and 116 Å) using solid 
state nuclear magnetic resonance (SS-NMR). They reported that the ibuprofen in the 
mesopores was not in a crystalline or amorphous state at ambient temperature (Azais 
et al., 2006), and proposed the concept of the drug existing as a molecular dispersion 
in the silica mesopores. The drug loaded onto SBA-15 by the impregnation, liquid 
and SC-CO2 processes appeared to be in a molecularly dispersed state as no Tg or Tm 
was observed. However as highlighted in Section 3.3.6, frozen water in the 
mesopores of mesoporous silica may have confounded the detection of the Tg for 
fenofibrate in these samples. In the melt sample, there was a small endotherm 
detected in the DSC thermogram around the drug’s melting point, which would 
indicate that some of the drug was still crystalline. It has been previously reported 
that fenofibrate existed in an amorphous state post loading onto silica. Van-
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Speybroeck and co-workers impregnated SBA-15 with fenofibrate and detected the 
drug Tg at – 20 
o
C, this was ascribed to the higher drug load (higher ratio of drug 
weight to silica surface area) which promoted drug-drug interactions (Van 
Speybroeck et al., 2010a). Sanganwar and Gupta reported the presence of residual 
crystallinity post processing of fenofibrate with aerosil using SC-CO2 (Sanganwar 
and Gupta, 2008). However, this may be due to the non-porous nature and hence 
lower surface area of aerosil and again, a relatively higher drug weight to silica 
surface area ratio. Other studies of drug-loading SBA-15 using an impregnation 
process have also reported that the drug was molecularly dispersed as there was no 
Tg or Tm observed (Mellaerts et al., 2010, Mellaerts et al., 2008a, Van Speybroeck et 
al., 2010b). Fenofibrate in melt, impregnation, liquid and SC-CO2 prepared samples 
was stabilised in the non-crystalline form after 12 month storage under accelerated 
storage conditions. Given that fenofibrate is very unstable in its amorphous form; it 
has a Tg of -20 
o
C, its re-crystallisation temperature is 40 
o
C and its reduced 
temperature scale is 0.6 (Zhou et al., 2002), it was difficult to isolate in the 
amorphous form due to its rapid re-crystallisation at ambient conditions. Therefore 
the prolonged stability at accelerated storage conditions must be attributed to its co-
processing with SBA-15. These results corresponded with those published by 
Mellaerts and co-workers who reported that itraconazole was maintained in the 
amorphous form for up to 12 months after processing with SBA-15 (Mellaerts et al., 
2010). Shen and co-workers published similar findings with respect to ibuprofen co-
spray-dried with SBA-15 (Shen et al., 2010). Another important factor for the 
stabilisation of the amorphous form is the effect of nanoconfinement on drug re-
crystallisation. A drug cannot re-crystallise when the space in which it is confined 
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does not exceed the drug molecule width by at least a factor of 10 (Rengarajan et al., 
2008, Sliwinska-Bartkowiak et al., 2001).  
There was a limited improvement in drug release rate in the physical mix sample, a 
result which was previously reported by Miura and co-workers, when they physically 
loaded the drug K-832 onto the silica material sylysia 350 (Miura et al., 2010). 
Interesting results were also obtained by Ambrogi and co-workers who also observed 
an improvement in drug dissolution of carbamazepine physically mixed with SBA-
15 which they attributed to partial amorphization of the drug (Ambrogi et al., 2013). 
In this work, the drug – silica prepared by both the physical mix and melt methods 
yielded a significantly lower release rate compared to the other processing methods. 
The drug release from the impregnation, liquid and SC-CO2 samples was rapid and 
similar. The enhanced rate of drug release was attributable to the more homogeneous 
distribution of the drug throughout the silica, which spread the drug throughout all of 
the available surface area. It has been long established that drug release rate can be 
enhanced by increasing the effective drug surface area in contact with the dissolution 
medium (Bruner, 1904, Nernst, 1904). The increased wettability of the drug after 
drug-loading (Wang et al., 2006) and the non-crystalline nature of the drug which 
has a higher Gibbs free energy compared to the crystalline form (Craig et al., 1999, 
Yu, 2001) were also contributing factors. The extent of drug release from the 
physical sample significantly increased after 1 month storage. It has been proposed 
that water may react with mesoporous silica during storage increasing the 
hydroxylation of the silica surface. The increased surface hydroxylation can lead to 
an increase in the extent of drug release; it has previously been reported that 
adsorbed water on mesoporous silica is advantageous for drug release (Mellaerts et 
al., 2011). Itraconazole loaded on mesoporous silica prepared using a solvent 
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impregnation method and stored at 25°C and 97 % RH showed an increase in the 
extent of drug dissolution post storage (Mellaerts et al., 2010). However, moisture 
analysis in this study did not show any significant increase. This may be due to the 
heterogeneous distribution of drug and SBA-15 in these samples which was noted in 
drug-loading measurements. The extent of drug release did not increase post 1 and 
12 month storage for the solvent impregnation, liquid and SC-CO2 samples. Similar 
findings were presented by Shen and co-workers who subjected a co-spray dried 
ibuprofen / SBA-15 sample to 12 month, storage at 40 
o
C and 75% RH (Shen et al., 
2010). The influence of moisture uptake on the release of drugs loaded on 
mesoporous silica appears to vary with the loading method and warrants further 
investigations. 
 
4.4 Summary 
The method of loading drug onto SBA-15 was shown to influence drug distribution 
which is evident by the differences in mesopore size and volume observed for the 
samples prepared. With the exception of the physical mix and melt samples, solid 
state and release properties were similar for all processed samples. All processing 
methods except the physical mix sample, loaded fenofibrate into the SBA-15 
mesopores where it was stabilised in a non-crystalline state for 12 month at 75% RH 
and 40 
o
C. Drug release rates were increased for all samples, but depended on 
loading method. While different loading methods may result in differences in drug 
distribution, these were not shown to affect solid state stability or drug release in the 
case of the impregnation, liquid and SC-CO2 processed samples. This was the first 
report of liquid CO2 being utilised to load silica with drug.   
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5 Optimising SC-CO2 processing paramters 
5.1 Introduction 
In this chapter, the influence of SC-CO2 processing conditions on drug-loading 
efficiency, solid state and release will be further investigated. The employment of 
supercritical fluids (SCF) like SC-CO2 for drug-loading offers many advantages 
compared to traditional organic solvents. An SCF is a fluid that is at or above its 
critical point and therefore possesses properties of both its liquid and gaseous states, 
including liquid-like density and gas-like diffusivity (Pasquali and Bettini, 2008). 
When the supercritical state is reached, properties like density, viscosity and the 
vapour-liquid equilibrium ratio become dependent on temperature at a certain 
pressure, which permits the solubility of solutes in the SCF to be controlled (Olson, 
1995). Another advantage includes the reduced processing complexity as there is no 
need for solvent removal steps associated with organic solvent usage (Fages et al., 
2004, Pasquali and Bettini, 2008, York, 1999). Carbon dioxide is the most widely 
used SCF because it has mild critical conditions (7.37 MPa, 31.2 
o
C), is inert, non-
flammable and inexpensive (Bush et al., 2007, Pasquali and Bettini, 2008). There 
have been a limited number of studies investigating drug-loading onto silica carriers 
using SC-CO2, with each using different parameters for processing in terms of 
pressurisation, temperature and drug-silica contact. No clear correlation between the 
processing variables used and the resultant sample properties such as quantity of 
drug-loaded has been presented. Sanganwar and Gupta investigated a processing 
pressure of 17.58 MPa and two temperatures, 40 and 50 
o
C for 150 min duration to 
load fenofibrate onto non-porous fumed silica. In the study, the silica material was 
sealed in a porous filter paper pouch, which was placed inside the pressure vessel 
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containing excess drug. The CO2 was pumped in and heat supplied to maintain 
constant pressure and temperature throughout the duration of the experiment; at the 
end of the experiment, depressurisation was carried out slowly over 4 h (Sanganwar 
and Gupta, 2008). Miura and co-workers employed SC-CO2 processing conditions of 
18 MPa and 60 
o
C to load a poorly water – soluble drug, K-832 onto mesoporous 
silica, Sylysia 350. Here the drug and silica were placed together inside the pressure 
cell, which was then filled with CO2 and heated to achieve the desired experimental 
conditions. The cell was maintained under the experimental conditions for a 5 h 
duration with stirring, before the CO2 was slowly released from the cell (Miura et al., 
2010). Belhadj-Ahmed and co-workers used a flow-through processing method 
which involved exposing vitamin E acetate to SC-CO2 and then passing the drug - 
SC-CO2 solution through the mesoporous silica carrier at a flowrate of 500 g.h
-1
. The 
pressure was 15 MPa, while the temperature was 60
o
C (Belhadj-Ahmed et al., 2009). 
In this work, the use of SC-CO2 to load drug onto SBA-15 was investigated at 
different processing conditions of pressure and duration time. Additionally, the effect 
of the ratio of drug to SBA-15 was examined to determine if a relationship between 
drug-loading efficiency and available SBA-15 surface area and pore volume existed. 
The effect of drug and SBA-15 contact during processing was evaluated in order to 
understand its impact on drug physicochemical properties and loading. The effect of 
CO2 depressurisation rate was investigated; while several studies have been 
published that employed SC-CO2 for drug-loading (Belhadj-Ahmed et al., 2009, 
Sanganwar and Gupta, 2008, Smirnova et al., 2004), there were no studies that 
explicitly investigated the effect of CO2 depressurisation rate on drug-loading 
efficiency, solid state and release rates. There have been some studies involving SC-
CO2 processing where the effect of depressurisation rate was investigated. Arora and 
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co-workers prepared polystyrene foams where depressurisation rate was reported to 
influence the size of the microcellular foams when the process temperature was 
above the glass transition temperature; rapid depressurisation led to larger 
microcellular foams, (Arora et al., 1998). Aucoin and Legge studied the effect of SC-
CO2 depressurisation rate on the activity of a biocatalyst, Lipozyme IM20. They 
found the higher the depressurisation rate, the lower the biocatalyst activity (Aucoin 
and Legge, 2001). In this work, for the first time CO2 depressurisation rate was 
investigated to determine its impact on drug – SBA-15 physicochemical properties. 
The depressurisation was step was controlled by allowing enough CO2 gas to escape 
in order to reduce the pressure by 0.69 MPa every minute. The list of process 
variables investigated in this chapter is presented in the table 5.1 below.  
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Table 5.1: List of experimental variables investigated in chapter 5, including 
processing pressure, duration time, CO2 depressurisation rate, contact method and 
drug – silica ratio. 
Pressure (MPa) Time (h) Depressurisation Contact Method Ratio 
13.79 4 Rapid Mix 1 mg to 3.00 m
2 
27.58 12 Rapid Mix 1 mg to 3.00 m
2
 
41.37 24 Rapid Mix 1 mg to 3.00 m
2
 
13.79 4 Rapid Mix 1 mg to 3.00 m
2
 
27.58 12 Rapid Mix 1 mg to 3.00 m
2
 
41.37 24 Rapid Mix 1 mg to 3.00 m
2
 
13.79 4 Rapid Mix 1 mg to 3.00 m
2
 
27.58 12 Rapid Mix 1 mg to 3.00 m
2
 
41.37 24 Rapid Mix 1 mg to 3.00 m
2
 
27.58 12 Rapid Mix 1 mg to 1.24 m
2
 
27.58 12 Rapid Mix 1 mg to 0.82 m
2
 
27.58 12 Rapid Bag 1 mg to 1.24 m
2
 
27.58 12 Rapid Bag 1 mg to 0.82 m
2
 
27.58 12 Slow, controlled Mix 1 mg to 3.00 m
2
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5.2 Results 
5.2.1 Drug-loading 
The theoretical amount of drug in each of the SC-CO2 processed samples prepared 
for the 3
2
 factorial experimental design was 16.67% based on the drug to silica ratio 
of 1 mg: 3 m
2
. However, the actual drug amount varied from 12.62 to 15.62%, which 
resulted in loading efficiencies ranging from 75.70 to 93.71%, Table 5.2. A 
statistically significant decrease in drug-loading was observed as processing pressure 
increased from 13.79 to 41.37 MPa. The duration of processing time had no 
significant impact on drug-loading (p > 0.05). In the case of samples where the drug 
to silica ratio was increased to 1 mg: 1.24 m
2
 and 1 mg: 0.82 m
2
 while maintaining 
constant SC-CO2 conditions of 27.58 MPa and 12 h, the drug-loading efficiencies for 
these samples were 74.86% (1 mg: 1.24 m
2
) and 69.17% (1 mg: 0.82 m
2
) 
respectively, Table 5.2. There was a significant decrease in drug-loading efficiency 
with increasing drug – silica ratio. Examination of the impact of physically mixing 
the drug and silica in the SC-CO2 environment (‘mix method’) as opposed to 
separating drug and silica by means of the porous bag (‘bag method’), confirmed that 
the drug solubilised in SC-CO2 was loaded onto the silica. The drug-loading 
efficiencies were reduced when using the ‘bag method’ compared to the ‘mix 
method’, Table 5.2. Comparison of the drug-loading efficiencies achieved with the 
mix method to the bag method showed that there was a significant decrease in drug-
loading efficiency. The drug-loading efficiency of the sample prepared with the 
standard SC-CO2 processing conditions with rapid depressurisation was 85.48% 
(±7.27), while that with controlled depressurisation was 86.25% (±5.92). These 
loading efficiencies were not significantly different (p > 0.05).  
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Table 5.2: Drug-loading efficiencies and % ΔPV of SC-CO2 processed samples across all variables, standard deviations in brackets. 
SC-CO2 Conditions Ratio Contact Depressurisation rate % Drug (w/w), (n = 9) % Drug-loading efficiency, (n =  9) ΔPV, (n =  6) 
13.79 MPa, 4 h 1 mg to 3.00 m2 Mix Rapid 15.62(±0.62) 93.71 (±3.70) 18.4 (±0.51) 
13.79 MPa, 12 h 1 mg to 3.00 m2 Mix Rapid 13.43 (±4.58) 80.54 (±27.45) 21.33 (±10.39) 
13.79 MPa, 24 h 1 mg to 3.00 m2 Mix Rapid 15.16 (±0.75) 90.96 (±4.48) 16.68 (±2.14) 
27.58 MPa, 4 h 1 mg to 3.00 m2 Mix Rapid 14.59 (±1.91) 87.52 (11.46) 16.44 (±1.24) 
27.58 MPa, 12 h 1 mg to 3.00 m2 Mix Rapid 15.33 (±1.10) 91.98 (±6.59) 19.12 (±4.17) 
27.58 MPa, 24 h 1 mg to 3.00 m2 Mix Rapid 15.03 (±0.83) 90.17 (±4.98) 18.01 (±1.52) 
41.37 MPa, 4 h 1 mg to 3.00 m2 Mix Rapid 14.63 (±1.06) 87.74 (±6.37) 17.17 (±2.12) 
41.37 MPa, 12 h 1 mg to 3.00 m2 Mix Rapid 13.69 (±0.22) 82.12 (±1.30) 16.65 (±1.99) 
41.37 MPa, 24 h 1 mg to 3.00 m2 Mix Rapid 12.62 (±1.64) 75.70 (±9.84) 19.15 (±8.22) 
27.58 MPa, 12 h 1 mg: 1.24m2 Mix Rapid 21.39 (±0.15) 74.86 (±0.70) 41.55 (±0.34) 
27.58 MPa, 12 h 1 mg: 0.82 m2 Mix Rapid 25.94 (±2.84) 69.17 (±10.93) 51.78 (±10.14) 
27.58 MPa, 12 h 1 mg: 1.24 m2 Bag Rapid 15.07 (±2.34) 52.76 (±15.56) 33.16 (±6.02) 
27.58 MPa, 12 h 1 mg: 0.82 m
2
 Bag Rapid 18.84 (±1.54) 50.35 (±8.14) 48.30 (±8.46) 
27.58 MPa, 12 h 1 mg to 3.00 m
2
 Mix Rapid 18.57 (±1.58) 85.48 (±7.27) 25.91 (±3.74) 
27.58 MPa, 12 h 1 mg to 3.00 m
2
 Mix Slow, controlled 18.73 (±1.29) 86.25 (±5.92) 24.21 (±2.61) 
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5.2.2 Drug distribution 
The SBA-15 had a large pore volume 0.57 cm
3
/g ( 0.03), whereas fenofibrate was 
non-porous. After SC-CO2 processing fenofibrate with SBA-15, there were marked 
changes in the SBA-15 pore properties. For all drug – silica SC-CO2 processed 
samples, the pore size distribution of SBA-15 shifted to the left after processing, 
indicating a reduction in the width of SBA-15 mesopores (Fig.5.1).  
 
 
Figure 5.1 Pore size distribution of (♦) unprocessed SBA-15 and (□) representative 
SC-CO2 processed fenofibrate-SBA-15 sample, P = 27.58 MPa, T = 12 h.  
 
This reduction may be due to the entrapment of fenofibrate molecules within the 
mesopores. There were no significant differences observed between the pore size 
distributions of any of the SC-CO2 processed samples, when the ratio of drug – silica 
was maintained at 1 mg: 3 m
2
. Increased loading of fenofibrate onto SBA-15 
accentuated the shift to a lower pore size distribution (Table 5.2 and Fig.5.2).  
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Figure 5.2: SC-CO2 processed fenofibrate-SBA-15 samples prepared with different 
ratios of drug: silica by ‘mix method’, processing conditions P = 27.58 MPa, T = 12 
h, (■) 1 mg to 3 m2, (▲) 1 mg to 1.24 m2 and (◊) 1 mg to 0.82 m2. 
 
This reduction in mesopore volume and decrease in mesopore sizes was also seen in 
the ‘bag’ samples (Fig.5.3).  
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Figure 5.3: SC-CO2 processed fenofibrate-SBA-15 samples prepared with different 
ratios of drug: silica by bag method, processing conditions P = 27.58 MPa, T =12 h, 
(♦) 1 mg to 1.24 m2 and (□) 1 mg to 0.82 m2. 
 
Using Eq.2.5, the predicted pore volume of the samples was calculated based on the 
fraction of SBA-15 and drug present. Large differences between the predicted and 
measured pore volumes were calculated (Eq.2.6); the percentage difference in pore 
volume (% ΔPV) ranged from 16.65 – 21.33% (Table 5.2) for the samples prepared 
under varied SC-CO2 conditions at a drug mass to silica surface ratio of 1 mg: 3m
2
. 
However, there were no statistically significant differences observed between the 
measured pore volumes of any of the SC-CO2 samples, (p > 0.05). Increases in drug 
– silica ratio resulted in a greater % ΔPV.  In the case of samples prepared using the 
‘bag method’, while drug-loading efficiency was considerably reduced compared to 
samples prepared using the ‘mix method’, the % ΔPV were comparable at the highest 
drug – silica ratio. There was a strong correlation between the amount of loaded drug 
and % ΔPV, the Pearson correlation coefficient (r) was calculated to be 0.85. SC-
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CO2 depressurisation rate did not affect the distribution of the drug inside the SBA-
15 mesopores; there was no significant difference between the % ΔPV of the rapid 
depressurisation SC-CO2 drug-loaded sample, 25.91% (±3.74) and that of the 
controlled depressurisation SC-CO2 drug-loaded sample, 24.21% (±2.61).  
 
5.2.3 Drug solid state 
There was no Tg or Tm observed in any of the samples and no peaks were observed 
in any of the diffractograms of the drug – silica SC-CO2 processed samples, which 
indicated that the fenofibrate was in the non-crystalline form (Fig.5.4).  
 
 
Figure 5.4 pXRD diffractogram of (1) unprocessed fenofibrate and (2) representative 
SC-CO2 sample (P = 27.58 MPa, T = 12 h).  
 
When the ratio of drug to SBA-15 was increased, the diffractograms showed the 
drug to be in a non-crystalline form for both the ‘mix’ and ‘bag methods’ (Fig.5.5). It 
was observed that the fenofibrate remaining outside the porous bag containing SBA-
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15 at the end of the experiment, which was not loaded onto the SBA-15, was in the 
crystalline form (Data not shown). 
 
 
Figure 5.5: pXRD diffractograms of SC-CO2 processed (1) ‘mix sample’, 1 mg to 
1.24 m
2, (2) ‘mix sample’, 1 mg to 0.82 m2, (3) ‘bag sample’, 1 mg to 1.24 m2, (4) 
‘bag sample’, 1 mg to 0.82 m2; processing conditions P = 27.58 MPa, T = 12 h. 
 
5.2.4 Molecular interactions 
FT-IR spectrum of SBA-15 shows characteristic peaks for silica; surface silanol (Si-
OH) stretching caused by adsorbed water (3000 - 4000 cm
-1
), asymmetric siloxane 
(Si–O–Si) stretching (1083 cm-1), Si-O-Si bending (456 cm-1), O-H bending 
(adsorbed water) (1600 cm
-1
) and Si-O asymmetric stretching (814 cm
-1
) which is in 
agreement with previously reported silica spectra (Coutinho et al., 2007, Das et al., 
2007, Izquierdo-Barba et al., 2010, Zheng et al., 2001, Parida et al., 2006). After SC-
CO2 processing fenofibrate with SBA-15, there was some evidence of intermolecular 
bonding in all samples. The Si-O peak shifted from 814 to 803 cm
-1 
(Fig.5.6), 
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indicating hydrogen bonding between silica’s silanol surface groups and 
fenofibrate’s carbonyl groups. Molecules containing carbonyl functional groups have 
previously been reported to be adsorbed onto silica surfaces and interactions with the 
silica surface was proposed to be through hydrogen bonding onto the surface silanol 
(Diaz et al., 2005). FTIR spectra of fenofibrate-silica samples prepared with 
increased drug – SBA-15 ratios and using the ‘bag method’ also showed similar peak 
shifts (Fig.5.6).  
 
 
Figure 5.6: FT-IR spectra of (1) unprocessed SBA-15 and selected SCO2 processsed 
samples detailed in table 5.2 (2) 1 mg to 3 m
2
 mix sample, (3) 1 mg to 1.24 m
2
 mix 
sample, (4) 1 mg to 0.82 m
2
 mix sample, (5) 1 mg to 1.24 m
2
 bag sample and (6) 1 
mg to 0.82 m
2
 bag sample (all drug – silica samples processed at P = 27.58 MPa and 
T = 12).     
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5.2.5 In vitro release  
SC-CO2 processed fenofibrate-SBA-15 samples showed a substantial increase in the 
release rate of fenofibrate compared to unprocessed fenofibrate (Fig.5.7).  
 
 
Figure 5.7: Release profiles of (♦) unprocessed fenofibrate and various representative 
SC-CO2 samples at a ratio of 1 mg to 3 m
2, (□) P = 13.79 MPa, T = 4 h, (■ with 
dashed line) P = 27.58 MPa, T = 12 h and (◊) P = 41.37 MPa, T = 24 h in 0.3% (w/v) 
SDS in 0.1M HCl media, sample in 0.3% w/v SDS in 0.1M HCl media (mean ± SD, 
n = 9).  
 
There were no significant differences in fenofibrate release profiles for any of the 
SC-CO2 processed fenofibrate-SBA-15 (1 mg: 3 m
2
) samples irrespective of 
processing conditions employed according to the f1, modified f1
’
 and f2 tests. The 
release profiles of the increased drug – silica samples are displayed here (Fig.5.8).  
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Figure 5.8: Release profiles of ‘mix samples’ (●) 1mg to 3 m2, (◊) 1 mg to 1.24 m2 
and (■ with dashed line) 1mg to 0.82 m2 (P = 27.58 MPa, T = 12 h) in 0.3% (w/v) 
SDS in 0.1M HCl media, sample in 0.3% w/v SDS in 0.1M HCl media (mean ± SD, 
n = 9).  
 
There were no significant differences in the release profiles of samples with drug: 
SBA-15 ratios of 1 mg: 3 m
2
, 1 mg: 1.24 m
2
 and 1 mg: 0.82 m
2
 samples prepared by 
the ‘mix method’, according to the according to both the f1, modified f1
’
 and f2 tests 
and repeated measures ANOVA.  
The release profiles of the samples prepared with the ‘bag method’ are shown in 
Fig.5.9.  
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Figure 5.9: Release profile of ‘bag samples’ at (○) 1 mg to 1.24 m2 and (■) 1 mg to 
0.82 m
2
 (P = 27.58 MPa, T = 12 h) in 0.3% (w/v) SDS in 0.1M HCl media sample in 
0.3% w/v SDS in 0.1M HCl media (mean ± SD, n = 9). 
 
When samples were prepared using the ‘bag method’ the release rates appeared to 
exhibit a greater degree of variability compared to the samples prepared using the 
‘mix method’, which suggested a greater heterogeneity in the dispersion of drug on 
the SBA-15. It was also seen that there was a significant decrease in drug release 
from the bag sample with the drug – silica ratio of 1 mg to 0.82 m2 compared to that 
with the ratio of 1 mg to 1.24 m
2 
according to the repeated measures ANOVA test. 
The release profiles of the mix and bag samples at the 1 mg to 0.82 m
2
 drug – silica 
ratio are shown here in Fig.5.10.  
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Figure 5.10: Release profiles of (■) mix and (∆) bag samples at drug – silica ratio of 
1 mg to 0.82 m
2
 (P = 27.58 MPa, T = 12 h) in 0.3% (w/v) SDS in 0.1M HCl media 
sample in 0.3% w/v SDS in 0.1M HCl media (mean ± SD, n = 9). 
 
There was a significant difference between the samples prepared by the ‘mix 
method’ and the ‘bag method’ at the 1 mg: 0.82 m2 drug – silica ratio, according to 
the f1, modified f1 and f2 tests and repeated measures ANOVA.  
The drug release rate from the sample prepared by controlled CO2 depressurisation 
was similar to that prepared with rapid CO2 depressurisation. The drug release 
reached approximately 80% after 10 min and was maintained at the level thereafter. 
There was no difference between these release rates according to the f1, modified f1 
and f2 tests.  
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5.3 Discussion 
The aim of this research was to understand the impact of supercritical processing 
conditions on the loading of drug onto SBA-15 and the resulting drug solid state and 
release properties. In pursuit of this objective, various supercritical processing 
variables such as pressure (13.79, 27.58, 41.37 MPa) and processing duration (4, 12, 
24 h), CO2 depressurisation rate, ratio of drug to SBA-15 (1 mg: 3 m
2
 , 1 mg: 3 m
2
 
and 1 mg: 0.82 m
2
) and methods to combine the SBA-15 with the drug were 
investigated. It was postulated that at higher pressures, more drug would dissolve in 
SC-CO2 as it has been reported that the solubility of solutes in SC-CO2 increases 
with increasing pressure (Belhadj-Ahmed et al., 2009, Gordillo et al., 1999, 
Macnaughton and Foster, 1994, Macnaughton et al., 1996, Crampon et al., 1999) and 
hence result in greater drug-loading onto SBA-15; the densities of the SC-CO2 at the 
experimental pressures of 13.79, 27.58 and 41.37 MPa were found to be 720, 910 
and 1001 kg/m
3
 respectively, using the Stryjek and Vera modification of the Peng-
Robinson equation of state (PRSV) (Stryjek and Vera, 1986). However, decreased 
drug-loading efficiencies were obtained at the higher pressures. This was attributed 
to the loss of dissolved drug during the depressurisation step because of faster 
transfer rates out of the pressure vessel at the higher pressures. The SC-CO2 drug-
loading method employed in this study and also reported by Sanganwar and Gupta, 
and Miura and co-workers, involved solubilisation of the drug in SC-CO2 and 
loading onto the silica carrier within the same pressurised vessel (Miura et al., 2010, 
Sanganwar and Gupta, 2008). While the loss of solubilised drug during the 
depressurisation step appeared to adversely impact the drug-loading efficiency using 
the processing method employed in this study, it is thought that this would not be the 
case for the impregnation method employed by Belhadj-Ahmed and co-workers in 
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which the drug was dissolved in SC-CO2 prior to passage through the silica at a 
controlled flow rate (Belhadj-Ahmed et al., 2009. Low intra-sample variation, less 
than 5% RSD, was determined for all SC-CO2 processed samples, which was 
indicative of homogeneous drug distribution throughout the SBA-15. As the ratio of 
fenofibrate to SBA-15 increased under constant SC-CO2 conditions, the % drug 
increased but the drug-loading efficiency decreased. These results suggest that 
fenofibrate drug-loading is limited by its solubility in SC-CO2 or by the capacity of 
SBA-15 to accommodate drug. When drug – silica samples were prepared by the 
‘bag method’, the drug-loading efficiencies were lower than fenofibrate-SBA-15 
samples prepared by the ‘mix method’ at the same ratios of drug and SBA-15. The 
reduced drug-loading observed was attributed to reduced contact between drug and 
SBA-15 and possibly due to the reduced surface area of SBA-15 exposed during 
processing. These findings are consistent with those of Chen and co-workers who 
reported that the amount of ibuprofen loaded by the solvent method was dependent 
upon the surface area of mesoporous silica (Chen et al., 2012). There has not been 
any study where the influence of CO2 depressurisation rate on drug-loading 
efficiency onto mesoporous silica was reported. There have been studies involving 
other substrates such as polymers (PLGA) where the depressurisation rate has been 
found to influence the size of drug-loaded polymer spheres; rapid depressurisation 
led to macrospheres while controlled depressurisation led to microspheres (Guney 
and Akgerman, 2002). However, within the limits of this work, CO2 depressurisation 
rate did not affect fenofibrate loading, distribution or release from SBA-15.  
The large % ΔPV values calculated for all the SC-CO2 samples were attributed to 
partial or complete filling of the mesopores by drug molecules as mentioned in 
chapter 4. Reductions in pore volume reflected both the degree of drug-loading and 
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the manner of drug molecule deposition within the SBA-15 pores. There were no 
statistically significant differences in measured pore volumes for any of the samples 
prepared at a constant drug – silica ratio of 1 mg: 3 m2 with varying SC-CO2 
conditions. The % ΔPV increased when the drug to SBA-15 ratio increased which 
correlated with increased drug-loading. Interestingly, the % ΔPV values calculated 
for the samples prepared by the ‘bag method’ were relatively high for the amount of 
drug actually loaded, when compared to samples prepared using the ‘mix method’. 
This was particularly the case for the highest drug – silica ratio sample. This 
suggests that drug may be obstructing the pore openings or that the drug-loaded by 
the ‘bag method’ was deposited in the SBA-15 mesopores in a different manner than 
in the ‘mix method’. There were no differences in drug distribution within the SBA-
15 mesopores and % ΔPV as a result of SC-CO2 depressurisation rate.  
Fenofibrate loaded onto SBA-15 was found to be in a non-crystalline state after SC-
CO2 processing in all samples. Retention of the drug in the non-crystalline form was 
observed after storage conditions of 75% RH and 40 
o
C for 12 months (See chapter 
4). None of the processing parameters such as pressure, duration time, drug – silica 
ratio, method of contact and SC-CO2 depressurisation rate showed any differences in 
terms of drug solid state structure. Analysis of unloaded drug recovered at the end of 
the drug-loading experiments using the ‘bag method’ showed that the drug retained 
its crystalline structure. FT-IR spectroscopy indicated the presence of hydrogen 
bonding between fenofibrate carbonyl groups and SBA-15 silanol groups in all 
processed samples. It has previously been reported that hydrogen bonding between a 
silica substrate and drug could be partly attributed to the loss of drug crystallinity 
(Madieh et al., 2007). Loading the drug onto SBA-15 resulted in a significant 
improvement in the drug’s release rate compared to the dissolution rate of the 
Chapter 5   Optimising SC-CO2 processing 
 
138 | P a g e  
 
unprocessed drug. This was attributed to a combination of (1) the increased effective 
drug surface area in contact with the dissolution medium after loading onto SBA-15 
as mentioned previously (Bruner, 1904, Nernst, 1904); (2) the induction of 
fenofibrate’s non-crystalline form (Yu, 2001) and (3) the increased wettability of 
fenofibrate after loading onto SBA-15 because of the hydrophilic nature of SBA-15 
(Brown et al., 1998). Fenofibrate release from all the fenofibrate-silica SC-CO2 
processed samples (1 mg: 3 m
2
) was rapid, with over 50% released by 5 minutes. 
After approximately 20 min, fenofibrate release reached a plateau and total drug 
release was not accomplished after 2 h. There was no difference in terms of in vitro 
drug release across the various supercritical conditions investigated; this result has 
recently been supported in the literature (Li-hong et al., 2013). Incomplete drug 
release behaviour was attributed to the possible presence of drug deep in the 
mesopores or in micropores which was potentially inaccessible to the release media 
due to surface tension effects. There was no significant difference in terms of release 
profile when the drug – silica ratio was increased in the mix samples. When the 
samples were prepared using the bag method, the drug release profiles exhibited 
greater hetereogeneity and at the highest drug – silica ratio of 1 mg to 0.82 m2, the 
release was significantly lower for the bag sample compared to the equivalent mix 
sample at this ratio. This reinforced the hypothesis that the drug-loaded by the ‘bag 
method’ was deposited into the SBA-15 mesopores in a different manner compared 
to the ‘mix method’. These results indicated that drug release can be altered with 
variations in the distribution of deposited drug on the silica substrate and that the 
drug release profiles can be tailored by altering the method of drug-loading. 
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5.4 Summary 
SC-CO2 loading of fenofibrate onto SBA-15 using supercritical processing has been 
demonstrated. Fenofibrate loaded on a SBA-15 carrier was shown to be in a non-
crystalline form. A number of variables including processing pressure, the ratio of 
drug to silica and  the contact between drug and silica, prior to and during to SC-CO2 
processing affected the amount of drug-loaded. The percentage drug-loaded 
increased as the drug – silica ratio increased but was reduced when drug and silica 
were physically separated during processing. The percentage drug-loaded was shown 
to be dependent on the silica surface area available for drug deposition. Pore volume 
measurements indicated differences in drug distribution on the porous silica samples. 
Both decreased pore volume measurements and fenofibrate release profiles indicated 
that drug was deposited to a greater degree in the pores when drug and silica were 
physically separated during processing. Physical mixing of drug and silica powders 
during SC-CO2 processing was shown to increase drug release rate and is therefore, 
more suitable for loading poorly water-soluble drugs. The successful application of 
SC-CO2 processing demonstrates its potential for loading poorly water-soluble drugs 
onto ordered mesoporous materials like SBA-15 to enhance dissolution rate and oral 
bioavailability.  
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6 Optimising drug release from drug – silica 
systems 
6.1 Introduction 
The objective of this chapter was to optimise the release of drug from drug – silica 
systems, namely to increase the release rate and extent of fenofibrate from drug - 
SBA-15 systems. Drug release rates are governed by several factors including 
wetting and effective surface area of drug in contact with the dissolution media. As 
stated previously, the Nernst-Bruner equation related drug dissolution rate to surface 
area with higher surface areas leading to faster dissolution rates (Bruner, 1904, 
Nernst, 1904). Wetting refers to the ability of a powder to attract a liquid and allow 
that liquid spread over the powder; the adhesive force between the powder and liquid 
is stronger than the cohesive force between the liquid. A powder that is easily wetted 
by water allows for extensive coverage of the solid by water which in turn allows for 
a greater effective surface area for drug dissolution leading to faster drug release 
rates. It is well known that the amorphous form of a drug exists in a 
thermodynamically unstable state and posseses a higher Gibbs free energy (Hancock 
and Zografi, 1997) and solubility (Hancock and Parks, 2000) compared to its 
corresponding crystalline form which allows for faster dissolution rates. In drug – 
silica systems, there are other factors that also need consideration. The extent of drug 
release from drug – silica systems is dependent on the amount of drug present in the 
system, the silica mesopore size (Horcajada et al., 2004), specific surface area (Chen 
et al., 2012) and mesopore volume (Heikkila et al., 2007).  
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In chapter 5, the application of SC-CO2 to load fenofibrate onto SBA-15 was 
investigated and it was established that processing pressure, supercritical processing 
duration time, CO2 depressurisation rate and the ratio of drug amount to SBA-15 
surface area did not affect drug solid state form or release rate, within the limits of 
the experiments performed. A relationship between the ratio of drug to SBA-15 and 
drug-loading efficiency was established; the drug-loading decreased from 91.98 
(±6.59) to 69.17 (±10.93) as the drug – silica ratio went from 1 mg: 3 m2 to 1 mg: 
0.82 m
2
 when the entire drug amount was loaded in a single processing step. 
Charnay and co-workers reported previously that successively impregnating silica 
with ibuprofen solution resulted in increased drug-loads and almost complete 
mesopore filling (Charnay et al., 2004). It was postulated that successive SC-CO2 
drug-loading steps could increase drug-loading efficiencies compared to a single 
processing step, without the drug solid state form or release rate being compromised.    
While the drug to SBA-15 ratios investigated in chapter 5 did not show any 
differences in terms of drug solid state form or release rate, it was postulated that 
there was a limit to the quantity of drug that can be loaded onto silica outside of 
these ranges, above which there would be a negative impact on these properties. 
Achieving the maximum drug-load without compromising drug release rate is an 
important target; increasing the mass of drug loaded onto SBA-15 would for 
example lower the amount of powder required in an oral dosage form and hence the 
number of dosage units. In this chapter the maximum drug that could be theoretically 
hosted within the silica mesopores was calculated based of the measured SBA-15 
mesopore volume and the measured drug true density (determined by a gas 
displacement method). The effect of drug-loading levels at, above and below this 
level, on subsequent drug physicochemical properties was then evaluated. 
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In relation to drug release behaviour from drug – silica systems investigated in 
chapter 4 and 5, it was interesting to note that the maximum percentage drug release 
was approximately 80% of the total drug, which was reached after 10 minutes and 
remained steady from 10 – 120 min. A possible explanation for this behaviour was 
that the release media could not fully access the SBA-15 mesoporous structure. To 
investigate this phenomenon, drug release experiments were performed and the 
undissolved drug – SBA-15 powders subsequently recovered by filtration and 
analysed.  The aim was to investigate if any drug remained in the SBA-15 mesopores 
or was it fully liberated during the release. This is the first study to explicitly 
investigate the location of drug within the silica matrix during release experiments. 
The impact of various in vitro dissolution media on the extent of fenofibrate release 
from SBA-15 was also studied. The properties of in vitro release media can affect 
drug release, for example ionizable drugs would be influenced by the media pH 
while in the case of fenofibrate, it is known that the fenofibrate solubility and hence 
release is enhanced in media containing increasing amounts of SDS (Jamzad and 
Fassihi, 2006). 
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6.2 Results 
6.3 Multiple step drug-loading 
In chapter 5, three ratios of drug mass (mg) to SBA-15 surface area (m
2
) were 
investigated; these were 1 mg: 3 m
2
, 1 mg: 1.24 m
2 
and 1 mg: 0.82 m
2
. These drug-
loading ratios were loaded using a single processing step. In this chapter a theoretical 
ratio of 1 mg: 1.24 m
2
 was loaded over two process steps, while for the 1 mg: 0.82 
m
2
 sample was loaded over three steps. As stated earlier the rationale behind loading 
the drug in multiple steps was to increase the drug-loading efficiency. The 
experimental procedure was described earlier in section 2.5.1.  
 
6.3.1 Drug-loading efficiency  
While the % drug load (w/w) increased with each drug-loading step, there were no 
significant differences in drug-loading efficiencies of the samples prepared by single 
or multiple steps at equivalent drug – silica ratios (Fig.6.1).  
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Figure 6.1: Drug-loading efficiency of samples prepared by single versus multiple 
steps, drug-loading efficiency standard deviations indicated by y-axis error bars (n = 
9). 
 
6.3.2 Drug distribution 
There was no significant difference between single and multiple drug-loading steps 
in terms of drug distribution, expressed as % ΔPV for the 1 mg to 1.24 m2 or 1 mg to 
0.82 m
2 
samples (Fig.6.2).  
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Figure 6.2: Comparison of percentage reduction in pore volume (% ΔPV)  of drug – 
silica samples prepared using single versus multiple loading steps, % ΔPV standard 
deviations indicated by y-axis error bars (n = 9). 
 
6.3.3 Drug solid state 
The solid state of the drug loaded with multiple steps onto the SBA-15 was in a non-
crystalline state. No peaks could be observed in the pXRD diffractograms similar to 
the samples prepared by single step drug-loading (Fig.6.3).  
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Figure 6.3: pXRD diffractograms of drug – silica samples prepared using: (1) a 
single step with the 1 mg to 1.24 m
2
 ratio, (2) a single step with 1 mg to 0.82 m
2
 
ratio, (3) 2 steps with 1 mg to 1.24 m
2
 ratio and (4) 3 steps with the 1 mg to 0.82 m
2 
ratio.  
 
6.3.4 In vitro release studies 
There were some differences between release profiles when the single and multiple 
step samples when compared at equivalent drug – silica ratios.  
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Figure 6.4: Comparison of drug release from (♦) single and (□) multiple step drug-
loaded samples at the ratio 1 mg to 1.24 m
2
 in 0.3% (w/v) SDS in 0.1M HCl media 
sample in 0.3% w/v SDS in 0.1M HCl media (mean ± SD, n = 9). 
 
There was a significant difference in drug release between the single and multiple 
step loaded samples at the 1 mg to 1.24 m
2
 drug – silica ratio according to the 
repeated measures ANOVA.  
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Figure 6.5: Comparison of release profiles of (♦) single and (□) multiple step drug-
loaded samples at the ratio 1 mg to 0.82 m
2
 in 0.3% (w/v) SDS in 0.1M HCl media 
sample in 0.3% w/v SDS in 0.1M HCl media (mean ± SD, n = 9). 
 
There was a significant difference in drug release between the single and multiple 
step loaded samples at the 1 mg to 0.82 m
2
 drug – silica ratio according to the 
repeated measures ANOVA.  
 
6.4 The effect of maximising drug-loading on drug 
release properties 
In this section, the amount of drug that can be loaded onto silica without 
compromising drug release rate was investigated. The maximum mass of drug that 
could be theoretically hosted within the silica mesopores was calculated based on the 
known SBA-15 mesopore volume and the measured drug true density (determined 
by He pycnometry) using Eq. 2.1 while the % theoretical mesopore fill was 
Chapter 6  Maximising drug loading and release 
149 | P a g e  
 
calculated according to Eq. 2.2. The major assumptions of this approach were that 
(1) the drug will pack into the entire mesopore volume, and there would be no 
volume lost through voids or blockages due to incomplete drug packing and (2) the 
true density of powder fenofibrate would be similar to the molecular density of 
fenofibrate present in the mesopores. The drug – silica system referred to as the 
‘standard sample’ was based on the ratio of 1 mg to 3 m2 which was investigated in 
chapters 4 and 5 and contained enough fenofibrate to theoretically occupy 32.50% of 
the available SBA-15 mesopore volume. The ‘maximum sample’ contained enough 
fenofibrate to theoretically fill 99% of the available SBA-15 mesopore volume while 
the ‘excess sample’ contained enough fenofibrate to theoretically fill 286% of the 
available SBA-15 mesopore volume. Section 2.5.2 contains more information on the 
preparation of these samples and the calculations involved.  
 
6.4.1 Drug-loading   
The % drug (w/w), % drug-loading efficiency and moisture content of the standard, 
maximum and excess samples are displayed below, Table 6.1 
 
Table 6.1: % drug, drug-loading efficiencies and % moisture for standard, maximum 
and excess samples, standard deviations in brackets (n = 9). 
Variable SBA-15 Standard Maximum Excess 
% drug  (w/w) N/A 19.31 (±2.22) 38.52 (±4.36) 49.26 (±2.65) 
Drug-loading efficiency (%) N/A 88.89 (±10.21) 83.84 (±9.49) 70.91 (±1.16) 
% Moisture (w/w) 10.00 (±2.88) 3.35 (±0.27) 1.54 (±0.41) 1.23 (±0.30) 
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There was a significant increase in % drug (w/w) as the amount of drug processed 
with the SBA-15 increased. However there was a significant decrease in the drug-
loading efficiency of the excess sample compared to the standard and maximum 
samples. The presence of drug loaded onto SBA-15 can be detected from the 
changes of its surface properties, one of which is the lower moisture content after 
drug-loading. A statistically significant reduction in the moisture content of SBA-15 
after loading with fenofibrate was observed in the standard, maximum and excess 
samples. While the standard sample had significantly higher moisture than the 
maximum and excess sample, there was no significant difference between the 
maximum and excess samples in terms of moisture content.   
 
6.4.2 Drug distribution 
A representative SEM image of the ‘standard sample’ is displayed below (Fig.6.6). It 
was not possible to observe any fenofibrate particles in this sample; it appeared that 
the fenofibrate had been deposited into the SBA-15 mesopore structure.  
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Figure 6.6: SEM image of the ‘standard sample’ with magnification of X750. 
 
The SEM image of the ‘maximum sample’ showed fenofibrate particles (Fig.6.7). 
The visible drug particle appeared to be less than 50 µm in diameter.  
 
 
Figure 6.7: SEM image of the ‘maximum sample’ at X350 magnification. 
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In the ‘excess sample’, drug particles were also observed throughout the SEM 
images. A large isolated fenofibrate particle was observed in Fig. 6.8a, while several 
smaller particles were visible in Fig. 6.8b.  
 
A  B  
Figure 6.8: SEM images of ‘excess sample’ at a magnification (A) X330 and (B) 
X1900.  
 
A type IV gas adsorption isotherm indicative of mesoporous materials (Brunauer et 
al., 1938) was observed in all drug-loaded samples (Fig.6.9).  
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Figure 6.9: BET isotherms of (♦) unprocessed SBA-15, (●) standard, (□) maximum 
and (▲) excess samples. 
 
The closure point of the hysteresis loop was reduced from 0.5 P/Po to 0.45 P/Po for 
the standard and maximum samples, an indication that there was a reduction in the 
mesopore size distribution. The reduction in the amount of N2 adsorbed highlighted 
the large reductions of the specific surface area and mesopore volume. The surface 
and mesopore properties of unprocessed SBA-15, standard, maximum and excess 
samples are displayed below, Table 6.2.   
 
Table 6.2: Surface area, mesopore volume and % ΔPV for standard, maximum and 
excess samples, standard deviations in brackets (n = 9).  
Variable SBA-15 Standard Maximum Excess 
Specific surface area (m
2
/g) 833.22 (±48.13) 305.47 (±4.49) 127.96 (±32.99) 33.62 (±13.39) 
Mesopore volume (cm
3
/g) 0.68 (±0.02) 0.41 (±0.02) 0.19 (±0.05) 0.05 (±0.02) 
% ΔPV N/A 25.91 (±3.74) 55.82 (±8.07) 84.34 (±4.98) 
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There were significant differences in specific surface area and mesopore volume 
across all samples. The % ΔPV increased significantly when the amount of drug 
present increased across all the standard, maximum and excess samples. However, 
complete mesopore filling was not achieved for either the maximum or excess 
samples, as evidenced by the fact that there remained a residual mesopore volume, 
which could also be observed (Fig.6.10).  
 
 
Figure 6.10: Pore size distribution of (▲) unprocessed SBA-15, (●) standard, (♦) 
maximum and (□) excess samples. 
 
The mean mesopore size of SBA-15 was 50.70 Å (±0.20) while it was 52.39 Å 
(±1.86) and 49.93 Å (±0.29) for the standard and maximum samples respectively; 
there was no significant differences between their mean mesopore sizes (Fig.6.11). 
However in the case of the excess sample, there was a significant increase in mean 
mesopore size to 61.18 Å (±6.90) compared to unprocessed SBA-15.  
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Figure 6.11: Mean mesopore sizes for unprocessed SBA-15, standard, maximum and 
excess samples; mean mesopore size standard deviations indicated by y-axis error 
bars (n = 6). 
 
6.4.3 Solid state properties 
There was no evidence of drug crystallinity observed in the pXRD diffractogram for 
the standard sample. There was strong evidence for the presence of crystalline drug 
in the pXRD diffractograms of the maximum and excess samples (Fig. 6.12).  In the 
excess sample, peaks were present at angles 14, 15, 16 and 23
o
. These peaks agreed 
with those observed for unprocessed crystalline fenofibrate in chapter 3.  
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Figure 6.12: pXRD diffractograms of (1) standard, (2) maximum and (3) excess 
samples. 
 
The DSC thermograms of the maximum and excess samples also displayed evidence 
of crystallinity. There was a visible endotherm in the thermal region corresponding 
to fenofibrate’s melting point, which was larger in the excess sample, compared to 
the maximum sample. The standard sample did not display evidence of a melting 
endotherm. There was no evidence in the form of Tg or Tcr to support the presence of 
an amorphous drug phase in any of the sample DSC thermograms observed 
(Fig.6.13) However, as previously mentioned the melting of frozen water in the 
SBA-15 mesopores occurs over the range of -20 – -12 oC and may have confounded 
the detection of the drug Tg in these samples.  
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Figure 6.13: DSC thermograms of (1) standard, (2) maximum and (3) excess 
samples. 
 
6.4.4 In vitro release 
The maximum and excess samples had a slower release rate and lower amount of 
drug release after 2 h compared to the standard sample (Fig. 6.14). 
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Figure 6.14: Release profiles of (●) unprocessed fenofibrate, (▲) standard, (◊) 
maximum and (■) excess samples in 0.3% (w/v) SDS in 0.1M HCl media sample in 
0.3% w/v SDS in 0.1M HCl media (mean ± SD, n = 9). 
 
The drug release profiles for both the maximum and excess samples were 
significantly reduced according to the f1, modified f1 and f2 tests, when compared to 
the standard sample. There was a singficant decrease in drug release from the 
maximum sample compared to the standard sample according to the repeated 
measures ANOVA test. This was also the case for the excess sample compared to the 
standard sample. All samples had significantly higher rate and extent of drug release 
compared to unprocessed fenofibrate over 2 h.  
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6.5 Investigating drug release behaviour from drug – 
SBA-15 systems 
As mentioned previously in chapters 4 and 5, the maximum percentage release of 
fenofibrate from drug – SBA-15 systems in a solution of 0.3% w/v SDS and 0.1M 
HCl solution (sink conditions) was approximately 80% after 2 h. In an attempt to 
identify why 80% seemed to be the maximum drug percentage release, release 
experiments were stopped after 15 min or 24 h and the powders were recovered and 
characterised after exposure to release media. In vitro release experiments were also 
performed in alternative release media, including 1.5% w/v SDS in deionised water, 
which was the recommended USP dissolution medium for fenofibrate (USP, 2013), 
1.5% w/v SDS in 0.1M HCl solution and 0.3% w/v SDS in deionised water.  
 
6.5.1 Characterisation of powders recovered after release 
studies 
 The release media was filtered at 15 min or 24 h, oven dried for 3 days and the 
recovered solid residue analysed. The sample investigated was SC-CO2 processed 
fenofibrate – SBA-15 with the ratio of 1 mg to 3 m2 (standard sample). The drug 
content (%), % drug recovered calculated from Eq.2.9 and % drug release of the 
‘standard sample’ prior to release experiments and the powders recovered from the 
release media after 15 min and 24 h are displayed below, Table 6.3.  
 
 
 
Chapter 6  Maximising drug loading and release 
160 | P a g e  
 
Table 6.3: % drug (w/w), % drug recovered (w/w) and % release of powders 
recovered after 15 min and 24 h in release media, standard deviations in brackets.  
Sample % Drug (w/w) (n = 9) % recovered (w/w) % Release(n = 9) 
Standard sample 18.57 (±1.58) N/A N/A 
Recovered after 15 min 6.96 (±0.68) 38.81 (±6.89), (n = 6) 85.42 (±7.24) 
Recovered after  24 h 7.45 (±1.96) 40.17 (±8.75), (n = 9) 45.73 (±7.02) 
 
The % drug release was unexpectedly found to decrease from over 80% at 2 h to 
45.73% (±7.02) after 24 h. However, this seemed to match with the % drug 
recovered after filtration, which suggested that the drug was not degraded during the 
release experiment.  The surface and porosity properties of unprocessed SBA-15, the 
‘standard sample’ and the powders recovered from the release media after 15 min 
and 24 h are shown, Table 6.4. 
 
Table 6.4: Surface and porosity properties of unprocessed SBA-15, standard 
sample and powders recovered after 15 min and 24 h from release media, 
standard deviations in brackets.  
Sample S.S.A (m2/g)  % ΔSSA P.V. (cm3/g) % ΔPV 
SBA-15 
833.22 (±48.13),  
(n = 9) 
N/A 
0.68 (±0.02),  
(n = 9) 
N/A 
Standard sample 
305.47 (±4.49),  
(n = 9) 
62.39 (±17.86),  
(n = 9) 
0.41 (±0.02),  
(n = 9) 
25.91 (±3.74),  
(n = 9) 
Recovered after 15 min 
548.63 (±31.65),  
(n = 3) 
29.22 (±4.41),  
(n = 3) 
0.55 (±0.03),  
(n = 3) 
13.16 (±4.75),  
(n = 3) 
Recovered after  24 h 
606.95 (±76.17),  
(n = 3) 
21.29 (±10.52),  
(n = 3) 
0.66 (±0.10),  
(n = 3) 
-5.53 (±16.87),  
(n = 3) 
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There was no significant difference between both recovered powders in terms of 
specific surface area; interestingly the 24 h recovered powder did have a 
significantly higher mesopore volume than the powder recovered at 15 min. In fact, 
there was no significant difference between the mesopore volume of unprocessed 
SBA-15 and the powder recovered after 24 h release. This implied that at 15 min, 
some of the drug was still in the SBA-15 mesopores, but after 24 h it had been fully 
liberated. This indicated that the drug inside the SBA-15 mesopores was fully 
accessible to the release media. The results of the % ΔPV also highlighted this point. 
It can be seen that the powder recovered after 24 h had a similar pore size 
distribution to the unprocessed SBA-15, pore size range approximately 4.5 – 8.5 nm 
(Fig. 6.15). 
 
 
Figure 6.15: Pore size distribution of (■) unprocessed SBA-15, (●) standard sample 
and powders recovered from release media after (□) 15 min and (▲) 24 h. 
 
Chapter 6  Maximising drug loading and release 
162 | P a g e  
 
The sample recovered after 15 min in release media seemed to have slightly reduced 
pore size distribution, from 4.5 – 7.5 nm. This is further evidence that some drug was 
in the mesopores at 15 min.  
 
6.5.2 Effect of in vitro media on drug release from SBA-15 
The fact that the drug release decreased from over 85.42% (±7.24) at 2 h to 45.73% 
(±7.02) after 24 h in 0.3% w/v SDS/0.1M HCl solution highlighted that it was 
possible that the release medium was influencing the release of fenofibrate from 
SBA-15. In this section, the dissolution/release media investigated were 0.3% w/v 
SDS and 1.5% SDS in deionised water and 0.3% w/v SDS and 1.5% SDS w/v in 
0.1M HCl solution. The solubility of fenofibrate in dissolution media can be altered 
by the addition of SDS; the greater the amount of SDS in the media, the higher 
fenofibrate’s solubility (Jamzad and Fassihi, 2006). The solubilities of unprocessed 
fenofibrate in the various media investigated after 48 h at 37 
o
C are shown in Table 
6.5.  
 
Table 6.5: Solubilities of unprocessed fenofibrate in different media after 48 h at 37 
o
C, standard deviations in brackets (n = 9). 
Dissolution media Media pH Solubility (µg/ml) 
SDS 0.3% w/v in deionised water 6.60 – 6.75 20.68  (±3.57) 
SDS 1.5% w/v in deionised water 7.84 – 8.83 525.05 (±21.99) 
SDS 0.3%  w/v in 0.1M HCl solution 1.35 – 1.38 67.21 (±4.81) 
SDS 1.5%  w/v in 0.1M HCl solution 1.37 – 1.38 256.00 (±30.21) 
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Interestingly, the effect of HCl on fenofibrate solubility was positive at the lower 
SDS concentration but negative at the higher SDS concentration. The media 
containing higher amounts of SDS resulted in higher fenofibrate solubilities. The 
critical micelle concentration (CMC) refers to the concentration of a surfactant above 
which micelles form (McNaught and Wilkinson, 1997) and is an important 
parameter affecting drug solubility in solutions containing SDS. The CMC of SDS in 
deionised water was previously reported to be 0.24% w/v (8 mM)  (Mukerjee and 
Mysels, 1972). In this work, it was determined that the CMC of SDS in deionised 
water at 37 
o
C was 0.21% w/v SDS while in 0.1M HCl solution at 37 
o
C it was 
0.023% w/v SDS. This could explain why there was higher fenofibrate solubility in 
0.3% w/v SDS/0.1M HCl solution than in 0.3% w/v SDS/deionised water. The 
dissolution of unprocessed fenofibrate in the various dissolution media up to 2 h is 
shown below (Fig. 6.16). 
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Figure 6.16: Unprocessed fenofibrate dissolution over 120 min in (□) 1.5% w/v SDS/ 
0.1M HCl solution, (♦) 1.5% w/v SDS /deionised water, (∆) 0.3% w/v SDS/ 0.1M 
HCl solution and (●) 0.3% w/v SDS /deionised water sample (mean ± SD, n = 3). 
 
The lowest drug dissolution was observed in 0.3% w/v SDS/deionised water, with 
the highest dissolution achieved in 1.5% w/v SDS/deionised water and 1.5% w/v 
SDS/0.1M HCl solution. The extent of drug dissolution in 0.3% w/v SDS in 
deionised water was significantly less than that in all other media over 2 h according 
to the f1, modified f1 and f2 tests. It was also seen in the repeated measures ANOVA 
test that the dissolution profile of drug in 0.3% w/v SDS/deionised water was 
singicantly less than that in 0.3% w/v SDS/0.1M HCl solution. There was a 
significant effect of SDS concentration on drug dissolution rate which was expected. 
There was no significant difference between the dissolution profiles obtained from 
1.5% w/v SDS/deionised water and 1.5% w/v SDS/0.1M HCl solution over 2 h when 
analysed by the f1, modified f1 and f2 tests. There was a significant increase in 
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percentage release between 2 to 24 h for unprocessed fenofibrate in all the media 
except in the 1.5% w/v SDS/0.1M HCl solution (Fig.6.17).  
 
 
Figure 6.17: Unprocessed fenofibrate % dissolution at 2 h (clear column) and 24 h 
(dark column) (mean ± SD, n = 3).  
 
While unprocessed fenofibrate was highly susceptible to the properties of the 
dissolution media; after SC-CO2 processing fenofibrate with SBA-15 (standard 
sample), the influence of the release media on the drug release properties was 
decreased (Fig.6.18).  
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Figure 6.18: Fenofibrate release from SC-CO2 processed drug – SBA-15 samples (1 
mg: 3 m
2) over 120 min in (□) 1.5% w/v SDS / 0.1M HCl solution, (♦) 1.5% w/v 
SDS /deionised water, (∆) 0.3% w/v SDS /0.1M HCl solution and (●) 0.3% w/v SDS 
/deionised water (mean ± SD, n = 9). 
  
The effect of 0.1M HCl in the release media was profound; the percentage release of 
drug from the SC-CO2 processed sample decreased from 2 to 24 h, while in media 
with no 0.1M HCl, there was no significant change from 2 to 24 h.   
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6.6 Discussion 
The aim of this chapter was to optimise the drug-loading and release of SC-CO2 
processed fenofibrate – SBA-15. Multiple step drug-loading was employed in order 
to achieve an increased drug-loading efficiency in comparison with single step drug-
loading. While the drug load increased after each step as expected, the multiple step 
approach did not yield an increase in drug-loading efficiency compared to loading an 
equivalent amount of drug in a single step. The drug was stabilised in a non-
crystalline form across all loading steps. This result corresponded to previous results 
obtained where fenofibrate was stabilised in a non-crystalline form, as mentioned in 
chapters 4 and 5. The significant improvement in drug release compared to 
unprocessed fenofibrate has already been explained in chapter 4. The drug release 
from the multiple step drug-loaded samples was significantly less than that of single 
step samples processed with equivalent drug – silica ratios. It is difficult to 
understand why this should be so as there was no observable difference in terms of 
drug solid state or release between the single and multiple step samples. It should be 
stated that after 20 min, there were no significant differences in drug release between 
the single and multiple step samples.   
To date, there has not been any report of how to calculate how much fenofibrate 
could be loaded into a known volume of SBA-15 mesopores, while ensuring that the 
drug is in a non-crystalline state with rapid release. In this chapter, the drug’s true 
density and silica mesopore volume were used to determine the amount of drug that 
could be accommodated in the mesopores. In the maximum sample, there was 
enough fenofibrate to completely fill the SBA-15 mesopores; however this did not 
occur as there was still mesopore volume measured by gas adsorption (BET). There 
were free drug particles observed on SEM images of both the maximum and excess 
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samples, which resulted in significant drug crystallinity compared to the ‘standard 
sample’. In chapter 4, it was seen that physically mixing fenofibrate and SBA-15 did 
not result in amorphous fenofibrate as the fenofibrate was not inside the mesopores. 
In the physical sample from chapter 4 and the maximum and excess samples in this 
chapter, the evident drug crystallinity lowered the rate and extent of drug release 
signifciantly. The moisture content of the maximum and excess samples was also 
significantly less compared to the standard sample; these samples were less 
hydrophilic which acted to reduce drug release. This work highlighted that loading 
drug based on its true density and the available silica mesopore volume was not a 
promising approach, because of the significant crystallinity and consequent reduction 
in the rate and extent of drug release. Perhaps, an approach utilising fenofibrate 
molecular density may offer a possible solution to this problem and could be an 
object worth pursuing, however this would be assuming that fenofibrate molecular 
density would not change on mesopore confinement.  
The maximum drug release obtained from the SC-CO2 processed drug – silica 
samples (standard sample) in the 0.3% w/v SDS/0.1M HCl solution was 
approximately 80% after 15 min and remained steady up to 2 h. The extent of release 
reduced to approximately 45% after 24 h. Analysis of the drug – silica powders 
recovered from the release media suggested that after 15 min, some of the drug was 
located inside the SBA-15 mesopores, but that by 24 h the majority of drug was 
outside the mesopores.  This was supported by the surface and porosity results of 
these samples which showed a significant difference between the mesopore volume 
of unprocessed SBA-15 and the drug – silica powder recovered after 15 min, 
whereas there was no significant difference between unprocessed SBA-15 and the 
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drug – silica powder recovered after 24 h. The drug was not degraded during the 
release experiments as it was recovered with the SBA-15 afterward.  
The influence of the in vitro release media on drug release was investigated to 
determine why the drug release was observed to decrease in 0.3% w/v in 0.1M HCl 
solution. Across all media investigated, the drug release rate from drug – silica 
samples was more rapid and with a greater extent compared to unprocessed 
fenofibrate. As expected, fenofibrate solubility and release increased as the SDS 
concentration increased (Jamzad and Fassihi, 2006). Maximal drug release (100%) 
was obtained in 1.5% w/v SDS/ deionised water after 10 min and was maintained for 
24 h. While 100% drug release was obtained in 1.5% w/v SDS/0.1M HCl solution, 
the release decreased between 2 and 24 h, interestingly this decrease in the quantity 
of drug released was only observed in media containing 0.1M HCl, and was more 
pronounced in the media with lower SDS concentration. While mesoporous silica 
has been documented as an adsorbent material that could remove pollutants from 
water (Walcarius and Mercier, 2010), it was felt that the observed decrease of 
fenofibrate release was not due to SBA-15 re-adsorption of the drug because it only 
occurred in media containing 0.1M HCl. It has been reported that negatively charged 
SDS micelles react with hydrogen ions to produce dodecyl sulfonic acid (DSA) and 
sodium chloride (NaCl) (Bayrak, 2003). This reaction would reduce the number of 
SDS micelles in solution and could potentially lead to re-crystallisation of the drug 
out of solution. It was also established that the CMC of SDS in 0.1M HCl solution at 
37 
o
C
 
was lower than the CMC of SDS in deionised water, which facilitated greater 
fenofibrate solubility and drug release in 0.3% w/v SDS/ 0.1M HCl compared to 
0.3% w/v SDS. Jain and co-workers reported the general equation for micellar 
concentration,  
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Equation 6.1:     Stot = Sw + kCmic  
 
Where Stot is the total molar solubility of the solute, Sw is the water solubility of the 
solute, k is the molar solubilisation capacity of the surfactant and Cmic is the total 
surfactant concentration minus the CMC (Jain et al., 2004). This equation 
demonstrated that a higher Cmic in the media containing 0.1M HCl compared to the 
media without 0.1M HCl would prevail because the CMC was lower in the media 
containing the 0.1M HCl.  
Another factor at play is the surface charge of silica across various pH values. The 
point of zero charge of silica has been reported to lie between pH 1.7 – 3.5 
(Kosmulski, 2001). Below a pH of 1.7, the silica surface is positively charged while 
above pH 3.5 the silica surface is negatively charged. In the media containing 0.1M 
HCl, the SBA-15 is positively charged and potentially able to attract the negatively 
charged SDS micelles. These results highlight the many interrelated factors to be 
considered in determining fenofibrate release from SBA-15 in vitro.  
 
6.7 Summary 
The application of multiple SC-CO2 drug-loading steps was investigated and found 
not to influence drug-loading efficiency or solid state; however it did slow down the 
release rate compared to single step loading over the first 15 min. Loading the 
maximum drug theoretically possible based on SBA-15 mesopore volume and 
fenofibrate true density negatively impacted drug release due to the presence of 
crystalline drug outside the SBA-15 mesopores, the reduced  effective surface area 
of drug in contact with the release medium and reduced hydrophilic nature of the 
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these samples. The use of the drug true density to calculate the maximum drug that 
can be hosted within the SBA-15 mesopores would not be recommended, perhaps, a 
more appropriate method would be to apply the molecular drug density.  
The release medium can profoundly influence drug release behaviour from SBA-15; 
maximal drug release was only achieved in 1.5% w/v SDS in deionised water and 
1.5% w/v SDS in 0.1M HCl solution. In the media containing 0.1M HCl, it was 
observed that the release declined from 2 to 24 h for the SC-CO2 processed drug – 
silica samples which could be due to a number of factors including the reaction of 
SDS with HCl and interaction between SBA-15 and SDS at low pH.  
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7 General Discussion 
7.1 Introduction to this discussion 
The aim of this thesis was to enhance the dissolution rate of the poorly water-soluble 
drug, fenofibrate by exploiting the high surface area carrier, mesoporous silica 
(SBA-15). The material properties and advantages of mesoporous silica for oral drug 
delivery have already been discussed earlier in the introduction to this thesis. As 
mentioned in the introductory chapter, the objectives of this research were to: 
 
 Enhance fenofibrate release through the application of the high surface area 
carrier mesoporous silica (SBA-15), 
 investigate various processing methods to load fenofibrate onto SBA-15 and 
determine what impact the loading process had on fenofibrate release from 
SBA-15, 
 investigate how SC-CO2 processing conditions  influenced drug-loading and 
release from fenofibrate - SBA-15 systems and  
 investigate physicochemical factors influencing drug release from fenofibrate 
– SBA-15 systems.  
 
The objective of this general discussion is to provide an overarching discussion how 
drug release can be enhanced from SBA-15 in the light of the variables investigated 
and results presented in this thesis. Therefore, this discussion will aim to consider the 
results across the all the chapters in terms of how drug release was enhanced after 
drug-loading into/onto mesoporous silica:  
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 how the drug solid state affected release properties and  
 
 how drug distribution within the silica matrix affected both drug solid state 
and release. 
 
7.2 Enhancement of fenofibrate release 
In every experiment where fenofibrate and SBA-15 were processed together, there 
was an enhancement of fenofibrate release from SBA-15 compared to unprocessed 
drug alone. This was not surprising because dissolution rate can be improved if the 
drug surface area, or in the case of drug – silica systems the effective drug surface 
area in contact with the dissolution medium is increased (Bruner, 1904, Nernst, 
1904). SBA-15 is also a very hydrophilic material and it readily attracts moisture 
from its surroundings, whereas fenofibrate is very hydrophobic. After processing 
fenofibrate with SBA-15, the drug is more easily wetted which improved the release. 
Wang and co-workers prepared solid dispersions of silica (Aerosil and Sylysia) and 
nitrendipine and reported that the increased hydrophilicity of the drug as a result of 
being in the dispersion led to increased wetting which enhanced the drug dissolution 
(Wang et al., 2006).  
 
7.3 The influence of the in vitro media on drug release 
from SBA-15 
The most striking affect on fenofibrate release from SBA-15 was the in vitro release 
media employed for the studies. As shown in chapter 6, the release of fenofibrate 
from SBA-15 is dependent on both the SDS concentration and the acidic nature of 
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the media. In 1.5% w/v SDS in deionised water, there was approximately 100% 
release achieved which was maintained up to 24 h. The effect of reducing SDS 
concentration was striking; the release after 24 h was approximately 66% in 0.3% 
w/v SDS in deionised water, in fact the difference was significant between the 
release profiles of 0.3-and-1.5% w/v SDS. Fenofibrate solubility is known to be 
sensitive to SDS concentration (Jamzad and Fassihi, 2006). While fenofibrate itself 
was not ionisable, the acidity of the release media affected fenofibrate release from 
SBA-15; when 0.1M HCl was in the solution, there was a measurable decrease in % 
release from 2 to 24 h. This decrease was not evident in the samples without 0.1M 
HCl (Refer to chapter 6). It has been reported that (a) SDS can react with HCl to 
form sulfonic acid (Bayrak, 2003) and (b) that SDS monomer and micelles have a 
negative charge while the surface of SBA-15 is positively charged at pH ~1.2 
(Kosmulski, 2001). The decrease was more evident in the media containing 0.3% 
w/v SDS in 0.1M HCl solution, which would tend to support the supposition that the 
SDS micelle concentration had been reduced over time.  The media containing 1.5% 
w/v SDS in 0.1M HCl solution should be affected less as there is a higher 
concentration of SDS micelles in the solution. There are several reports of immediate 
drug release of various drugs from different silicas in acidic media including 
simulated gastric fluid with 0.5 wt% SDS with pH 1.2 (Charnay et al., 2004, 
Mellaerts et al., 2007, Van Speybroeck et al., 2010a, Vialpando et al., 2012, Li-hong 
et al., 2013). These publications typically reported release over 1 – 2 h and did not 
observe the impact of HCl on SDS micelle concentration. 
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7.4 The influence of drug distribution within the silica 
matrix on release 
In this thesis, drug distribution was defined as whether the drug was inside the SBA-
15 mesopores or not and was determined using surface area and pore size analysis by 
N2 adsorption. It was not possible to directly observe drug in the mesopores due to 
the resolution of chemical imaging techniques, instead the difference between 
theoretical and measured mesopore volumes, the % ΔPV term was employed to 
understand drug distribution within the SBA-15 matrix. The distribution of drug 
within the silica matrix had the greatest affect on drug release in the context of 
whether the drug was in the mesopores or not. First of all, the fenofibrate that was 
not loaded into the SBA-15 mesopores had a slower release rate and lower extent 
compared to drug within the mesopores, this can be seen with the physical mix 
sample in chapter 4 and the excess sample in chapter 6. In chapter 4, the 
impregnation, liquid and SC-CO2 loading methods were shown to load drug into the 
mesopores. These methods were very similar in terms of drug-loading efficiency but 
the SC-CO2 sample had a much lower % ΔPV of 19.12 (±4.17) compared to the 
impregnation % ΔPV of 33.12 (±2.08) and liquid CO2 % ΔPV of 32.06 (±1.55) at the 
drug – silica ratio of 1 mg to 3 m2. Based on the % ΔPV, it was thought that the drug 
was loaded deepest into the SBA-15 mesopores by the SC-CO2 method. However, 
there was no observable impact on drug release (Refer to chapter 4). While it has 
been reported that the length of the mesopores can influence drug release (Chen et 
al., 2012, Qu et al., 2006), in this work the SBA-15 mesopores should have been of 
similar length across batches.  
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While the ‘mix’ and ‘bag sample’ prepared at the drug – silica ratio of 1 mg to 3 m2 
with constant SC-CO2 conditions had similar % ΔPVs, the ‘mix sample’ had a higher 
drug-loading efficiency than the ‘bag’ sample. It was hypothesised that the samples 
prepared by the ‘bag method’ were deposited into the SBA-15 mesopores  in a 
different manner compared to the ‘mix method’ which led to the ‘bag samples’ 
having a signficasntly lower release extent than the ‘mix sample’ according to the f1, 
modified f1 and f2 factors and repeated measures ANOVA (Fig.7.1).  
 
 
Figure 7.1: Release profiles of 1 mg to 0.82 m
2
 samples (■) ‘mix method and (∆) 
‘bag method’ in 0.3% w/v SDS in 0.1M HCl media (mean ± SD, n = 9).  
 
The most obvious effect of drug distribution on drug release was the comparison 
between drug deposited in the mesopores and drug not in the mesopores. The 
physical mix had a % ΔPV of 1.88 (±5.37), the melt method a % ΔPV of 37.51 
(±5.63) while the SC-CO2 recorded a % ΔPV of 19.12 (±4.17) at the drug – silica 
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ratio of 1 mg to 3 m
2
. The physical mix did not distribute drug into the mesopores, 
consequently its release rate was significantly slower and extent lower than the melt 
and SC-CO2 samples (Fig.7.2).       
 
 
Figure 7.2: Release profiles of 1 mg to 3 m
2
 samples, (◊) physical mix, (●) melt 
method and (■) SC-CO2 in 0.3% w/v SDS in 0.1M HCl media (mean ± SD, n = 9). 
 
The melt sample had a significantly lower release compared to the SC-CO2 sample, 
which could have been due to different distribution of the drug in this compared to 
the SC-CO2 or the residual crystallinity it contained (Refer to chapter 4). 
 
7.5 The influence of drug solid state form on release  
It is well established that the amorphous form of drugs have higher solubilities than 
their crystalline forms (Hancock and Parks, 2000). In this thesis, the rate and extent 
of fenofibrate release from SBA-15 was strongly influenced by the drug solid state 
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form. The release profiles of samples containing crystallinity are compared against a 
sample without crystalline drug (Fig.7.3).  
 
 
Figure 7.3: Release profiles of samples containing crystalline drug, (●) unprocessed 
fenofibrate (n = 3), (■) physical mix (n = 9), (▲) ‘excess sample’ (n = 3) and a 
sample containing non-crystalline drug (○) “standard sample” (n = 9) in 0.3% w/v 
SDS in 0.1M HCl media.  
 
All drug – silica samples showed enhanced drug release compared to crystalline, 
unprocessed fenofibrate only. While both the standard and excess samples were 
prepared by SC-CO2 processing, the standard sample contained drug in a non-
crystalline state whereas the ‘excess sample’ contained both crystalline and non-
crystalline drug. The physical mix also contained crystalline fenofibrate and 
displayed a limited enhancement in drug release. The physical mix and the standard 
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sample were prepared at the drug – silica ratio of 1 mg to 3 m2. It was quite clear that 
drug solid state had a significant impact on subsequent release properties. Mellaerts 
and co-workers showed results where itraconazole loaded onto SBA-15 by a melt 
method retained some drug crystallinity which led to lower release extent compared 
to an equivalent sample prepared by impregnation with no crystallinity (Mellaerts et 
al., 2008a). Cha and co-workers also showed the negative influence of fenofibrate 
crystallinity where the release from Neusilin UFL2
®
 was suppressed in drug – silica 
samples containing crystallinity (Cha et al., 2012).  
 
7.6 The influence of drug distribution within the silica 
matrix on drug solid state form  
The meaning of drug distribution within the silica matrix has been explained in 
section 7.4. The solid state of fenofibrate after processing with SBA-15 was found to 
be dependent on its distribution within the silica matrix; that is, whether the drug was 
inside or outside the silica mesopores. Fenofibrate retained its crystalline nature after 
SC-CO2 processing when not in contact with silica. Crystalline fenofibrate was 
recovered from the bottom of the high-pressure cell; this was drug that was not in 
contact with the SBA-15. This highlighted very clearly that fenofibrate not in contact 
with the SBA-15 would remain crystalline after SC-CO2. The physical mix of 
fenofibrate and SBA-15 displayed several Bragg’s peaks typical of crystalline 
fenofibrate. This agreed with previous work where K-832, prednisolone, flurbiprofen 
and salicylamide were physically mixed with mesoporous silicas and retained their 
crystallinity (Miura et al., 2010, Nishiwaki et al., 2009, Tozuka et al., 2005, Tozuka 
et al., 2003). For the sake of completeness, it should be stated that there have been 
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reports where physical mixing of high vapour pressure compounds with silica gel led 
to crystalline compounds becoming amorphous over a period of time; however this 
process occurred in the absence of moisture and was reversed when moisture was 
introduced to the system (Qian et al., 2012, Qian et al., 2011, Qian and Bogner, 
2011). In the ‘excess sample’, there was measurable drug crystallinity which was 
considered to be the result of free fenofibrate particles outside the SBA-15 
mesopores; drug particles were observed during SEM analysis (Refer to chapter 6). 
Sanganwar and Gupta loaded fenofibrate onto the non-porous silica, Aerosil
®
 with a 
SC-CO2 method and found that the drug was not stable in the amorphous form. It is 
known that drugs confined within spaces that are less than 10 times their molecule 
diameter cannot re-crystallise (Rengarajan et al., 2008, Sliwinska-Bartkowiak et al., 
2001). Azais and co-workers studied the confinement of ibuprofen in MCM-41 
mesopores (3.5 and 11.6 nm) with solid state, nuclear magnetic resonance (SS-
NMR) and reported that the mesoporous confined ibuprofen was neither crystalline 
nor amorphous at ambient temperature (Azais et al., 2006). Therefore, if the drug 
was loaded into the mesopores, it would be in a non-crystalline state. The drug – 
SBA-15 samples prepared by the impregnation, liquid and SC-CO2 processes 
appeared to be in a molecularly dispersed state as there were no observed thermal 
events like a Tg on the DSC thermogram. There have been several reports where 
drugs loaded onto SBA-15 using an impregnation process were reported to be 
molecularly dispersed as there was no Tg or Tm observed (Mellaerts et al., 2010, 
Mellaerts et al., 2008a, Nishiwaki et al., 2009, Van Speybroeck et al., 2010b).  
Fenofibrate, which has a Tg of -20 
o
C, a Tcr of 40 
o
C and Tr of 0.6 (Zhou et al., 2002) 
is very unstable in its amorphous form, yet it was stabilised in the non-crystalline 
form inside SBA-15 mesopores after 12 months under accelerated storage conditions 
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in the impregnation, liquid and SC-CO2 prepared samples. This corresponded to 
results published by Mellaerts and co-workers who reported that itraconazole was 
maintained in an amorphous form for up to 12 months after processing with SBA-15 
(Mellaerts et al., 2010) and Shen and co-workers who published similar findings 
with respect to ibuprofen co-spray-dried with SBA-15 (Shen et al., 2010). The fact 
that it was stabilised in the non-crystalline form was further evidence that the drug 
was in the mesopores and highlighted that it was critical for the drug to be 
distributed into the silica mesopores.  
 
7.7 Factors that influence drug distribution within the 
silica matrix 
There are many potential ways which drug is distributed on silica. A schematic of 
potential drug distribution within the silica matrix is presented below (Fig7.4). 
 
 
Figure 7.4: Potential drug distribution within silica matrices.  
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In the first case, it is possible that the drug particles could be on the external surface 
of the silica. Secondly, there could be drug molecules obstructing mesopore 
openings or thirdly be obstructing the mesopores further within; this could also 
include lining or coating the mesopores and causing a reduction in the mesopore 
size. Fourthly, there could be free drug particles not associated with the silica at all. 
The factors identified in this thesis that influenced drug distribution within the silica 
matrix were: (a) the drug-loading process and (b) the drug – silica ratio. The loading 
method is important because the drug powder must be dissolved in some solvent 
(e.g. acetronitrile or CO2) before it can be molecularly dispersed into the silica 
mesopores. Physically mixing drug and silica particles cannot facilitate drug entry 
into the mesopores because the drug remained in a particulate state. It was found in 
this work that SC-CO2 loaded drug somewhat differently into SBA-15 than melt, 
solvent impregnation and liquid CO2 methods because a larger mesopore volume 
was observed for the SC-CO2 samples after drug-loading. This larger mesopore 
volume may be due to the fact the drug molecules were deeper within the mesopores 
after SC-CO2 processing whereas the processing methods like the melt method may 
have deposited the drug nearer the surface of the mesopores.   
The drug – silica ratio heavily influenced drug distribution. No publication has 
reported a satisfactory manner of calculating the maximum drug that can be 
accommodated within SBA-15. In a manufacturing process, it would be important to 
efficiently load the drug into the silica mesopores without exceeding the quantity of 
drug that can be accommodated within the mesopore volume. In chapter 6, a method 
of determining the maximum drug mass per SBA-15 mesopore volume was 
presented. The results highlighted that there were limitations using drug true density 
and mesopore volume for calculating the mass of drug to be loaded. Possibly one 
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approach that could be utilised is to apply the drug molecular density and calculate 
the drug amount from that method. 
 
Chapter 7  General Discussion 
184 | P a g e  
 
7.8 Key findings of this thesis 
There were several key findings of this thesis. These are listed below: 
 
 For the first time it was shown that the method of processing drug with SBA-
15 had important consequences in terms of the drug distribution throughout 
the SBA-15 matrix, drug solid state form and drug release rate from the 
SBA-15.  
 
 It was highlighted that drug particles must be dissolved or otherwise 
disrupted if the drug is to be induced into a non-crystalline molecular 
dispersion or amorphous form.  
 
 SC-CO2 processing deposited the drug molecules deepest inside SBA-15, 
while simple melting of drug ensured that the molecules were comparatively 
closer to the surface of the mesopores. This is due to the drug molten 
viscosity; a lower molten viscosity should encourage greater freedom of drug 
to move inside SBA-15 mesopores. 
 
 It was found that the SBA-15 surface area and mesopore volume have an 
influence on how much drug could be loaded on to SBA-15. Increasing the 
amount of drug to SBA-15 surface area lowered the drug-loading efficiency 
when the drug: silica ratio was increased from 1 mg : 3 m
2
 to 1 : 0.82 m
2
.  
 
 It was shown that SC-CO2 processing variables such as processing pressure 
(13.79 – 41.37 MPa), duration time (4 – 24 h) and depressurisation rate 
(rapid or controlled) did not influence the drug distribution within the SBA-
Chapter 7  General Discussion 
185 | P a g e  
 
15 matrix, drug solid state form or release rate and extent, even after 12 
months under accelerated storage conditions. Higher processing pressures 
(41.37 MPa) did result in reduced drug-loading efficiency which was 
attributed to the rapid mass transfer rates of CO2 out of the high-pressure cell. 
 
 It was demonstrated that the rate and extent of fenofibrate release depended 
on (1) the loading method, (2) distribution of drug on the silica substrate and 
(3) the composition of the release medium employed.   
1 
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7.9 Future Work 
 One potential avenue to be explored is the utilisation of other drug molecules 
to investigate the robustness of SC-CO2 to load SBA-15 with different drugs 
that have a range of chemistries and molecular weights.  
 
 The applicability of higher resolution SEM and TEM may allow drug 
molecules be visualised inside silica mesopores. Any technique that could 
identify drug molecules inside silica mesopores should be considered.  
 
 Further studies on the drug supersaturating properties of SBA-15 in 
biorelevant media such as FaSSIF should be undertaken, especially the effect 
of drug – silica ratio and crystallinity in drug – silica samples on the extent 
and duration of fenofibrate supersaturation. 
 
 At present, the mathematical models of drug release do not seem applicable 
to drug release from silica mesopores. A new equation to describe fenofibrate 
release from silica mesopores would be a useful addition to knowledge of 
drug release from silica mesopores. The diffusion of drug from the 
mesopores and potential adsorptive properties of mesopores silica need to be 
understood in this context.  
 
 The issues surrounding SBA-15 usage in a pharmaceutical manufacturing 
environment need also to be addressed. Is it possible to manufacture an oral 
formulation using large percentages of SBA-15 and could it be possible to 
simultaneously load the drug onto the SBA-15 and granulate in the SC-CO2 
environment.    
1 
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